Generated Narrative: CodeSystem HIVConcepts Profiles: CRMI Shareable CodeSystem, CRMI Publishable CodeSystem, http://smart.who.int/base/StructureDefinition/SGCodeSystem This case-insensitive code system http://smart.who.int/hiv/CodeSystem/HIVConcepts defines the following codes: Code Display Definition HIV.A.DE1 First name Client's first or given name HIV.A.DE2 Family name Client's family name or last name HIV.A.DE3 Visit date The date and time of the client's visit HIV.A.DE4 Referral If client was referred for care HIV.A.DE5 Referred by How the client was referred HIV.A.DE6 Community Referred by the community level services HIV.A.DE7 Facility Referred by the health facility HIV.A.DE8 Unique identifier Unique identifier generated for new clients or a universal ID, if used in the country HIV.A.DE9 National ID National unique identifier assigned to the client, if used in the country HIV.A.DE10 National health ID National health unique identifier assigned to the client, if used in the country HIV.A.DE11 National programme ID National programme unique identifier assigned to the client, if used in the country HIV.A.DE12 National health insurance ID National health insurance unique identifier assigned to the client, if used in the country HIV.A.DE13 Country of birth Country where the client was born HIV.A.DE14 Date of birth The client's date of birth (DOB) if known HIV.A.DE15 Date of birth unknown Is the client's DOB is unknown? HIV.A.DE16 Estimated age If DOB is unknown, enter the client's estimated age. Display client's age in number of years. HIV.A.DE17 Age Calculated age (number of years) of the client based on date of birth HIV.A.DE18 Gender Gender of the client HIV.A.DE19 Female Client identifies as female HIV.A.DE20 Male Client identifies as male HIV.A.DE21 Transgender male Client identifies as transgender male HIV.A.DE22 Transgender female Client identifies as transgender female HIV.A.DE23 Other Additional category HIV.A.DE24 Other (specify) Additional category (please specify) HIV.A.DE25 Sex Sex of the client assigned at birth HIV.A.DE26 Female Client identifies as female HIV.A.DE27 Male Client identifies as male HIV.A.DE28 Other Client identifies in non-binary way or as a sexual and gender minority (or minorities) HIV.A.DE29 Address Client's home address or address which the client is consenting to disclose HIV.A.DE30 Marital Status Client's current marital status HIV.A.DE31 Unmarried Client does not have an active marriage contract HIV.A.DE32 Never married Client has never entered into a marriage contract HIV.A.DE33 Married A current marriage contract is active HIV.A.DE34 Polygamous Client is in a polygamous union HIV.A.DE35 Divorced Client is divorced, whereby marriage contract has been declared dissolved and inactive HIV.A.DE36 Widowed Client's spouse has died HIV.A.DE37 Unknown Client does not wish to disclose marital status HIV.A.DE38 Domestic partner Client reports that they are in a domestic partnership HIV.A.DE39 Annulled Client's marriage contract has been declared null and to have not existed HIV.A.DE40 Legally separated Client is legally separated from their spouse HIV.A.DE41 Interlocutory Client is subject to an interlocutory decree HIV.A.DE42 Telephone number Client's telephone number (a landline or a mobile phone number) HIV.A.DE43 Administrative Area This should be a context-specific list of administrative areas, such as villages, districts, etc. The purpose of this data element is to allow for grouping and flagging of client data to a particular facility's catchment area. This can be input into the system by the end user OR it can be automated in the database based on the end user's attributes. HIV.A.DE44 Communication consent Indication that client gave consent to be contacted HIV.A.DE45 Reminder messages Whether client wants to receive text or other messages as follow-up for HIV services HIV.A.DE46 Communication preference(s) How the client would like to receive family planning communications HIV.A.DE47 Text message/SMS The client would like to receive communications via Text message/SMS HIV.A.DE48 Voice call Client would like to receive communications via voice call HIV.A.DE49 Client's email Client's primary email account where the client can be contacted HIV.A.DE50 Alternate contact's name Name of an alternate contact, which could be next of kin (e.g. partner, husband, mother, sibling, etc.). The alternate contact would be used in the case of an emergency situation. HIV.A.DE51 Alternate contact's phone number Phone number of the alternate contact HIV.A.DE52 Alternate contact's address Alternate contact's home address or address which the client is consenting to disclose HIV.A.DE53 Alternate contact relationship The alternate contact's relationship to the client (e.g. partner, husband, mother, sibling, etc.) HIV.B.DE1 Reason for visit Reason for HIV testing services visit HIV.B.DE2 First-time HIV test First encounter for screening for human immunodeficiency virus HIV.B.DE3 Retesting for HIV Retesting for human immunodeficiency virus HIV.B.DE4 HIV testing services visit Client attending facility for HIV testing services visit HIV.B.DE5 Referred through partner services Client reported coming to the facility after receiving a provider-assisted referral or patient referral from a contact or partner HIV.B.DE6 Partner or contact of an index case The client is a contact or partner of a person diagnosed with HIV (an index case) HIV.B.DE7 Partner or contact of an HIV testing client (non-index case) The client is a contact or partner identified through partner or social network services, but is not known to be a partner of an index-case HIV.B.DE8 Type of contact or partner for partner services Client's relationship to the person that referred the client for partner services or family services HIV.B.DE9 Biological child Client is the biological child of the person that referred the client for family services HIV.B.DE10 Drug-injecting partner Client is a drug-injecting partner of the person that referred the client for partner services HIV.B.DE11 Sexual partner Client is a sexual partner of the person that referred the client for partner services HIV.B.DE12 Social contact Client is a social contact of the person that referred the client for social-network services HIV.B.DE13 Contact with and (suspected) exposure to HIV When the client is reported to have had suspected exposure to HIV HIV.B.DE14 Date/time of suspected exposure to HIV Date and time when the client had suspected exposure to HIV HIV.B.DE15 Testing entry point Whether testing is happening in the community or at a facility HIV.B.DE16 Community-level testing Testing is happening in the community, which includes mobile testing HIV.B.DE17 Facility-level testing Testing is happening at a facility HIV.B.DE18 Entry point for community-level testing Specific point in the community where testing is happening HIV.B.DE19 Mobile testing (e.g. through vans or temporary testing facilities) The client tested through mobile testing, such as through vans or temporary testing facilities HIV.B.DE20 Voluntary counselling and testing centres (not within a health facility setting) The client tested at a voluntary counselling and testing centre (not in a health facility setting) HIV.B.DE21 Other community-based testing The client tested through another type of community-based testing HIV.B.DE22 Entry point for facility-level testing Specific point where testing is happening at a facility HIV.B.DE23 Provider-initiated tested in a clinic or emergency facility The client tested though provider-initiated HIV testing & counselling, which could be at an emergency facility HIV.B.DE24 Antenatal care clinic The client tested at an antenatal care clinic, including labour and delivery HIV.B.DE25 Voluntary counselling and testing (within a health facility setting) The client tested through voluntary counselling and testing (within a health facility setting) HIV.B.DE26 Family planning clinic The client tested at a family planning clinic HIV.B.DE27 Other facility-level testing The client tested at another type of facility HIV.B.DE28 Tuberculosis (TB) clinic The client tested at a TB clinic HIV.B.DE29 Currently pregnant Client is currently pregnant HIV.B.DE30 Gestational age Gestational age in weeks and/or days depending on the source of gestational age HIV.B.DE31 Expected date of delivery (EDD) Expected date of delivery based on gestational age HIV.B.DE32 Breastfeeding Infant is being breastfed by mother HIV.B.DE33 Partner HIV status (reported) The HIV status of the client's partner. HIV.B.DE34 HIV-positive Client's partner is HIV-positive HIV.B.DE35 HIV-negative Client's partner is HIV-negative HIV.B.DE36 Unknown Don't know HIV status - client does not know partner's HIV status HIV.B.DE37 Partner is from a key population Client's partner is a member of a key population, that has an increased risk of HIV HIV.B.DE38 Sex worker Client's partner is a sex worker HIV.B.DE39 Men who have sex with men Client's partner is a man who has sex with men HIV.B.DE40 Trans and gender-diverse people Client's partner identifies as trans and gender-diverse HIV.B.DE41 People who inject drugs Client's partner is a person who injects drugs HIV.B.DE42 People living in prisons and other closed settings Client's partner lives in a prison or other closed setting HIV.B.DE43 Has used an HIV self-test before (reported) The client reported having used an HIV self-test before HIV.B.DE44 HIV self-test result Results from the reported HIV self-test HIV.B.DE45 Reactive The HIV self-test was reactive HIV.B.DE46 Non-reactive The HIV self-test was non-reactive HIV.B.DE47 Invalid The HIV self-test was invalid HIV.B.DE48 Date of HIV self-test Date when the HIV self-test was conducted HIV.B.DE49 Key population member Client is a member of a key population that has an increased risk of HIV HIV.B.DE50 Key population member type The type of key population that the client is included in HIV.B.DE51 Sex worker Client is a sex worker HIV.B.DE52 Men who have sex with men Client is a man who has sex with men HIV.B.DE53 Trans and gender-diverse people Client identifies as trans and gender-diverse HIV.B.DE54 People who inject drugs Client is a person who injects drugs HIV.B.DE55 People living in prisons and other closed settings Client lives in a prison or another closed setting HIV.B.DE56 Adolescent girl Calculated field based on age and gender, if client is 10 years or older and under 20 years old HIV.B.DE57 Young woman Calculated field based on age and gender, if client is 20 years or older and under 25 years old HIV.B.DE58 Orphan or vulnerable child Client considered an orphan or vulnerable child HIV.B.DE59 Informed of HIV test result Client has been informed of their HIV test result HIV.B.DE60 Date HIV test results returned Date HIV test result returned to client HIV.B.DE61 HIV exposure type Ways in which the client was exposed to HIV HIV.B.DE62 Occupational Occupational exposure to HIV HIV.B.DE63 Non-occupational violent Non-occupational violent exposure to HIV HIV.B.DE64 Non-occupational consensual sex Exposure to HIV through non-occupational consensual sex HIV.B.DE65 Date informed of HIV-positive diagnosis The date on which the client was diagnosed with HIV HIV.B.DE66 HIV diagnosing facility The facility where the client received an HIV-positive diagnosis HIV.B.DE67 Date of first positive test indicative of HIV diagnosis Earliest date of HIV diagnosis determined according to the national HIV testing algorithm HIV.B.DE68 HIV serotype The client's HIV serotype HIV.B.DE69 HIV-1 The client has HIV-1 HIV.B.DE70 HIV-2 The client has HIV-2 HIV.B.DE71 HIV diagnosis date Date diagnosis was returned to client HIV.B.DE72 ART start date The date on which the client started or restarted antiretroviral therapy (ART) HIV.B.DE73 Age at diagnosis The client's age (in years) when given an HIV diagnosis HIV.B.DE74 Type of contact elicited Client's relationship to the contact identified for voluntary partner services or family services HIV.B.DE75 Biological child Contact identified for family services is the biological child of the client HIV.B.DE76 Drug-injecting partner Contact identified for partner services is a drug-injecting partner of the client HIV.B.DE77 Sexual partner Contact identified for partner services is a sexual partner of the client HIV.B.DE78 Social contact Contact identified for social-network services is a social contact of the client HIV.B.DE79 HIV test ordered An HIV test of the client was ordered by the provider HIV.B.DE80 HIV test conducted An HIV test was performed on the client during the visit HIV.B.DE81 HIV test type Type of HIV test HIV.B.DE82 Rapid diagnostic test for HIV Antibody test for HIV performed with a rapid diagnostic HIV.B.DE83 Enzyme immunoassay for HIV Antibody test for HIV performed with an enzyme immunoassay HIV.B.DE84 Nucleic acid test for HIV Virological test, which includes testing for early infant diagnosis HIV.B.DE85 Dual HIV/syphilis rapid diagnostic test Antibody test for HIV and syphilis performed with a rapid diagnostic HIV.B.DE86 HIV self-test Antibody test for HIV performed by self-tester using a rapid diagnostic HIV.B.DE87 Date HIV test sent Date HIV specimen was sent to lab HIV.B.DE88 Assay number in testing strategy The number of the assay (test kit) in the HIV testing strategy HIV.B.DE89 Assay 0 A community outreach test-for-triage or self-test which is not included in the HIV testing strategy HIV.B.DE90 Assay 1 The first test in the HIV testing strategy HIV.B.DE91 Assay 2 The second test in the HIV testing strategy HIV.B.DE92 Assay 3 The third test in the HIV testing strategy HIV.B.DE93 Assay 1 repeated The first test in the HIV testing strategy HIV.B.DE94 Test result of HIV assay 1 The result of the first HIV assay in the testing strategy HIV.B.DE95 Reactive The result of the HIV assay in the testing strategy was reactive HIV.B.DE96 Non-reactive The result of the HIV assay in the testing strategy was non-reactive HIV.B.DE97 Invalid The result of the HIV assay in the testing strategy was invalid HIV.B.DE98 Test result of HIV assay 2 The result of the second HIV assay in the testing strategy HIV.B.DE99 Reactive The result of the HIV assay in the testing strategy was reactive HIV.B.DE100 Non-reactive The result of the HIV assay in the testing strategy was non-reactive HIV.B.DE101 Invalid The result of the HIV assay in the testing strategy was invalid HIV.B.DE102 Test result of HIV assay 3 The result of the third HIV assay in the testing strategy HIV.B.DE103 Reactive The result of the HIV assay in the testing strategy was reactive HIV.B.DE104 Non-reactive The result of the HIV assay in the testing strategy was non-reactive HIV.B.DE105 Invalid The result of the HIV assay in the testing strategy was invalid HIV.B.DE106 Test result of HIV assay 1 repeated The result of the repeated first HIV assay in the testing strategy HIV.B.DE107 Reactive The result of the HIV assay in the testing strategy was reactive HIV.B.DE108 Non-reactive The result of the HIV assay in the testing strategy was non-reactive HIV.B.DE109 Invalid The result of the HIV assay in the testing strategy was invalid HIV.B.DE110 HIV test date Date of the HIV test HIV.B.DE111 HIV test result The result from HIV testing after applying the testing algorithm HIV.B.DE112 HIV-positive Test result is HIV-positive HIV.B.DE113 HIV-negative Test result is HIV-negative HIV.B.DE114 HIV-inconclusive Test result is HIV-inconclusive HIV.B.DE115 HIV status HIV status reported after applying the national HIV testing algorithm. No single HIV test can provide an HIV-positive diagnosis. HIV.B.DE116 HIV-positive Client is HIV-positive HIV.B.DE117 HIV-negative Client is HIV-negative HIV.B.DE118 Unknown Client has unknown HIV status HIV.B.DE119 Date positive HIV test confirmed Date patient received positive HIV test confirmation (with written documentation) HIV.B.DE120 Site where positive HIV test confirmed Name or identifier of health facility where HIV test was confirmed HIV.B.DE121 Probable route of transmission Probable route(s) of transmission of HIV to client HIV.B.DE122 Heterosexual sex Probable route of HIV transmission was through heterosexual sex HIV.B.DE123 Sex between men Probable route of HIV transmission was through sex between men HIV.B.DE124 Unprotected intercourse during sex work Probable route of HIV transmission was through unprotected intercourse during sex work HIV.B.DE125 Injecting drug use with unsterile equipment Probable route of HIV transmission was through injecting drug use with unsterile equipment HIV.B.DE126 Nosocomial Probable route of HIV transmission was nosocomial HIV.B.DE127 Vertical Probable route of HIV transmission to an infant was during pregnancy, labour, delivery and breastfeeding (vertical transmission) HIV.B.DE128 Other Probable route of HIV transmission was other and may include needle accidents, blood transfusion, blood products or organ/tissue donations, tattoos, piercings, circumcision, or acupuncture. HIV.B.DE129 Partner HIV test conducted If the client does not know the HIV status of the client's partner(s), offer to test and add results here HIV.B.DE130 Partner HIV test ordered An HIV test for the client's partner has been ordered HIV.B.DE131 Partner HIV test date Date of client's partner's HIV test HIV.B.DE132 Partner HIV test result The HIV test result of the client's partner HIV.B.DE133 HIV-positive Test result is HIV-positive HIV.B.DE134 HIV-negative Test result is HIV-negative HIV.B.DE135 HIV-inconclusive Test result is HIV-inconclusive HIV.B.DE136 Partner HIV status (confirmed) The HIV status of a sexual or drug-injecting partner of the client, based on a confirmed test result HIV.B.DE137 HIV-positive Client's partner is HIV-positive HIV.B.DE138 HIV-negative Client's partner is HIV-negative HIV.B.DE139 Unknown Client's partner HIV status is unknown HIV.B.DE140 Partner on ART Partner of the client is on ART HIV.B.DE141 Partner virally suppressed on ART ART and virally suppression status of a partner of the client HIV.B.DE142 Counselling provided Whether counselling was provided to a client during the visit HIV.B.DE143 HIV-positive counselling conducted Whether counselling was provided to a client who has been diagnosed with HIV HIV.B.DE144 Hepatitis B positive counselling conducted Whether counselling was provided to a client who has been diagnosed with hepatitis B HIV.B.DE145 Hepatitis C positive counselling conducted Whether counselling was provided to a client who has been diagnosed with hepatitis C HIV.B.DE146 Syphilis counselling, treatment and further testing Whether counselling and treatment was provided to a client who has been diagnosed with syphilis. Additional testing (RPR test) recommended. HIV.B.DE147 Linked to enrolment in care and ART initiation Linkage made from HIV testing to enrolment in care following an HIV diagnosis HIV.B.DE148 VMMC counselling provided Whether counselling for voluntary medical male circumcision (VMMC) was provided following an HIV-negative test HIV.B.DE149 Prevention services offered and referrals Offer or refer to prevention services HIV.B.DE150 Offer male and female condoms and condom-compatible lubricants Offer male and female condoms and condom-compatible lubricants HIV.B.DE151 Offer pre-exposure prophylaxis (PrEP) for people at elevated risk for HIV acquisition Offer pre-exposure prophylaxis (PrEP) to people with substantial ongoing risk of HIV infection HIV.B.DE152 Offer post-exposure prophylaxis (PEP) following suspected exposure Offer or refer client for PEP following suspected exposure HIV.B.DE153 Voluntary medical male circumcision (VMMC) Offer referral for VMMC services HIV.B.DE154 Harm reduction for people who inject drugs Offer or refer to harm reduction services for people who inject drugs (needle and syringe programmes, opioid substitution therapy, other drug-dependence treatment and opioid overdose prevention and management) HIV.B.DE155 Behavioural interventions to support risk reduction, particularly for people with HIV and members of key populations Offer or refer to behavioural interventions to support risk reduction, particularly for people with HIV and members of key populations HIV.B.DE156 HIV testing for partners and biological children Offer voluntary testing for all partners and biological children of positive cases (includes partner services and index case testing), as welll as partners and social contacts of people from key populations, where appropriate HIV.B.DE157 HIV testing for partners and social contacts of people from key populations, where appropriate Offer voluntary testing for partners and social contacts of people from key populations, where appropriate HIV.B.DE158 Sexual and reproductive health integrated services Offer or refer to sexual and reproductive health services HIV.B.DE159 Contraception and family planning Offer contraception and family planning services HIV.B.DE160 Check pregnancy status Check women's pregnancy status HIV.B.DE161 Prevention of mother-to-child transmission counselling Offer services for prevention of mother-to-child transmission (counselling) HIV.B.DE162 Cervical cancer screening and treatment counselling Offer cervical cancer screening and treatment counselling and services HIV.B.DE163 Anal cancer screening (for men who have sex with men) Offer services for anal cancer screening (for men who have sex with men) HIV.B.DE164 STI testing and treatment services Offer sexually transmitted infection (STI) testing and treatment services HIV.B.DE165 Offer other clinical services Other clinical services offered or referrals given to the client HIV.B.DE166 Assessment and provision of vaccinations Assessment and provision of vaccinations, such as for people from key populations, pregnant women and infants; and, where appropriate, tetanus vaccination for adolescent boys and men receiving VMMC HIV.B.DE167 Hepatitis B (HBV) and hepatitis C virus (HCV) testing and treatment provided Offer or refer for HBV and/or HCV testing and treatment HIV.B.DE168 Co-trimoxazole chemoprophylaxis to prevent Pneumocystis carinii pneumonia provided Offer or refer for co-trimoxazole chemoprophylaxis to prevent pneumocystis carinii pneumonia HIV.B.DE169 Intensified TB case finding and linkage to TB treatment provided Offer or refer for intensified TB case finding and linkage to TB treatment HIV.B.DE170 Provision of isoniazid preventive therapy if person does not have TB Offer or refer for provision of isoniazid preventive therapy if person does not have TB HIV.B.DE171 Malaria prevention (such as bed nets and prophylaxis), depending on epidemiology Offer or refer for malaria prevention (such as bed nets and prophylaxis), depending on epidemiology HIV.B.DE172 Other support services Offer or refer for other support services HIV.B.DE173 Mental health services Offer or refer for mental health services HIV.B.DE174 Psychosocial counselling, support and treatment adherence counselling Offer or refer for psychosocial counselling, support and treatment adherence counselling HIV.B.DE175 Support for disclosure and partner services Offer or refer for support for disclosure and partner services HIV.B.DE176 Legal and social services Offer or refer for legal and social services HIV.B.DE177 Services for responding to violence against women Offer or refer for services for responding to violence against women, including first-line support and psychosocial support, post-rape care and other support services including shelters, legal services and women and child protection services HIV.B.DE178 Clinical enquiry for intimate partner violence (IPV) done Whether a clinical enquiry for intimate partner violence was conducted HIV.B.DE179 Intimate partner violence enquiry results Result of medical inquiry for intimate partner violence HIV.B.DE180 Client received treatment and/or counselling as needed Client received treatment and/or counselling as needed HIV.B.DE181 Client was referred Client was referred to another provider/facility HIV.B.DE182 No action necessary No additional action was deemed necessary HIV.B.DE183 Other IPV result Other intimate partner violence (IPV) result not described above HIV.B.DE184 Other IPV result (specify) Other intimate partner violence (IPV) result not described above (specify) HIV.B.DE185 Offered voluntary partner services Whether the client was offered voluntary partner services or family services HIV.B.DE186 Count of contacts or partners given for social network-based/partner services The quantity of contacts or partners given by a client that accepts social network-based/partner services for follow-up HIV.B.DE187 Offered social network-based/partner services Whether the client was offered social network-based partner services HIV.B.DE188 Accepted social network-based/partner services Whether the client accepted social network-based partner services HIV.B.DE189 Contact first name to offer social network-based/partner services First name of each contact given by the client to offer social network-based/partner services HIV.B.DE190 Contact last name to offer social network-based/partner services Last or family name of each contact given by the client to offer social network-based/partner services HIV.B.DE191 Type of follow-up appointment Type of follow-up appointment for testing services HIV.B.DE192 Retesting for HIV Retesting follow-up appointment HIV.B.DE193 Other Other reason for the follow-up appointment HIV.B.DE194 Other reason for the follow-up appointment (specify) Other reason for the follow-up appointment (specify) HIV.B.DE195 Date/time of follow-up appointment Date the patient is to return for monitoring, re-supply or any other reason HIV.B.DE196 Recommended follow-up date Date when follow-up is recommended based on follow up requirements HIV.B.DE197 VMMC procedure Whether a voluntary medical male circumcision procedure was performed HIV.B.DE198 VMMC procedure date Date on which a voluntary medical male circumcision procedure was performed HIV.B.DE199 Adverse event reported from a VMMC Whether an adverse event was reported associated with a voluntary medical male circumcision (VMMC) procedure HIV.B.DE200 Serious adverse event Complications from voluntary medical male circumcision (VMMC) procedure resulted in death or hospitalization within 30 days of the procedure or permanent disability HIV.B.DE201 Adverse event severity Severity of the adverse event associated with voluntary medical male circumcision (VMMC) procedure HIV.B.DE202 Moderate Severity of the adverse event associated with VMMC procedure was moderate HIV.B.DE203 Severe Severity of the adverse event associated with VMMC procedure was severe HIV.B.DE204 Timing of adverse event When the adverse event associated with VMMC procedure occurred HIV.B.DE205 Intraoperative The adverse event associated with VMMC procedure occurred during the procedure HIV.B.DE206 Postoperative The adverse event associated with VMMC procedure occurred within the first 30 days after the procedure HIV.B.DE207 Type of adverse VMMC event Type of adverse event associated with voluntary medical male circumcision (VMMC) procedure HIV.B.DE208 Abnormal pain Client experienced abnormal pain HIV.B.DE209 Anaesthesia-related effects Client had anaesthesia-related effects HIV.B.DE210 Bleeding Client had bleeding HIV.B.DE211 Damage to the penis Client had damage to the penis HIV.B.DE212 Difficulty urinating Client had difficulty urinating HIV.B.DE213 Excessive bleeding Client experienced excessive bleeding HIV.B.DE214 Excessive skin removal Client experienced excessive skin removal HIV.B.DE215 Excessive swelling Client experienced excessive swelling HIV.B.DE216 Haematoma Client experienced haematoma HIV.B.DE217 Infection Client experienced infection HIV.B.DE218 Injury to glans Client experienced injury to glans HIV.B.DE219 Scar or disfigurement Client experienced scar or disfigurement HIV.B.DE220 Sharps injury to personnel During VMMC procedure there was sharps injury to personnel HIV.B.DE221 Wound disruption Client experienced wound disruption HIV.B.DE222 Other Client experienced other adverse VMMC event HIV.B.DE223 Other (specify) Client experienced other adverse VMMC event (specify) HIV.B.DE224 HIV retest prior to starting ART conducted HIV retest prior to starting ART conducted HIV.B.DE225 At elevated risk for HIV acquisition Client is at elevated risk for HIV acquisition HIV.B.DE226 Syndrome/STI diagnosed Syndrome or STI for which client is diagnosed HIV.B.DE227 Urethral discharge syndrome Client diagnosed with urethral discharge syndrome HIV.B.DE228 Vaginal discharge syndrome Client diagnosed with vaginal discharge syndrome HIV.B.DE229 Lower Abdominal pain Client diagnosed with lower abdominal pain HIV.B.DE230 Genital ulcer disease syndrome Client diagnosed with genital ulcer disease syndrome HIV.B.DE231 Anorectal discharge Client diagnosed with anorectal discharge HIV.B.DE232 Sent for testing Specimen sent for testing HIV.B.DE233 Other Other syndrome/STI diagnosed HIV.B.DE234 Other (specify) Other syndrome/STI diagnosed (specify) HIV.B.DE235 Any STI syndrome diagnosed Was the client diagnosed with any of the five STI syndromes during this visit? HIV.B.DE236 Date of STI test Date on which the STI test was conducted HIV.B.DE237 STI tested for STI for which the client was tested HIV.B.DE238 Neisseria gonorrhoeae Client tested for Neisseria gonorrhoeae HIV.B.DE239 Chlamydia trachomatis Client tested for Chlamydia trachomatis HIV.B.DE240 Trichomonas vaginalis Client tested for Trichomonas vaginalis HIV.B.DE241 Syphilis (Treponema pallidum) Client tested for Syphilis (treponema pallidum) HIV.B.DE242 Herpes simplex virus (HSV1, HSV2) Client tested for herpes simplex virus (HSV1, HSV2) HIV.B.DE243 Mycoplasma genitalium Client tested for Mycoplasma genitalium HIV.B.DE244 Mpox Client tested for Mpox HIV.B.DE245 Hepatitis B Client tested for Hepatitis B HIV.B.DE246 Hepatitis C Client tested for Hepatitis C HIV.B.DE247 Other Client tested for other STI HIV.B.DE248 Other (specify) Client tested for other STI (specify) HIV.B.DE249 Syphilis test date Date of syphilis test HIV.B.DE250 Syphilis test result Result from syphilis test HIV.B.DE251 Positive Test result is positive for syphilis HIV.B.DE252 Negative Test result is negative for syphilis HIV.B.DE253 Inconclusive Test result is inconclusive HIV.B.DE254 Syphilis treatment start date Date of initiation of syphilis treatment HIV.B.DE255 Gonorrhoea test date Date of Gonorrhoea test HIV.B.DE256 Gonorrhoea test result Result from Gonorrhoea test HIV.B.DE257 Positive Test result is positive for Neisseria gonorrhoeae HIV.B.DE258 Negative Test result is negative for Neisseria gonorrhoeae HIV.B.DE259 Inconclusive Test result is inconclusive HIV.B.DE260 Gonorrhoea treatment start date Date of initiation of Gonorrhoea treatment HIV.B.DE261 Type of specimen Type of specimen to be collected HIV.B.DE262 Blood Blood specimen to be collected HIV.B.DE263 Urine Urine specimen to be collected HIV.B.DE264 Cervical or vaginal swab Cervical or vaginal swab to be collected HIV.B.DE265 Urethral or penile swab Urethral or penile swab to be collected HIV.B.DE266 Rectal swab Rectal swab to be collected HIV.B.DE267 Other Other specimen type to be collected HIV.B.DE268 Other type of specimen (specify) Other specimen type to be collected (specify) HIV.B.DE269 Syphilis test type Type of diagnostic test used for syphilis (treponema pallidum) HIV.B.DE270 Treponemal Treponemal test used HIV.B.DE271 Non-treponemal Non-treponemal test used HIV.B.DE272 POC Test Point-of-care (POC) test used HIV.B.DE273 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.B.DE274 Other Other test used HIV.B.DE275 Other syphilis test type (specify) Other test used (specify) HIV.B.DE276 Neisseria gonorrhoeae test type Type of diagnostic test used for Neisseria gonorrhoeae HIV.B.DE277 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.B.DE278 POC Test Point-of-care (POC) test used HIV.B.DE279 Culture Culture test used HIV.B.DE280 Microscopy Microscopy test used HIV.B.DE281 Other Other type of test used HIV.B.DE282 Other (specify) Other type of test used (specify) HIV.B.DE283 POC Test for Neisseria gonorrhoeae (specify) Point-of-care (POC) test used for Neisseria gonorrhoeae (specify) HIV.B.DE284 Chlamydia trachomatis test type Type of diagnostic test used for Chlamydia trachomatis HIV.B.DE285 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.B.DE286 POC Test Point-of-care (POC) test used HIV.B.DE287 Culture Culture test used HIV.B.DE288 ELISA ELISA test used HIV.B.DE289 Microscopy Microscopy test used HIV.B.DE290 Other Other type of test used HIV.B.DE291 Other test for Chlamydia (specify) Other type of test used for Chlaymdia (specify) HIV.B.DE292 POC Test type for Chlamydia test (specify) Point-of-care (POC) test used for Chlamydia (specify) HIV.B.DE293 Trichomonas vaginalis test type Type of diagnostic test used for Trichomonas vaginalis HIV.B.DE294 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.B.DE295 POC Test Point-of-care (POC) test used HIV.B.DE296 Culture Culture test used HIV.B.DE297 Microscopy Microscopy test used HIV.B.DE298 Other Other type of test used HIV.B.DE299 Other (specify) Other type of test used (specify) HIV.B.DE300 POC Test type for Trichomonas vaginalis test (specify) Point-of-care (POC) test used (specify) HIV.B.DE301 Herpes simplex virus (HSV) test type Type of diagnostic test used for herpes simplex virus (HSV) HIV.B.DE302 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.B.DE303 Antibody test Antibody test used HIV.B.DE304 Other Other type of test used HIV.B.DE305 Other (specify) Other type of test used for Herpes simplex virus (HSV) test (specify) HIV.B.DE306 Mycoplasma genitalium test type Type of diagnostic test used for Mycoplasma genitalium HIV.B.DE307 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.B.DE308 Microscopy Microscopy test used HIV.B.DE309 Other Other type of test used HIV.B.DE310 Other (specify) Other type of test used for Mycoplasma genitalium test (specify) HIV.B.DE311 Test type for other STI tested for (specify) Test type used for the other specified STI HIV.B.DE312 STI test result Result from STI test HIV.B.DE313 Positive Test result is positive HIV.B.DE314 Negative Test result is negative HIV.B.DE315 Inconclusive Test result is inconclusive HIV.B.DE316 Date of STI confirmatory test Date of STI confirmatory test HIV.B.DE317 Confirmatory syphilis test type Type of test ued for confirmatory syphilis test HIV.B.DE318 Treponemal Treponemal test used HIV.B.DE319 Non-treponemal Non-treponemal test used HIV.B.DE320 POC Test Point-of-care (POC) test used HIV.B.DE321 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.B.DE322 Other Other test used HIV.B.DE323 Other (specify) Other test used for confirmatory syphilis test (specify) HIV.B.DE324 Confirmatory test type for other STI (specify) Confirmatory test type for other STI HIV.B.DE325 Confirmatory STI test result Result from confirmatory STI test HIV.B.DE326 Positive Test result is positive HIV.B.DE327 Negative Test result is negative HIV.B.DE328 Inconclusive Test result is inconclusive HIV.B.DE329 Date STI treatment prescribed Date STI treatment was prescribed to the client HIV.B.DE330 Date STI treatment dispensed Date STI treatment dispensed to the client HIV.B.DE331 STI treatment dispensed (specify) STI treatment dispensed to the client HIV.C.DE1 Reason for PrEP visit Client's reason for the prevention visit HIV.C.DE2 First time counselling on PrEP The client is interested in discussing pre-exposure prophylaxis (PrEP) for the first time HIV.C.DE3 Follow-up appointment for PrEP or PEP Client is at a follow-up or refill pre-exposure prophylaxis (PrEP) appointment HIV.C.DE4 Restarting PrEP Client has previously taken pre-exposure prophylaxis (PrEP) and may like to restart taking it HIV.C.DE5 Counselling on PEP Counselling on post-exposure prophylaxis (PEP) HIV.C.DE6 Unscheduled visit for side effects Patient visit for management of side effects related to PrEP HIV.C.DE7 3-month PrEP visit Client is visiting for the recommended 3-month pre-exposure prophylaxis (PrEP) visit HIV.C.DE8 Contact with and (suspected) exposure to HIV The client had suspected or known exposure to HIV HIV.C.DE9 Date/time of suspected exposure to HIV When the suspect exposure to HIV took place HIV.C.DE10 Currently on PrEP The client is currently taking PrEP. Oral pre-exposure prophylaxis (PrEP) of HIV is the use of ARV drugs by people who are not infected with HIV to block the acquisition of HIV. HIV.C.DE11 PrEP dosing type Way in which pre-exposure prophylaxis (PrEP) is taken (daily or event-driven) HIV.C.DE12 Daily oral PrEP Pre-exposure prophylaxis (PrEP) is taken every day HIV.C.DE13 Event-driven PrEP (2+1+1) Event-driven pre-exposure prophylaxis (PrEP) is taken on an even-driven basis (2+1+1) HIV.C.DE14 Other PrEP dosing type Other PrEP dosing type HIV.C.DE15 Other PrEP dosing type (specify) Other PrEP dosing type (specify) HIV.C.DE16 Used event-driven PrEP for at risk exposures over the past 3 months Client reports taking ED-PrEP for at risk exposures over a 3-month period HIV.C.DE17 Current PrEP regimen HIV pre-exposure prophylaxis (PrEP) regimen HIV.C.DE18 TDF + FTC Treated with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) pre-exposure prophylaxis (PrEP) regimen (oral PrEP) HIV.C.DE19 TDF Treated with single-agent tenofovir disoproxil fumarate (TDF) pre-exposure prophylaxis (PrEP) regimen (oral PrEP) HIV.C.DE20 TDF + 3TC Treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) pre-exposure prophylaxis (PrEP) regimen (oral PrEP) HIV.C.DE21 Other TDF-based regimen Treated with other tenofovir disoproxil fumarate (TDF)-based regimen (oral PrEP) HIV.C.DE22 Dapivirine vaginal ring (DVR) Dapivirine vaginal ring (DVR) for HIV prevention HIV.C.DE23 CAB-LA Long-acting injectable cabotegravir HIV.C.DE24 Experience with PrEP The client's experience in taking PrEP HIV.C.DE25 First-time user The client has never used pre-exposure prophylaxis (PrEP) before (naive) HIV.C.DE26 Continuing user The client has used PrEP before and is continuing to use PrEP HIV.C.DE27 Restarting following a period of not taking PrEP The client is restarting PrEP following a period of not taking PrEP HIV.C.DE28 PrEP start date The date on which the client started or restarted pre-exposure prophylaxis (PrEP) HIV.C.DE29 Stopped PrEP Client stopped taking pre-exposure prophylaxis (PrEP) HIV.C.DE30 Date PrEP stopped Date client stopped taking pre-exposure prophylaxis (PrEP) HIV.C.DE31 PEP history The client's history in taking post-exposure prophylaxis (PEP) for HIV prevention HIV.C.DE32 First-time user The client has never used post-exposure prophylaxis (PEP) before HIV.C.DE33 Repeat user The client has used post-exposure prophylaxis (PEP) before HIV.C.DE34 Date(s) of past PEP use Dates when the client previously used post-exposure prophylaxis (PEP) HIV.C.DE35 Date client completes PEP course Date client completes PEP course HIV.C.DE36 Signs of substantial risk of HIV infection Signs the client is at a substantial risk of HIV infection HIV.C.DE37 No condom use during sex with more than one partner in the past 6 months Recent vaginal or anal sexual intercourse without a condom with more than one partner HIV.C.DE38 STI in the past 6 months A recent history (in the last 6 months) of a sexually transmitted infection (STI ) by laboratory testing, self-report or syndromic STI treatment HIV.C.DE39 A sexual partner in the past 6 months had one or more HIV risk factors A recent sex partner of the client had HIV risk factors HIV.C.DE40 PrEP requested by client Client is requesting PrEP, reflecting a decision-making process has already taken place and suggesting of substantial risk of HIV HIV.C.DE41 Pregnancy intention in serodiscordant partnerships Client's intention or desire in the next year to either become pregnant or prevent a future pregnancy (in serodiscordant partnerships) HIV.C.DE42 Yes, I want to become pregnant Client intends to become pregnant HIV.C.DE43 I'm OK either way Client is not intending to become pregnant, but would not be adverse to becoming pregnant HIV.C.DE44 No, I don't want to become pregnant Client does not intend to become pregnant HIV.C.DE45 Unsure Client is unsure or undecided about her pregnancy intentions HIV.C.DE46 Acute HIV infection symptoms Symptoms that could suggest an acute HIV infection HIV.C.DE47 Fever Client's symptoms include a fever HIV.C.DE48 Sore throat Client's symptoms include a sore throat HIV.C.DE49 Aches Client's symptoms include aches HIV.C.DE50 Pains Client's symptoms include pains HIV.C.DE51 Swollen glands Client's symptoms include swollen glands HIV.C.DE52 Mouth sores Client's symptoms include a mouth sores HIV.C.DE53 Headaches Client's symptoms include a headaches HIV.C.DE54 Rash Client's symptoms include a rash HIV.C.DE55 Sex partner's HIV treatment status Treatment adherence of client's sex partner for partners that are HIV-positive HIV.C.DE56 Not on ART Sex partner is HIV-positive and not on ART HIV.C.DE57 On ART less than 6 months Sex partner is HIV-positive and is on ART less than 6 months. ART may take up to 6 months to suppress viral load. In studies of serodiscordant couples, pre-exposure prophylaxis (PrEP) has provided a useful bridge to full viral suppression by the partner during that time. HIV.C.DE58 Partner has suspected low adherence to ART Sex partner is HIV-positive and is suspected to have low adherence to ART. There have been gaps in the partner's treatment adherence or the couple is not communicating openly about treatment adherence and viral load test results. HIV.C.DE59 Partner is not virally suppressed Sex partner is HIV-positive and not virally suppressed HIV.C.DE60 Partner is virally suppressed and has been on ART for 6 months or more Sex partner is HIV-positive and virally suppressed with 6 months or more on ART HIV.C.DE61 Suitable for PrEP The client is suitable for PrEP HIV.C.DE62 Offered PrEP After being evaluated as suitable for PrEP, the client was offered PrEP HIV.C.DE63 Screenings and diagnostics for PrEP users Listing of tests for clients on or starting pre-exposure prophylaxis (PrEP) that may be recommended or should be considered HIV.C.DE64 Serum creatinine test Test serum creatinine to identify pre-existing renal disease (estimated creatinine clearance less than 60 ml/min) HIV.C.DE65 Hepatitis B test Hepatitis B test recommended for client HIV.C.DE66 Hepatitis C test Hepatitis C test recommended for client HIV.C.DE67 Syphilis test Syphilis test recommended for client HIV.C.DE68 Other screening for STIs Other STI screening recommended for client HIV.C.DE69 Pregnancy testing Pregnancy testing for client HIV.C.DE70 Review vaccination history Review vaccination history recommended for client HIV.C.DE71 Serum creatinine test date Test serum creatinine to identify pre-existing renal disease (estimated creatinine clearance less than 60 ml/min) HIV.C.DE72 Serum creatinine test result Test serum creatinine to identify pre-existing renal disease (estimated creatinine clearance less than 60 ml/min). HIV.C.DE73 Date medications dispensed Date the client was dispensed medications HIV.C.DE74 Date medications prescribed Date the client was prescribed medications HIV.C.DE75 Medications prescribed Medications the client was prescribed HIV.C.DE76 PrEP for HIV prevention Client was prescribed pre-exposure prophylaxis (PrEP) for HIV prevention HIV.C.DE77 PEP for HIV prevention Client was prescribed post-exposure prophylaxis (PEP) for HIV prevention HIV.C.DE78 Other Client was prescribed other medications HIV.C.DE79 Other (specify) Client was prescribed other medications (specify) HIV.C.DE80 PrEP product prescribed PrEP product that the client was prescribed HIV.C.DE81 Oral PrEP Client was prescribed oral PrEP HIV.C.DE82 Dapivirine vaginal ring (DVR) Client was prescribed dapivirine vaginal ring (DVR) HIV.C.DE83 CAB-LA Client was prescribed long-acting cabotegravir (CAB-LA) HIV.C.DE84 Other Client was prescribed other PrEP product HIV.C.DE85 Other (specify) Client was prescribed other PrEP product (specify) HIV.C.DE86 Date PrEP prescribed Date client was prescribed PrEP, including initial prescription and repeats HIV.C.DE87 Date PrEP dispensed Date client was dispensed PrEP HIV.C.DE88 Volume of PrEP product prescribed/dispensed Volume of PrEP product the client was prescribed or dispensed (for example, number of pills, number of devices) HIV.C.DE89 Date PEP prescribed Date the client was prescribed PEP HIV.C.DE90 Date PEP course completion Date client completes PEP course HIV.C.DE91 Preferred PEP backbone regimen Preferred backbone regimen for PEP HIV.C.DE92 TDF + 3TC Preferred backbone containing tenofovir disoproxil fumarate and lamivudine HIV.C.DE93 TDF + FTC Preferred backbone containing tenofovir disoproxil fumarate and emtricitabine HIV.C.DE94 AZT + 3TC Preferred backbone containing zidovudine and lamivudine HIV.C.DE95 Alternative PEP backbone regimen Alternative backbone regimen for PEP HIV.C.DE96 ABC + 3TC Alternative backbone containing abacavir and lamivudine HIV.C.DE97 TDF + 3TC Alternative backbone containing tenofovir disoproxil fumarate and lamivudine HIV.C.DE98 TDF + FTC Alternative backbone containing tenofovir disoproxil fumarate and emtricitabine HIV.C.DE99 Preferred third PEP drug Preferred third drug for PEP HIV.C.DE100 DTG Preferred third drug of dolutegravir HIV.C.DE101 Alternative third PEP drug Alternative third drug for PEP HIV.C.DE102 ATV/r Alternative third drug of atazanavir/ritonavir (ATV/r) HIV.C.DE103 DRV/r Alternative third drug of darunavir/ritonavir (DRV/r) HIV.C.DE104 LPV/r Alternative third drug of lopinavir/ritonavir (LPV/r) HIV.C.DE105 RAL Alternative third drug of raltegravir (RAL) HIV.C.DE106 Estimated creatinine clearance Estimated creatinine clearance of the client returned from lab in mL/min HIV.C.DE107 Sex factor for estimating creatinine clearance Value used for gender for calculating creatinine clearance if required. For transgender populations, the sex at birth is used in the Cockcroft-Gault equation if the person is not using hormone therapy; among transgender populations using hormone therapy for more than three months, the current gender can be used. HIV.C.DE108 Male Male client HIV.C.DE109 Female Female client HIV.C.DE110 Estimated creatinine clearance (Cockcroft–Gault equation) If the laboratory does not have the capacity to estimate creatinine clearance, the provider can use the Cockcroft–Gault equation to calculate estimated creatinine clearance based on measured serum creatinine, the client’s sex at birth, age and estimated lean body weight. HIV.C.DE111 Date of sample collection Date when the specimen was collected HIV.C.DE112 Contraindications to PrEP usage Listing of contraindications to pre-exposure prophylaxis (PrEP) HIV.C.DE113 Tenofovir disoproxil fumarate (TDF) allergy or contraindication Allergy to pre-exposure prophylaxis (PrEP) tenofovir disoproxil fumarate (TDF) HIV.C.DE114 HIV-positive Client is HIV-positive HIV.C.DE115 Low estimated creatinine clearance Estimated creatinine clearance of less than 60 ml/min (if known) HIV.C.DE116 Acute HIV infection symptoms Symptoms that could suggest an acute HIV infection HIV.C.DE117 Probable recent exposure to HIV When the client is reported to have had probable recent exposure to HIV HIV.C.DE118 Other allergy or contraindication to a medicine in the PrEP regimen Client has another allergy or contraindication to a medicine in the pre-exposure prophylaxis (PrEP) regimen HIV.C.DE119 Other allergy or contraindication to a medicine in the PrEP regimen (specify) Client has another allergy or contraindication to a medicine in the pre-exposure prophylaxis (PrEP) regimen (specify) HIV.C.DE120 Prescribed PrEP at initial visit Client was prescribed pre-exposure prophylaxis (PrEP) on a first visit HIV.C.DE121 Number of days prescribed Days of medication client has been prescribed HIV.C.DE122 PrEP regimen prescribed HIV pre-exposure prophylaxis (PrEP) regimen prescribed HIV.C.DE123 Adherence counselling provided Whether adherence counselling was provided HIV.C.DE124 Date/time of follow-up appointment Date the client is to return for monitoring, re-supply, or any other reason HIV.C.DE125 Type of follow-up appointment Type of follow-up appointment for testing services HIV.C.DE126 Retesting for HIV Retesting follow-up appointment HIV.C.DE127 Follow-up appointment for PrEP Retesting follow-up appointment HIV.C.DE128 Other Other reason for the follow-up appointment HIV.C.DE129 Other (specify) Other reason for the follow-up appointment (specify) HIV.C.DE130 Linked to enrolment in care and ART initiation Linkage made from HIV testing to enrolment in care following an HIV diagnosis HIV.C.DE131 Prevention services offered and referrals Offer or refer to prevention services HIV.C.DE132 Male and female condoms and condom-compatible lubricants offered Offer male and female condoms and condom-compatible lubricants HIV.C.DE133 Voluntary medical male circumcision (VMMC) referral Offer referral for VMMC services HIV.C.DE134 Harm reduction for people who inject drugs Offer or refer to harm reduction for people who inject drugs (needle and syringe programmes, opioid substitution therapy, other drug-dependence treatment and opioid overdose prevention and management) services HIV.C.DE135 Behavioural interventions to support risk reduction Offer or refer to services for behavioural interventions to support risk reduction, particularly for people with HIV and members of key populations HIV.C.DE136 Date provided condoms Date client was provided with condoms HIV.C.DE137 Condoms distributed Number of condoms given to the client, if any were distributed HIV.C.DE138 Condom type Type of condom provided to client HIV.C.DE139 Male condom Male condoms were provided to the client HIV.C.DE140 Female condom Female condoms were provided to the client HIV.C.DE141 HIV self-test kits accepted Whether any HIV self-test kits were given to the client HIV.C.DE142 Number of HIV self-test kits distributed Number of HIV self-test kits distributed to the client HIV.C.DE143 HIV self-test distributed for use by Whom the client plans to give the HIV self-test kit (self, sexual partner, social contact, etc.) HIV.C.DE144 Self Client plans to use the self-test kit HIV.C.DE145 Family member Client plans to give the self-test kit to a family member to use HIV.C.DE146 Drug-injecting partner Client plans to give the self-test kit to a drug-injecting partner HIV.C.DE147 Sexual partner Client plans to give the self-test kit to a sexual partner HIV.C.DE148 Social contact Client plans to give the self-test kit to a social contact HIV.C.DE149 Sexual and reproductive health integrated services Offer or refer to sexual and reproductive health services HIV.C.DE150 Contraception and family planning Offer contraception and family planning services HIV.C.DE151 Check pregnancy status Check woman's pregnancy status HIV.C.DE152 Prevent mother-to-child transmission Offer services (counselling) to help prevent of mother-to-child transmission HIV.C.DE153 Cervical cancer screening and treatment Offer cervical cancer screening and treatment services HIV.C.DE154 Anal cancer screening (for men who have sex with men) Offer anal cancer screening (for men who have sex with men) services HIV.C.DE155 STI testing and treatment Offer STI testing and treatment services HIV.C.DE156 HIV testing for partners and biological children Offer testing for all partners and biological children of positive cases (includes partner services and index case testing), as well as partners and social contacts of people from key populations, where appropriate HIV.C.DE157 Offer other clinical services Other clinical services offered or referrals given to the client HIV.C.DE158 Assessment and provision of vaccinations Assessment and provision of vaccinations, such as for people from key populations, pregnant women and infants; and, where appropriate, tetanus vaccination for adolescent boys and men receiving VMMC HIV.C.DE159 Hepatitis B virus (HBV) and hepatitis C virus (HCV) testing and treatment Offer or refer for HBV testing and vaccination and HCV testing and treatment HIV.C.DE160 Co-trimoxazole chemoprophylaxis to prevent pneumocystis carinii pneumonia Offer or refer for co-trimoxazole chemoprophylaxis to prevent pneumocystis carinii pneumonia HIV.C.DE161 Intensified TB case finding and linkage to TB treatment Offer or refer for TB case finding and linkage to TB treatment HIV.C.DE162 Provision of isoniazid preventive therapy if person does not have TB Offer or refer for provision of isoniazid preventive therapy if person does not have TB HIV.C.DE163 Malaria prevention (such as bed nets and prophylaxis), depending on epidemiology Offer or refer for malaria prevention (such as bed nets and prophylaxis), depending on epidemiology HIV.C.DE164 Other support services Offer or refer for other support services HIV.C.DE165 Mental health services Offer or refer for mental health services HIV.C.DE166 Psychosocial counselling, support and treatment adherence counselling Offer or refer for psychosocial counselling, support and treatment adherence counselling HIV.C.DE167 Support for disclosure and partner services Offer or refer for support for disclosure and partner services HIV.C.DE168 Legal and social services Offer or refer for legal and social services HIV.C.DE169 Services for responding to violence against women Offer or refer for services for responding to violence against women, including first-line support and psychosocial support, post-rape care and other support services including shelters, legal services and women and child protection services HIV.D.DE1 Reason for visit Whether visit was scheduled or unscheduled, clinical only, or for ARV drug pick-up HIV.D.DE2 First clinical visit The client's first appointment for clinical care by a provider at the facility HIV.D.DE3 Clinical visit Appointment for clinical care by a provider HIV.D.DE4 ART initiation Appointment for initiation of ART HIV.D.DE5 ART drug pick up Appointment for an antiretroviral drug pick up HIV.D.DE6 Issues and concerns Visit to address issues and concerns HIV.D.DE7 Post-treatment follow-up visit for cervical precancer lesions or invasive cervical cancer Appointment for a post-treatment follow-up visit for cervical precancer lesions or invasive cervical cancer HIV.D.DE8 Scheduled visit Is this is a scheduled visit? HIV.D.DE9 Body temperature Temperature of the client in Celsius HIV.D.DE10 Respiratory rate The number of breaths per minute HIV.D.DE11 Heart rate The number of heartbeats per minute HIV.D.DE12 Body height The client's height in centimetres HIV.D.DE13 Body weight The client's current weight in kilograms HIV.D.DE14 Systolic blood pressure Systolic blood pressure (SBP) in mmHg HIV.D.DE15 Diastolic blood pressure Diastolic blood pressure (DBP) in mmHg HIV.D.DE16 Blood pressure cannot be taken If the client's blood pressure cannot be taken, this should be indicated here. Otherwise, blood pressure should be measured. HIV.D.DE17 Signs of serious illness Signs that may indicate the client has a serious illness and needs triage or an emergency referral HIV.D.DE18 Fever of 39 C or greater Client has a fever with a measured temperature of 102.2 F/39 C or greater HIV.D.DE19 Tachycardia Heart rate above a rate per minute based on age HIV.D.DE20 Tachypnea Respiratory rate above a number of breaths per minute based on age HIV.D.DE21 Unable to walk unaided Client is not able to walk without help HIV.D.DE22 Lethargy Client is exhibiting lethargy as a sign of serious illness HIV.D.DE23 Unconsciousness Client is currently unconscious HIV.D.DE24 Convulsions Client is convulsing HIV.D.DE25 Unable to drink Child is not able to drink HIV.D.DE26 Unable to breastfeed Infant or child is not able to breastfeed HIV.D.DE27 Repeated vomiting Client is repeatedly vomiting HIV.D.DE28 Headache Client is exhibiting a headache HIV.D.DE29 Other sign of serious illness Client is exhibiting another sign of a serious illness HIV.D.DE30 Other sign of serious illness (specify) Client is exhibiting another sign of a serious illness (specify) HIV.D.DE31 Currently pregnant Client is currently pregnant HIV.D.DE32 Breastfeeding Client is giving infant breast milk HIV.D.DE33 Number of pregnancies (gravida) Total number of times the woman has been pregnant (gravida) HIV.D.DE34 Number of miscarriages and/or abortions Total number of pregnancies lost/ended due to miscarriages and/or abortions before 22 weeks/5 months HIV.D.DE35 Number of live births Total number of live births after 22 weeks HIV.D.DE36 Parity Calculated parity is the total number of live and stillbirths HIV.D.DE37 Serodiscordant partner Client's HIV status is different from a current partner's HIV status HIV.D.DE38 On ART Client is currently taking ART HIV.D.DE39 ART start date The date on which the client started or restarted ART HIV.D.DE40 Stopped ART Client stopped taking ART HIV.D.DE41 Date ART stopped Date on which client stopped ART HIV.D.DE42 Established on ART Is the client successfully established on ART? HIV.D.DE43 ART start type Whether the client is ART naive or is restarting ART HIV.D.DE44 First-time user of ART Client is ART naive, having never taken ART to treat HIV before HIV.D.DE45 Restarting ART Client is restarting ART after stopping treatment for any reason HIV.D.DE46 Date of initiation on ART The date on which the client was first initiated on ART HIV.D.DE47 Time on ART Time the client has been on ART since starting or restarting it in years and months HIV.D.DE48 Date(s) ART restarted Date(s) client restarted ART after stopping (intentionally interrupting) for any number of reasons (see 'Reason ART stopped') HIV.D.DE49 ART cohort Month and year client originally started ART (documented) at a health facility in the system. The cohort is a group of patients who started ART in the same month (or quarter) and year, whose status is followed over time, using the ART register. HIV.D.DE50 Transfer in for HIV care Client is transferring in with records or known ART drugs and ART start date HIV.D.DE51 Date of transfer in Date client presented at facility (with transfer/referral slip) from another facility (and on ART) within the system HIV.D.DE52 Facility transferred from Name of health facility client was transferred from HIV.D.DE53 Date enrolled in HIV care Date client first enrols in HIV care at the facility. Begins when a person with a confirmed HIV diagnosis presents to a facility where HIV care is provided and a medical record, patient card, file or chart is opened for the first time. This could be at an HIV care/ART, MNCH or TB clinic. HIV.D.DE54 Age at enrolment Client's age when the client was enrolled in ART care HIV.D.DE55 Facility where client first enrolled in HIV care Facility where the client first enrolled in HIV care HIV.D.DE56 Antiretroviral (ARV) drugs received prior to enrolment Whether or not the client received ARV drugs prior to enrolling into HIV care HIV.D.DE57 No prior ARVs Client received no prior ARVs HIV.D.DE58 Received ARVs prior without records/documentation Client received ARVs prior without records/documentation HIV.D.DE59 Received ARVs during pregnancy or breastfeeding Client received ARVs during pregnancy or breastfeeding HIV.D.DE60 Received ARVs for PEP or PrEP Client received ARVs for post-exposure prophylaxis (PEP) or PrEP HIV.D.DE61 ARV prophylaxis for an HIV-exposed infant Client received ARV prophylaxis for an HIV-exposed infant HIV.D.DE62 Date ARV drugs received prior to enrolment Date ARV drugs were started prior to enrolment into HIV care/ART HIV.D.DE63 Location ARV drugs received prior to enrolment Health facility (or other location) where ARV drugs were received prior to enrolment into HIV care/ART HIV.D.DE64 ARV drug regimen received prior to enrolment ARV drug regimen received prior to enrolment into HIV care/ART HIV.D.DE65 Existing chronic health conditions Does the client have any current chronic health conditions or problems? HIV.D.DE66 No chronic or past health conditions Client does not have chronic diseases or any past health conditions HIV.D.DE67 Don't know Client does not know whether she has any chronic diseases or past health conditions HIV.D.DE68 Diabetes other or unspecified Client has diabetes of other or unspecified type HIV.D.DE69 Diabetes pre-existing type 1 Client has pre-existing type 1 diabetes mellitus HIV.D.DE70 Diabetes pre-existing type 2 Client has pre-existing type 2 diabetes mellitus HIV.D.DE71 Hypertension High blood pressure HIV.D.DE72 Other Other health conditions not included in the list HIV.D.DE73 Other (specify) Other health conditions not included in the list (specify) HIV.D.DE74 Original first-line ART regimen Original full, first-line ARV drug regimen patient started on at this facility HIV.D.DE75 Current ART regimen The current ART regimen the client is taking HIV.D.DE76 Current ART regimen start date The date on which the client started taking the current ART regimen HIV.D.DE77 Preferred first-line ART regimen The preferred first-line ART regimen for the client according to WHO (or national) guidelines HIV.D.DE78 Alternative first-line ART regimen The alternative first-line ART regimen for the client according to WHO (or national) guidelines HIV.D.DE79 First-line ART regimen under special circumstances The first-line ART regimen for the client under special circumstances according to WHO (or national) guidelines HIV.D.DE80 Preferred second-line ART regimen The preferred second-line ART regimen for the client according to WHO (or national) guidelines HIV.D.DE81 Alternative second-line ART regimen The alternative second-line ART regimen for the client according to WHO (or national) guidelines HIV.D.DE82 Optimal regimen for transition The optimal regimen for transition to DTG-based regimens for children established on ART HIV.D.DE83 Current ART regimen (first-, second-, or third-line) ART regimen for treating clients living with HIV, based on national guidance HIV.D.DE84 First-line ART regimen for adults and adolescents First-line ART regimen for adults and adolescents living with HIV HIV.D.DE85 First-line ART regimen for children First-line ART regimen for children living with HIV HIV.D.DE86 First-line ART regimen for neonates First-line ART regimen for neonates living with HIV HIV.D.DE87 Second-line ART regimen for adults and adolescents Second-line ART regimen for adults and adolescents living with HIV HIV.D.DE88 Second-line ART regimen for children Second-line ART regimen for children living with HIV HIV.D.DE89 Third-line ART regimen Third-line ART regimen for people living with HIV (Not defined by WHO. National programmes should develop policies for third-line ART) HIV.D.DE90 ART regimen List of ART regimens HIV.D.DE91 ABC + 3TC + ATV/r Regimen containing abacavir, lamivudine, and atazanavir/ritonavir HIV.D.DE92 ABC + 3TC + DTG Regimen containing abacavir, lamivudine, and dolutegravir HIV.D.DE93 ABC + 3TC + EFV Regimen containing abacavir, lamivudine, and efavarinez HIV.D.DE94 ABC + 3TC + LPV/r Regimen containing abacavir, lamivudine, and lopinavir/ritonavir HIV.D.DE95 ABC + 3TC + NVP Regimen containing abacavir, lamivudine, and nevirapine HIV.D.DE96 ABC + 3TC + RAL Regimen containing abacavir, lamivudine, and raltegravir HIV.D.DE97 AZT + 3TC + ATV/r Regimen containing zidovudine, lamivudine, and atazanavir/ritonavir HIV.D.DE98 AZT + 3TC + DRV/r Regimen containing zidovudine, lamivudine, and darunavir/ritonavir HIV.D.DE99 AZT + 3TC + DTG Regimen containing zidovudine, lamivudine, and dolutegravir HIV.D.DE100 AZT + 3TC + EFV Regimen containing zidovudine, lamivudine, and efavirenz HIV.D.DE101 AZT + 3TC + EFV 600 mg Regimen containing zidovudine, lamivudine, and efavirenz 600 mg HIV.D.DE102 AZT + 3TC + LPV/r Regimen containing zidovudine, lamivudine, and lopinavir/ritonavir HIV.D.DE103 AZT + 3TC + NVP Regimen containing zidovudine, lamivudine, and nevirapine HIV.D.DE104 AZT + 3TC + RAL Regimen containing zidovudine, lamivudine, and raltegravir HIV.D.DE105 TAF + 3TC + DTG Regimen containing tenofovir alafenamide, lamivudine, and dolutegravir HIV.D.DE106 TAF + FTC + DTG Regimen containing tenofovir alafenamide, emtricitabine, and dolutegravir HIV.D.DE107 TDF + 3TC + ATV/r Regimen containing tenofovir disoproxil fumarate, lamivudine, and atazanavir/ritonavir HIV.D.DE108 TDF + 3TC + DRV/r Regimen containing tenofovir disoproxil fumarate, lamivudine, and darunavir/ritonavir HIV.D.DE109 TDF + 3TC + DTG Regimen containing tenofovir disoproxil fumarate, lamivudine, and dolutegravir HIV.D.DE110 TDF + 3TC + EFV Regimen containing tenofovir disoproxil fumarate, lamivudine, and efavirenz HIV.D.DE111 TDF + 3TC + EFV 400 mg Regimen containing tenofovir disoproxil fumarate, lamivudine, and efavirenz (400 mg) HIV.D.DE112 TDF + 3TC + EFV 600 mg Regimen containing tenofovir disoproxil fumarate, lamivudine, and efavirenz (600 mg) HIV.D.DE113 TDF + 3TC + LPV/r Regimen containing tenofovir disoproxil fumarate, lamivudine, and lopinavir/ritonavir HIV.D.DE114 TDF + 3TC + NVP Regimen containing tenofovir disoproxil fumarate, lamivudine, and nevirapine HIV.D.DE115 TDF + 3TC + PI/r Regimen containing tenofovir disoproxil fumarate, lamivudine, and a boosted protease inhibitor HIV.D.DE116 TDF + 3TC + RAL Regimen containing tenofovir disoproxil fumarate, lamivudine, and raltegravir HIV.D.DE117 TDF + FTC + ATV/r Regimen containing tenofovir disoproxil fumarate, emtricitabine, and atazanavir/ritonavir HIV.D.DE118 TDF + FTC + DRV/r Regimen containing tenofovir disoproxil fumarate, emtricitabine, and darunavir/ritonavir HIV.D.DE119 TDF + FTC + DTG Regimen containing tenofovir disoproxil fumarate, emtricitabine, and dolutegravir HIV.D.DE120 TDF + FTC + EFV Regimen containing tenofovir disoproxil fumarate, emtricitabine, and efavirenz HIV.D.DE121 TDF + FTC + EFV 600 mg Regimen containing tenofovir disoproxil fumarate, emtricitabine, and efavirenz (600 mg) HIV.D.DE122 TDF + FTC + LPV/r Regimen containing tenofovir disoproxil fumarate, emtricitabine, and lopinavir/ritonavir HIV.D.DE123 TDF + FTC + NVP Regimen containing tenofovir disoproxil fumarate, emtricitabine, and nevirapine HIV.D.DE124 TDF + FTC + PI/r Regimen containing tenofovir disoproxil fumarate, emtricitabine, and a boosted protease inhibitor HIV.D.DE125 TDF + FTC + RAL Regimen containing tenofovir disoproxil fumarate, emtricitabine, and raltegravir HIV.D.DE126 Other Other regimen based upon WHO recommendations HIV.D.DE127 Other (specify) Other regimen based upon WHO recommendations (specify) HIV.D.DE128 ART regimen composition Drug composition of client's current ART regimen HIV.D.DE129 ABC Treated with abacavir (ABC) HIV.D.DE130 FTC Treated with emtricitabine (FTC) HIV.D.DE131 3TC Treated with lamivudine (3TC) HIV.D.DE132 AZT Treated with zidovudine (AZT) HIV.D.DE133 DDI Treated with didanosine (DDI) HIV.D.DE134 D4T Treated with stavudine (D4T) HIV.D.DE135 TDF Treated with tenofovir (TDF) HIV.D.DE136 EFV Treated with efavirenz (EFV) HIV.D.DE137 ETV Treated with etravirine (ETV) HIV.D.DE138 NVP Treated with nevirapine (NVP) HIV.D.DE139 RIL Treated with rilpivirine (RIL) HIV.D.DE140 ATV/r Treated with atazanavir/ritonavir (ATV/r) HIV.D.DE141 LPV/r Treated with lopinavir/ritonavir (LPV/r) HIV.D.DE142 DRV/r Treated with darunavir/ritonavir (DRV/r) HIV.D.DE143 RTV Treated with ritonavir (RTV) HIV.D.DE144 DTG Treated with dolutegravir (DTG) HIV.D.DE145 RAL Treated with raltegravir (RAL) HIV.D.DE146 ART regimen drug class Drug class of current ART regimen HIV.D.DE147 NRTI Treated with nucleoside reverse transcriptase inhibitors (NRTIs) HIV.D.DE148 NtRTI Treated with nucleotide reverse-transcriptase inhibitors (NtRTIs) HIV.D.DE149 NNRTI Treated with non-nucleoside reverse transcriptase inhibitors (NNRTIs) HIV.D.DE150 PI Treated with protease inhibitors (PIs) HIV.D.DE151 INSTI Treated with integrase strand transfer inhibitors (INSTIs) HIV.D.DE152 Prevention services offered and referrals Offer or refer for prevention services HIV.D.DE153 Offer male and female condoms and condom-compatible lubricants Offer male and female condoms and condom-compatible lubricants HIV.D.DE154 Harm reduction for people who inject drugs Offer or refer people who inject drugs to harm reduction services (needle and syringe programmes, opioid substitution therapy, other drug-dependence treatment and opioid overdose prevention and management) HIV.D.DE155 Behavioural interventions to support risk reduction Offer or refer to services for behavioural interventions to support risk reduction, particularly for people with HIV and members of key populations HIV.D.DE156 Sexual and reproductive health integrated services Offer or refer to sexual and reproductive health services HIV.D.DE157 Contraception and family planning Offer contraception and family planning services HIV.D.DE158 Check pregnancy status Check woman's pregnancy status HIV.D.DE159 Prevention of mother-to-child transmission Offer prevention of mother-to-child transmission services (counselling) HIV.D.DE160 STI testing and treatment Offer STI testing and treatment services HIV.D.DE161 HBsAg test date Date client was tested for hepatitis B virus (HBV) HIV.D.DE162 HBsAg test result Hepatitis B virus test result (HBsAg) HIV.D.DE163 Positive HBsAg test result was positive HIV.D.DE164 Negative HBsAg test result was negative HIV.D.DE165 Indeterminate HBsAg test result was indeterminate HIV.D.DE166 Date HBV test result returned to client Date HBV test result (HBsAG) was returned to client HIV.D.DE167 HBV treatment (TDF) start date Date when client started treatment (TDF) for hepatitis B virus (HBV) HIV.D.DE168 HBV treatment regimen prescribed Hepatitis B virus treatment regimen prescribed HIV.D.DE169 HCV test date Date client was tested for hepatitis C virus (HCV antibody, HCV RNA or HCV core antigen) HIV.D.DE170 HCV test result Hepatitis C virus test result (HCV antibody, HCV RNA or HCV core antigen) HIV.D.DE171 Positive HCV test result was positive HIV.D.DE172 Negative HCV test result was negative HIV.D.DE173 Indeterminate HCV test result was indeterminate HIV.D.DE174 Date HCV test result returned to client Date HCV test result was returned to client HIV.D.DE175 HCV treatment start date Date when client started treatment for hepatitis C virus (HCV) HIV.D.DE176 HCV treatment completion date Date when client completed treatment for hepatitis C virus (HCV) HIV.D.DE177 HCV treatment regimen prescribed Hepatitis C virus treatment regimen prescribed HIV.D.DE178 HCV viral load test date Hepatitis C viral load test date HIV.D.DE179 HCV viral load test result Hepatitis C viral load test result (qualitative) HIV.D.DE180 Detected HCV was detected HIV.D.DE181 Not detected HCV was not detected HIV.D.DE182 HCV medicine type Type of medicine client is prescribed HIV.D.DE183 Interferon Client is prescribed interferon HIV.D.DE184 Direct acting antivirals Client is prescribed direct acting antivirals HIV.D.DE185 Currently on TDF-based ART Client is currently on TDF-based ART regimen HIV.D.DE186 HIV clinical stage WHO clinical stage of client based on signs and symptoms. WHO clinical staging is a way to categorize HIV disease severity based on new or recurrent clinical events. There are 4 WHO clinical stages that range from mild symptoms (WHO clinical stage 1) to severe symptoms (WHO clinical stage 4). HIV.D.DE187 WHO HIV clinical stage 1 Client is currently assessed to be at a clinical stage 1, based on clinical assessment and diagnostics HIV.D.DE188 WHO HIV clinical stage 2 Client is currently assessed to be at a clinical stage 2, based on clinical assessment and diagnostics HIV.D.DE189 WHO HIV clinical stage 3 Client is currently assessed to be at a clinical stage 3, based on clinical assessment and diagnostics HIV.D.DE190 WHO HIV clinical stage 4 Client is currently assessed to be at a clinical stage 4, based on clinical assessment and diagnostics HIV.D.DE191 Number of missed doses Number of doses of antiretroviral therapy (ART) the client missed since the last visit, used for monitoring adherence HIV.D.DE192 Received viral load test result Client received results from viral load test HIV.D.DE193 Date viral load test results received by client The date on which the client received results from viral load test HIV.D.DE194 Date of viral load sample collection Date and time when the sample was collected to test the client's HIV viral load HIV.D.DE195 Date of scheduled review of viral load test results Expected date when client's viral load test results will be returned and reviewed HIV.D.DE196 Date of ART interruption Date of client's ART interruption (ART stop or missed drug pick-up) HIV.D.DE197 Reason(s) for adherence problem Reason why client was not adherent HIV.D.DE198 Forgot Client reported not being adherent because they forgot HIV.D.DE199 Toxicity/side effects Client reported not being adherent because of toxicity/side effects HIV.D.DE200 Busy Client reported not being adherent because they were busy HIV.D.DE201 Change of routine Client reported not being adherent because of a change of routine HIV.D.DE202 Travel cost Client reported not being adherent because of travel cost HIV.D.DE203 Distance to clinic Client reported not being adherent because of distance to clinic HIV.D.DE204 Client lost/ran out of pills Client reported not being adherent because client lost/ran out of pills HIV.D.DE205 Stock-out Client reported not being adherent because of a stock-out HIV.D.DE206 Too ill Client reported not being adherent because of being too ill HIV.D.DE207 Pill burden Client reported not being adherent because of the pill burden HIV.D.DE208 Felt well Client reported not being adherent because they felt well HIV.D.DE209 Depression Client reported not being adherent because of depression HIV.D.DE210 Alcohol use Client reported not being adherent because of alcohol use HIV.D.DE211 Substance use Client reported not being adherent because of substance use (i.e. drugs) HIV.D.DE212 Stigma/disclosure concerns Client reported not being adherent because of stigma/disclosure concerns HIV.D.DE213 Lack of food Client reported not being adherent because of a lack of food HIV.D.DE214 Poor palatability Client reported not being adherent because of poor palatability HIV.D.DE215 Other reason for nonadherence Client reported not being adherent because of other reason for nonadherence HIV.D.DE216 Other reason for nonadherence (specify) Client reported not being adherent because of other reason for nonadherence (specify) HIV.D.DE217 Reason ART stopped Reason client intentionally stopped ART HIV.D.DE218 Toxicity/side effects Client stopped ART because of toxicity/side effects HIV.D.DE219 Severe illness, hospitalization Client stopped ART because of severe illness, hospitalization HIV.D.DE220 Drugs out of stock Client stopped ART because drugs were out of stock HIV.D.DE221 Client lacks finances Client stopped ART because of lack of finances HIV.D.DE222 Excluded HIV infection in infant Client stopped ART because HIV infection in infant was excluded HIV.D.DE223 Other reason for stopping ART Client stopped ART because of other reason HIV.D.DE224 Other reason for stopping ART (specify) Client stopped ART because of other reason (specify) HIV.D.DE225 Treatment failure ART treatment failure HIV.D.DE226 Clinical failure New or recurrent clinical event indicating severe immunodeficiency in adults or advanced or severe immunodeficiency in children HIV.D.DE227 Immunological failure CD4 count at or below 250 cells/mm3 following clinical failure HIV.D.DE228 Virological failure The inability to achieve or maintain viral suppression below a certain threshold indicated by viral load above 1000 copies/mL based on two consecutive viral load measurements in 3 months, with adherence support following the first viral load test HIV.D.DE229 General care activities recommended General care activities to be performed during the care visit HIV.D.DE230 Determine WHO clinical stage Determine WHO clinical stage based on past and current HIV-related conditions HIV.D.DE231 Determine if advanced disease Determine if client is in an advanced stage of HIV, as a special package of services may be provided HIV.D.DE232 Prepare for ART Prepare client new to ART HIV.D.DE233 Prepare, assess and support adherence Prepare, assess and support adherence HIV.D.DE234 Manage current medications Manage current medications being taken by the client HIV.D.DE235 Check pregnancy status Check woman's pregnancy status HIV.D.DE236 Provide family planning and contraception Provide family planning and contraception counselling HIV.D.DE237 Support disclosure and partner notification Support disclosure and partner notification HIV.D.DE238 Counsel on risk reduction and prevention Counsel on risk reduction and combination HIV prevention approaches HIV.D.DE239 Assess, prevent and manage noncommunicable diseases Assess, prevent and manage noncommunicable diseases HIV.D.DE240 Screen for and manage mental health problems Screen for and manage mental health problems HIV.D.DE241 Screen for and manage and substance use issues Screen for and manage and substance use issues HIV.D.DE242 Provide psychosocial counselling and support Provide psychosocial counselling and support HIV.D.DE243 Manage pain and symptoms Manage pain and symptoms client is experiencing HIV.D.DE244 Conduct a nutritional assessment and counsel on nutrition Conduct a nutritional assessment and counsel on nutrition HIV.D.DE245 Conduct a growth and development assessment Conduct a growth and development assessment HIV.D.DE246 Provide support on infant and child feeding Provide support on infant and child feeding to mother or care giver HIV.D.DE247 Preventing and treating coinfections Coinfection prevention and treatment activities performed during the care visit HIV.D.DE248 Provide co-trimoxazole preventive therapy (CPT) Provide co-trimoxazole prophylaxis for clients new to ART or identified as taking it HIV.D.DE249 Intensified TB case finding and linkage to TB treatment Offer or refer for intensified TB case finding and linkage to TB treatment HIV.D.DE250 Provide isoniazid preventive therapy Provide isoniazid preventive therapy HIV.D.DE251 Screen for cryptococcal infection and fungal prophylaxis Screen for cryptococcal infection and fungal prophylaxis HIV.D.DE252 Screen for hepatitis B Screen for hepatitis B virus HIV.D.DE253 Screen for hepatitis C Screen for hepatitis C virus HIV.D.DE254 Prevent malaria Prevent malaria including with insecticide-treated bed-nets and prophylaxis HIV.D.DE255 Screen for STIs Screen for STIs HIV.D.DE256 Prevent and screen for cervical cancer Prevent and screen for cervical cancer HIV.D.DE257 Anal cancer screening (for men who have sex with men) Offer anal cancer screening (for men who have sex with men) HIV.D.DE258 Assessment and provision of vaccinations Assessment and provision of vaccinations, such as for people from key populations, pregnant women and infants; and, where appropriate, tetanus vaccination for adolescent boys and men receiving VMMC HIV.D.DE259 Risk factors, comorbidities and coinfections signs and symptoms Signs and symptoms of opportunistic infections or other comorbidities experienced by client HIV.D.DE260 Oral candidiasis Client's comorbidities or coinfections or symptoms of these include oral candidiasis (after the first 6-8 weeks of life) HIV.D.DE261 Vaginal candidiasis Client's comorbidities or coinfections or symptoms of these include vaginal candidiasis HIV.D.DE262 Cough Client's comorbidities or coinfections or symptoms of these include cough HIV.D.DE263 Prolonged fever Client's comorbidities or coinfections or symptoms of these include prolonged fever HIV.D.DE264 Night sweats Client's comorbidities or coinfections or symptoms of these include night sweats HIV.D.DE265 Weight loss Client's comorbidities or coinfections or symptoms of these include weight loss HIV.D.DE266 Difficulty breathing Client's comorbidities or coinfections or symptoms of these include difficulty breathing HIV.D.DE267 Pneumonia Client's comorbidities or coinfections or symptoms of these include pneumonia HIV.D.DE268 Urethral discharge Client's comorbidities or coinfections or symptoms of these include urethral discharge HIV.D.DE269 Syphilis Client's comorbidities or coinfections or symptoms of these include syphilis HIV.D.DE270 Pelvic inflammatory disease Client's comorbidities or coinfections or symptoms of these include pelvic inflammatory disease HIV.D.DE271 Ulcers - skin Client's comorbidities or coinfections or symptoms of these include ulcers - skin HIV.D.DE272 Ulcers - mouth or other Client's comorbidities or coinfections or symptoms of these include ulcers - mouth or other HIV.D.DE273 Ulcers - male genital Client's comorbidities or coinfections or symptoms of these include ulcers - male genital HIV.D.DE274 Vaginal discharge Client's comorbidities or coinfections or symptoms of these include vaginal discharge HIV.D.DE275 Malaria Client's comorbidities or coinfections or symptoms of these include malaria HIV.D.DE276 Chronic obstructive pulmonary disease Client's comorbidities or coinfections or symptoms of these include chronic obstructive pulmonary disease HIV.D.DE277 Hypertension Client's comorbidities or coinfections or symptoms of these include hypertension HIV.D.DE278 Diabetes Client's comorbidities or coinfections or symptoms of these include diabetes HIV.D.DE279 Gestational diabetes Client's comorbidities or coinfections or symptoms of these include gestational diabetes HIV.D.DE280 Mental health disorders Client's comorbidities or coinfections or symptoms of these include mental health disorders (including depression, dementia, encephalitis, seizures) HIV.D.DE281 Diarrhoea or abdominal pain Client's comorbidities or coinfections or symptoms of these include diarrhoea or abdominal pain HIV.D.DE282 Presumptive TB Client's comorbidities or coinfections or symptoms of these include presumptive TB HIV.D.DE283 Severe or complicated malnutrition Client's comorbidities or coinfections or symptoms of these include severe or complicated malnutrition HIV.D.DE284 Poor growth or development Client's comorbidities or coinfections or symptoms of these include poor growth or development HIV.D.DE285 Oedema Client's comorbidities or coinfections or symptoms of these include oedema HIV.D.DE286 Previously treated for TB Client has previously been treated for tuberculosis (TB) HIV.D.DE287 Other Other comorbidities or coinfection signs or symptoms HIV.D.DE288 Other (specify) Other comorbidities or coinfection signs or symptoms (specify) HIV.D.DE289 WHO HIV clinical stage condition or symptom New or recurrent clinical events used to categorize HIV disease severity based at baseline and follow up HIV.D.DE290 Asymptomatic No HIV-related symptoms reported and no clinical signs on examination HIV.D.DE291 Persistent generalized lymphadenopathy Persistent enlarged lymph nodes >1 cm at two or more non-contiguous sites (excluding inguinal) without known cause HIV.D.DE292 Moderate unexplained weight loss Moderate unexplained weight loss (<10% of presumed or measured body weight) HIV.D.DE293 Recurrent respiratory tract infections Client's symptoms include recurrent respiratory tract infections including sinusitis, tonsillitis, otitis media or pharyngitis HIV.D.DE294 Unexplained persistent hepatosplenomegaly Client's symptoms include unexplained persistent hepatosplenomegaly HIV.D.DE295 Herpes zoster Client's symptoms include herpes zoster HIV.D.DE296 Angular cheilitis Client's symptoms include angular cheilitis HIV.D.DE297 Linear gingival erythema Client's symptoms include linear gingival erythema HIV.D.DE298 Recurrent oral ulceration Client's symptoms include recurrent oral ulceration HIV.D.DE299 Papular pruritic eruption Client's symptoms include papular pruritic eruption HIV.D.DE300 Fungal nail infections Client's symptoms include fungal nail infections HIV.D.DE301 Seborrhoeic dermatitis Client's symptoms include seborrhoeic dermatitis HIV.D.DE302 Extensive wart virus infection Client's symptoms include extensive wart virus infection HIV.D.DE303 Extensive molluscum contagiosum Client's symptoms include extensive molluscum contagiosum HIV.D.DE304 Unexplained persistent parotid enlargement Client's symptoms include unexplained persistent parotid enlargement HIV.D.DE305 Unexplained severe weight loss in adults Unexplained severe weight loss (>10% of presumed or measured body weight) HIV.D.DE306 Unexplained moderate malnutrition not adequately responding to standard therapy Defined as weight-for-height < - 2 z-score or mid-upper arm circumference 115 mm to <125 mm. For children younger than five years of age: stunting is defined as severe acute malnutrition - either weight for height < -3 z-score or mid-upper arm circumference <115 mm or the presence of oedema. HIV.D.DE307 Unexplained chronic diarrhoea for longer than 1 month Client's symptoms include unexplained chronic diarrhoea for longer than 1 month HIV.D.DE308 Unexplained persistent diarrhoea (14 days or more) Client's symptoms include unexplained persistent diarrhoea (14 days or more) HIV.D.DE309 Unexplained persistent fever (above 37.5 C, intermittent or constant, for longer than one 1 month) Client's symptoms include unexplained persistent fever (above 37.5 C, intermittent or constant, for longer than one 1 month) HIV.D.DE310 Persistent oral candidiasis Client's symptoms include persistent oral candidiasis HIV.D.DE311 Oral hairy leukoplakia Client has fine white small linear or corrugated lesions on lateral borders of the tongue that do not scrape off HIV.D.DE312 Pulmonary TB Client's symptoms include pulmonary TB HIV.D.DE313 Lymph node TB Client's symptoms include lymph node TB HIV.D.DE314 Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, meningitis, bacteraemia) Client's symptoms include severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, meningitis, bacteraemia) HIV.D.DE315 Severe recurrent bacterial pneumonia Client's symptoms include severe recurrent bacterial pneumonia HIV.D.DE316 Acute necrotizing ulcerative stomatitis Client's symptoms include acute necrotizing ulcerative stomatitis HIV.D.DE317 Acute necrotizing ulcerative gingivitis Client's symptoms include acute necrotizing ulcerative gingivitis HIV.D.DE318 Acute necrotizing ulcerative periodontitis Client's symptoms include acute necrotizing ulcerative periodontitis HIV.D.DE319 Unexplained anaemia (<8 g/dL) Client's symptoms include unexplained anaemia (<8 g/dL) HIV.D.DE320 Neutropaenia (<0.5 x 10^9/L) Client's symptoms include neutropaenia (<0.5 x 10^9/L) HIV.D.DE321 Chronic thrombocytopaenia (<50 x 10^9/L) Client's symptoms include chronic thrombocytopaenia (<50 x 10^9/L) HIV.D.DE322 Symptomatic lymphoid interstitial pneumonitis Client's symptoms include symptomatic lymphoid interstitial pneumonitis HIV.D.DE323 Chronic HIV-associated lung disease, including bronchiectasis Client's symptoms include chronic HIV-associated lung disease, including bronchiectasis HIV.D.DE324 HIV wasting syndrome Unexplained involuntary weight loss (>10% baseline body weight), with obvious wasting or body mass index <18.5; PLUS EITHER unexplained chronic reported for longer than one month; OR reports of fever or night sweats for more than one month without other cause and lack of response to antibiotics or antimalarial agents; malaria must be excluded in malarious areas. HIV.D.DE325 Unexplained severe wasting not responding to standard therapy Client has unexplained severe wasting not responding to standard therapy . For under 5 years old, defined as weight-for-height < -3 z-score HIV.D.DE326 Unexplained stunting not responding to standard therapy Client has unexplained stunting not responding to standard therapy . For under 5 years old, defined as length-for- age/height-for-age < -2 z-score HIV.D.DE327 Unexplained severe malnutrition not responding to standard therapy Client has unexplained severe malnutrition not responding to standard therapy . For under 5 years old, weight for height < -3 z-score or mid-upper arm circumference <115 mm or the presence of oedema HIV.D.DE328 Pneumocystis (jirovecii) pneumonia Client's symptoms include pneumocystis (jirovecii) pneumonia HIV.D.DE329 Recurrent severe bacterial pneumonia Client's symptoms include recurrent severe bacterial pneumonia HIV.D.DE330 Recurrent severe bacterial infections (such as empyema, pyomyositis, bone or joint infection, meningitis, but excluding pneumonia) Client's symptoms include recurrent severe bacterial infections (such as empyema, pyomyositis, bone or joint infection, meningitis, but excluding pneumonia) HIV.D.DE331 Empyema Client's symptoms include recurrent empyema HIV.D.DE332 Pyomyositis Client's symptoms include recurrent pyomyositis HIV.D.DE333 Bone or joint infection Client's symptoms include recurrent bone or joint infections HIV.D.DE334 Meningitis Client's symptoms include recurrent meningitis HIV.D.DE335 Chronic herpes simplex infection (orolabial or cutaneous of more than 1 month duration or visceral at any site) Client's symptoms include chronic herpes simplex infection (orolabial or cutaneous of more than 1 month duration or visceral at any site) HIV.D.DE336 Chronic herpes simplex infection (orolabial, genital or anorectal of more than 1 month in duration or visceral at any site) Client's symptoms include chronic herpes simplex infection (orolabial, genital or anorectal of more than one month in duration or visceral at any site) HIV.D.DE337 Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) Client's symptoms include oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) HIV.D.DE338 Extrapulmonary TB Client's symptoms include extrapulmonary tuberculosis HIV.D.DE339 Kaposi sarcoma Client's symptoms include Kaposi sarcoma HIV.D.DE340 Cytomegalovirus infection (retinitis or infection of other organs) Client's symptoms include cytomegalovirus infection (retinitis or infection of other organs) HIV.D.DE341 Central nervous system toxoplasmosis Client's symptoms include central nervous system toxoplasmosis HIV.D.DE342 HIV encephalopathy Client's symptoms include HIV encephalopathy HIV.D.DE343 Extrapulmonary cryptococcosis, including meningitis Client's symptoms include extrapulmonary cryptococcosis, including meningitis HIV.D.DE344 Disseminated nontuberculous mycobacterial infection Client's symptoms include disseminated nontuberculous mycobacterial infection HIV.D.DE345 Progressive multifocal leukoencephalopathy Client's symptoms include progressive multifocal leukoencephalopathy HIV.D.DE346 Chronic cryptosporidiosis Client's symptoms include chronic cryptosporidiosis HIV.D.DE347 Chronic cryptosporidiosis (with diarrhoea) Client's symptoms include chronic cryptosporidiosis (with diarrhoea) HIV.D.DE348 Chronic isosporiasis Client's symptoms include chronic isosporiasis HIV.D.DE349 Disseminated mycosis (extrapulmonary histoplasmosis, coccidioidomycosis) Client's symptoms include disseminated mycosis (extrapulmonary histoplasmosis, coccidioidomycosis) HIV.D.DE350 Disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidioidomycosis, penicilliosis) Client's symptoms include disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidioidomycosis, penicilliosis) HIV.D.DE351 Cerebral lymphoma Client's symptoms include cerebral lymphoma HIV.D.DE352 B-cell non-Hodgkin lymphoma Client's symptoms include b-cell non-Hodgkin lymphoma HIV.D.DE353 HIV-associated nephropathy or cardiomyopathy Client's symptoms include HIV- associated nephropathy or cardiomyopathy HIV.D.DE354 Recurrent septicaemia (including nontyphoidal Salmonella) Client's symptoms include recurrent bacteraemia (septicaemia) (including nontyphoidal salmonella) HIV.D.DE355 Invasive cervical carcinoma Client's symptoms include invasive cervical carcinoma HIV.D.DE356 Atypical disseminated leishmaniasis Client's symptoms include atypical disseminated leishmaniasis HIV.D.DE357 Neutropenia Client's symptoms include neutropenia, an abnormally low count of a type of white blood cell (neutrophils) HIV.D.DE358 Clinical stage at start of ART WHO clinical stage of client based on signs and symptoms at start of ART HIV.D.DE359 WHO clinical stage 1 Client is assessed to be at a clinical stage of 1 at the time of starting ART, based on clinical assessment and diagnostics HIV.D.DE360 WHO clinical stage 2 Client is assessed to be at a clinical stage of 2 at the time of starting ART, based on clinical assessment and diagnostics HIV.D.DE361 WHO clinical stage 3 Client is assessed to be at a clinical stage of 3 at the time of starting ART, based on clinical assessment and diagnostics HIV.D.DE362 WHO clinical stage 4 Client is assessed to be at a clinical stage of 4 at the time of starting ART, based on clinical assessment and diagnostics HIV.D.DE363 Date of clinical status change Date on which the client's WHO HIV clinical stage changed, including the date when the client's stage is first determined HIV.D.DE364 CD4 count CD4 cell count in cells/mm^3 HIV.D.DE365 CD4 cell percentage CD4 cell percentage HIV.D.DE366 Date of CD4 count test Date and time when CD4 count test was conducted HIV.D.DE367 Baseline CD4 count CD4 count performed at HIV diagnosis HIV.D.DE368 Date of baseline CD4 count test Date and time when baseline CD4 count test was conducted HIV.D.DE369 Late ART initiation Client had late ART initiation. That is, the client's first CD4 count from baseline CD4 test performed (such as at HIV diagnosis) was a count of <200 cells/mm3 HIV.D.DE370 Reasons for delayed ART initiation Reason why ART was not initiated at diagnosis or within 7 days of diagnosis HIV.D.DE371 Patient self-reported as not ready/willing Client did not initiate ART at diagnosis or within 7 days of diagnosis because client self-reported as not ready/willing HIV.D.DE372 Not completed education, support and preparation for ART Client did not initiate ART at diagnosis or within 7 days of diagnosis because client had not completed education, support and preparation for ART HIV.D.DE373 Fear of disclosure Client did not initiate ART at diagnosis or within 7 days of diagnosis because of client's fear of disclosure HIV.D.DE374 Patient lacks finances Client did not initiate ART at diagnosis or within 7 days of diagnosis because client lacks finances HIV.D.DE375 Initiated on TB treatment Client did not initiate ART at diagnosis or within 7 days of diagnosis because client initiated on TB treatment HIV.D.DE376 Patient initiated on treatment for TB meningitis Client did not initiate ART at diagnosis or within 7 days of diagnosis because client initiated on treatment for TB meningitis HIV.D.DE377 Patient diagnosed with cryptococcal meningitis Client did not initiate ART at diagnosis or within 7 days of diagnosis because client diagnosed with cryptococcal meningitis HIV.D.DE378 Patient diagnosed with histoplasmosis Client did not initiate ART at diagnosis or within 7 days of diagnosis because client diagnosed with histoplasmosis HIV.D.DE379 Patient critically/severely ill Client did not initiate ART at diagnosis or within 7 days of diagnosis because client critically/severely ill HIV.D.DE380 Other Client did not initiate ART at diagnosis or within 7 days of diagnosis because of other reason HIV.D.DE381 Other (specify) Client did not initiate ART at diagnosis or within 7 days of diagnosis because of other reason (specify) HIV.D.DE382 ART initiated within 7 days of diagnosis Client initiated ART within 7 days of diagnosis HIV.D.DE383 Time to start ART Time from HIV diagnosis to when client started ART HIV.D.DE384 Within 7 days of HIV diagnosis Client started ART within 7 days HIV.D.DE385 Within 30 days of HIV diagnosis Client started ART within 30 days of ART initiation (but over 7 days) HIV.D.DE386 Within 90 days of HIV diagnosis Client started ART within 90 days of ART initiation (but over 30 days) HIV.D.DE387 Viral load test result Result from the viral load test in number of copies/mL HIV.D.DE388 Virally suppressed The client is virally suppressed for HIV, based on the client's most recent viral load test result being less than 1000 copies/mL HIV.D.DE389 Date viral load test results received Date the viral load test result was received from the lab or completed in the facility HIV.D.DE390 Viral load suppression date Date on which the client tested as becoming virally suppressed, as indicated by a viral load test result under 1000 copies/mL HIV.D.DE391 Reason for HIV viral load test Whether the viral load is being tested for routine monitoring on a set schedule or for targeted monitoring for suspected treatment failure HIV.D.DE392 Routine viral load test Routine refers to viral load tests obtained at standard intervals following ART initiation to monitor viral load response to ART HIV.D.DE393 Targeted viral load monitoring Targeted refers to viral load tests obtained based on a specific clinical indication (such as concern about disease progression or failure to respond to ART) HIV.D.DE394 Initial viral load test The first viral load test of the client HIV.D.DE395 Follow-up viral load test after receiving enhanced adherence counselling A follow-up viral load test within 3-6 months after enhanced adherence counselling after client received a high viral load test result HIV.D.DE396 Hepatitis B test required Hepatitis B test is required HIV.D.DE397 Hepatitis C test recommended Hepatitis C test is recommended or should be considered HIV.D.DE398 Syphilis test required Syphilis test is required HIV.D.DE399 Monitoring examinations Name of examinations, test and results for any relevant investigations carried out for client HIV.D.DE400 Haemoglobin (Hb) Provider ordered a Haemoglobin (Hb) test, number in g/dL test HIV.D.DE401 Pregnancy test Provider ordered a pregnancy test for client HIV.D.DE402 Syphilis test Provider ordered a syphilis test HIV.D.DE403 Chest X-ray (CXR) Provider ordered a chest X-ray (CXR) HIV.D.DE404 Sputum or culture for TB Provider ordered sputum or culture for TB HIV.D.DE405 HBsAg test (HBV) Provider ordered an HBsAg test (HBV) test HIV.D.DE406 HIV viral load test ordered Provider ordered an HIV viral load test HIV.D.DE407 HIV viral load test scheduled Scheduled an HIV viral load test with client HIV.D.DE408 CD4 count ordered Provider ordered a CD4 cell count HIV.D.DE409 CD4 count test scheduled Scheduled a CD4 test with client HIV.D.DE410 Cryptococcal antigen test Provider ordered a cryptococcal antigen test HIV.D.DE411 Histoplasmosis antigen test Provider ordered a histoplasmosis antigen test HIV.D.DE412 Cervical cancer screening scheduled Scheduled cervical cancer screening with client HIV.D.DE413 Date of scheduled monitoring examination Date of scheduled monitoring examination HIV.D.DE414 Hepatitis C test ordered Hepatitis C test has been ordered HIV.D.DE415 Syphilis test ordered Syphilis test has been ordered HIV.D.DE416 Received viral load test results Client received results from viral load test HIV.D.DE417 Date viral load test results received by client The date on which the client received results from a viral load test HIV.D.DE418 Reason for ARV drug regimen substitution Reason why a substitution was made to the antiretroviral (ARV) drug regimen HIV.D.DE419 Toxicity/side effects A substitution was made to the regimen because of toxicity/side effects HIV.D.DE420 Drug-drug interaction A substitution was made to the regimen because of a drug-drug interaction HIV.D.DE421 Pregnancy A substitution was made to the regimen because of pregnancy HIV.D.DE422 New TB A substitution was made to the regimen because of new tuberculosis (TB) HIV.D.DE423 New drug available A substitution was made to the regimen because a new drug was available HIV.D.DE424 Drug out of stock A substitution was made to the regimen because drug was out of stock HIV.D.DE425 Other reason for regimen substitution A substitution was made for another reason HIV.D.DE426 Other reason for regimen substitution (specify) A substitution was made for another reason (specify) HIV.D.DE427 Switch to second-line ART regimen recommended A switch to second-line ART regimen is recommended HIV.D.DE428 Switch to third-line ART regimen recommended A switch to third-line ART regimen is recommended HIV.D.DE429 Regimen switch made Provider has made a regimen switch HIV.D.DE430 Reason for regimen switch Reason why a switch to a second- or third-line regimen was made HIV.D.DE431 Clinical treatment failure A switch was made to the regimen because of clinical treatment failure HIV.D.DE432 Immunological failure A switch was made to the regimen because of immunological failure HIV.D.DE433 Virological failure A switch was made to the regimen because of virological failure HIV.D.DE434 Other A switch was made to the regimen for another reason HIV.D.DE435 Other (specify) A switch was made to the regimen for another reason (specify) HIV.D.DE436 Regimen substitution recommended A drug substitution is recommended HIV.D.DE437 Dose adjustment recommended A dosage change is recommended HIV.D.DE438 Regimen substitution made Provider has made a regimen substitution HIV.D.DE439 Co-trimoxazole prophylaxis start date Date co-trimoxazole prophylaxis prescribed to client HIV.D.DE440 Co-trimoxazole prophylaxis completion date Completion date of co-trimoxazole prophylaxis prescribed to client HIV.D.DE441 Co-trimoxazole prophylaxis dosage Dose of co-trimoxazole prophylaxis prescribed to client HIV.D.DE442 Co-trimoxazole prophylaxis number of days prescribed Number of days of co-trimoxazole prophylaxis prescribed to client HIV.D.DE443 Suspicion of treatment failure or interruption Client has been on ART, but has stopped taking it or a treatment failure is suspected HIV.D.DE444 ART regimen prescribed INCLUDE VALUE SETS OF REGIMENS HIV.D.DE445 Antiretroviral toxicity Client is experiencing antiretroviral drug (ARV) toxicity HIV.D.DE446 Coinfection status at ART start Clients status of coinfections at the time when ART was initiated HIV.D.DE447 Hepatitis B Client was hepatitis B positive at the start of ART HIV.D.DE448 Hepatitis C Client was hepatitis C positive at the start of ART HIV.D.DE449 Pregnant and breastfeeding status at ART start ART status of women to prevent mother-to-child transmission HIV.D.DE450 Pregnant at ART start Client was pregnant when ART was initiated HIV.D.DE451 Postpartum at ART start Client was postpartum when ART was initiated HIV.D.DE452 ART start at labour and delivery Client initiated ART at labour and delivery HIV.D.DE453 Breastfeeding at ART start Client was breastfeeding when ART was initiated HIV.D.DE454 Delivery date of infant Date of delivery/birth of infant if breastfeeding at ART start HIV.D.DE455 Serodiscordant partner at ART start Client living with HIV was in an ongoing sexual relationship with an HIV-negative partner when ART was started HIV.D.DE456 Regimen start date The date on which the client started taking the current ART regimen HIV.D.DE457 Medications prescribed Name or regimen code of all other medications prescribed during the visit HIV.D.DE458 Date medications prescribed Date the medications were prescribed HIV.D.DE459 Dose of medications prescribed Number of doses (quantity taken at a single point in time) of drugs prescribed/dispensed HIV.D.DE460 Number of days medications prescribed Number of days supply of each medication or regimen prescribed during the visit HIV.D.DE461 Medications dispensed Any other medications that were dispensed to client, including preventive treatment HIV.D.DE462 Number of days of medications dispensed Number of days supply of each medication or regimen dispensed during the visit HIV.D.DE463 Dosage Prescribed dosage of the medication HIV.D.DE464 Frequency Prescribed frequency for taking the medication HIV.D.DE465 Adherence counselling provided Counselling was carried out during visit HIV.D.DE466 Type of treatment-limiting toxicity Type of treatment-limiting toxicity experienced by client. Treatment-limiting toxicity is defined as a serious adverse drug reaction that results in drug discontinuation or substitution. In addition, any reaction that leads to treatment interruption or requires changing the drug or regimen because of an adverse drug reaction is also considered a serious adverse drug reaction. HIV.D.DE467 Gastrointestinal Treatment-limiting toxicity due to GI issues (nausea, diarrhoea, abdominal pain, vomiting) HIV.D.DE468 Skin issues Treatment-limiting toxicity due to skin issues (rash, hypersensitivity reaction) HIV.D.DE469 Peripheral neuropathy Treatment-limiting toxicity due to peripheral neuropathy (burning/numbness/ tingling) HIV.D.DE470 Central nervous system symptoms Treatment-limiting toxicity due to central nervous system symptoms (dizzy, anxiety, nightmare, depression, seizures) HIV.D.DE471 Weight gain Treatment-limiting toxicity due to weight gain HIV.D.DE472 Hepatic dysfunction Treatment-limiting toxicity due to hepatic dysfunction (jaundice) HIV.D.DE473 Haematological disorders Treatment-limiting toxicity due to haematological (anaemia, neutropenia) disorders HIV.D.DE474 Fatigue Treatment-limiting toxicity due to fatigue HIV.D.DE475 Headache Treatment-limiting toxicity due to headache HIV.D.DE476 Bone dysfunction Treatment-limiting toxicity due to bone dysfunction (fractures, osteopenia) HIV.D.DE477 Metabolic symptoms Treatment-limiting toxicity due to metabolic symptoms (body fat changes, hyperglycaemia, dyslipidaemia) HIV.D.DE478 Kidney dysfunction Treatment-limiting toxicity due to kidney dysfunction (nephrolithiasis, renal insufficiency) HIV.D.DE479 Unexpected adverse drug reaction Client experienced an unexpected adverse drug reaction HIV.D.DE480 Unexpected adverse drug reaction (specify) Specify the type of unexpected adverse drug reaction the client experienced HIV.D.DE481 Date(s) of substitution within first-line regimen Date on which ARV drug regimen (one or more drugs) for client was changed within the first-line regimen (substitution) HIV.D.DE482 Reason(s) for substitution within first-line regimen Reason(s) why one ore more drugs in client's first-line ARV drug regimen was changed (substituted) HIV.D.DE483 New antiretroviral regimen after substitution within first-line regimen New antiretroviral (ARV) drugs after client changed regimen within the first-line regimen HIV.D.DE484 Date of switch to second-line regimen Date client was changed from a first-line to second-line ARV drug regimen (switch) HIV.D.DE485 New regimen after switch to second-line regimen New ART regimen after switch to second-line ART regimen HIV.D.DE486 Reason for switch to second-line regimen Reason why client was switched from first- to second-line ARV drug regimen (see 'Reason for regimen switch' for levels) HIV.D.DE487 Date(s) of substitution within second-line regimen Date on which ARV drug regimen for client was changed within the second-line regimen (substitution) HIV.D.DE488 Reason(s) for substitution within second-line regimen Reason(s) why client changed drug regimen (within the second-line) HIV.D.DE489 New regimen(s) after substitution within second-line regimen New ARV drugs after client changed regimen within the second- line regimen HIV.D.DE490 Date of switch to third-line regimen Date client was changed from a second- to third-line ARV drug regimen (switch) HIV.D.DE491 New regimen after switch to third-line regimen New ART regimen after switch to third-line ART regimen HIV.D.DE492 Reason for switch to third-line regimen Reason why client was switched from second- to third-line ARV drug regimen (see 'Reason for regimen switch' for levels) HIV.D.DE493 Date(s) of substitution within third-line regimen Date on which ARV drug regimen for client was changed within the third-line (substitution) HIV.D.DE494 Reason(s) for substitution within third-line regimen Reason(s) why client changed drug regimen (within the third-line) HIV.D.DE495 New regimen(s) after substitution within third-line regimen New ARV drugs after client changed regimen within the third-line regimen HIV.D.DE496 Enhanced adherence counselling provided Enhanced adherence counselling was provided to the client during the visit HIV.D.DE497 First enhanced adherence counselling session completed A first enhanced adherence counselling was provided to the client during the visit HIV.D.DE498 Date of first enhanced adherence counselling session completed The date on which the first enhanced adherence counselling was provided to the client HIV.D.DE499 Second enhanced adherence counselling session completed A second enhanced adherence counselling was provided to the client during the visit HIV.D.DE500 Date of second enhanced adherence counselling session completed The date on which the second enhanced adherence counselling was provided to the client HIV.D.DE501 Third enhanced adherence counselling session completed A third enhanced adherence counselling was provided to the client during the visit HIV.D.DE502 Date of third enhanced adherence counselling session completed The date on which the third enhanced adherence counselling was provided to the client HIV.D.DE503 Name of treatment supporter Full name of person providing support to client for adherence, care, treatment and other needs (e.g. ARV pick-up if ill) HIV.D.DE504 Address of treatment supporter Full address or description of home of treatment supporter HIV.D.DE505 Telephone number of treatment supporter Telephone number if available, or else telephone number of neighbour/friend HIV.D.DE506 Home-based care provider Name of individual or organization that provides home-based care to client HIV.D.DE507 Counselling provided on diagnoses Counselling provided on diagnoses HIV.D.DE508 Hepatitis B positive counselling conducted Whether counselling was provided to a client who has been diagnosed with hepatitis B HIV.D.DE509 Hepatitis C positive counselling conducted Whether counselling was provided to a client who has been diagnosed with hepatitis C HIV.D.DE510 Syphilis counselling and treatment Whether counselling and treatment was provided to a client who has been diagnosed with syphilis HIV.D.DE511 Syphilis counselling, treatment and further testing Whether counselling and treatment was provided to a client who has been diagnosed with syphilis. Additional testing (RPR test) recommended. HIV.D.DE512 Accepted partner services Client accepted offer for partner services HIV.D.DE513 HIV testing for partners and biological children Offer voluntary testing for all partners and biological children of positive cases (includes partner services and index case testing), as well as partners and social contacts of people from key populations, where appropriate HIV.D.DE514 HIV status of family member HIV status of each family member at time of patient's enrolment, including partner (for mothers) HIV.D.DE515 Unique ID of family member Unique ID number of each family member if enrolled in HIV care according to national guidelines (see unique ID number) HIV.D.DE516 Date of death of family member Date of death for each family member as appropriate HIV.D.DE517 Offered voluntary partner services Whether the client was offered voluntary partner services or family services HIV.D.DE518 Provided support for disclosure and partner services Offer or refer for support for disclosure and partner services HIV.D.DE519 Other support services Offer or refer for other support services HIV.D.DE520 Mental health services Offer or refer for mental health services HIV.D.DE521 Psychosocial counselling, support and treatment adherence counselling Offer or refer for psychosocial counselling, support and treatment adherence counselling HIV.D.DE522 Legal and social services Offer or refer for legal and social services HIV.D.DE523 Services for responding to violence against women Offer or refer for services for responding to violence against women, including first-line support and psychosocial support, post-rape care and other support services including shelters, legal services and women and child protection services HIV.D.DE524 Date/time of follow-up appointment Date the client is to return for monitoring, re-supply or any other reason HIV.D.DE525 Type of follow-up appointment Whether the visit will be clinical only, ARV drug pick-up or other. Client may have multiple follow-ups scheduled. HIV.D.DE526 Clinical visit Appointment for clinical care by a provider HIV.D.DE527 Antiretroviral drug pick up Appointment for a drug pick up HIV.D.DE528 Post-treatment follow-up visit for cervical precancer lesions or invasive cervical cancer Appointment for a post-treatment follow-up visit for cervical precancer lesions or invasive cervical cancer HIV.D.DE529 Other Other reason for the follow-up appointment HIV.D.DE530 Other (specify) Other reason for the follow-up appointment (specify) HIV.D.DE531 Follow-up test recommended date A test or screening recommended for the client's care plan at a future date HIV.D.DE532 Reason blood pressure reading not done Reason why test was not performed HIV.D.DE533 BP cuff (sphygmomanometer) not available Blood pressure cuff is not available HIV.D.DE534 BP cuff (sphygmomanometer) is broken Blood pressure cuff is broken HIV.D.DE535 Other Other reason blood pressure can not be taken HIV.D.DE536 Other (specify) Other reason blood pressure can not be taken (specify) HIV.D.DE537 Current medications List of all of the medications the client is currently taking HIV.D.DE538 No medications The client is currently not on any medications HIV.D.DE539 Don't know of any current medications The client does not know if she is on any medications HIV.D.DE540 Analgesic Analgesic medication (painkiller) HIV.D.DE541 Antacids Antacids HIV.D.DE542 Antibiotics (broad-spectrum) Client is currently taking broad-spectrum antibiotics HIV.D.DE543 Anticonvulsive Anticonvulsive medication HIV.D.DE544 Antidiabetic Antidiabetic medication HIV.D.DE545 Antifungals Client is currently taking antifungals HIV.D.DE546 Antihelmintic Antihelmintic or antiparasitic medication HIV.D.DE547 Antihypertensive Antihypertensive medication HIV.D.DE548 Antimalarials Antimalarial medication HIV.D.DE549 Antiretrovirals (ARVs) Antiretrovirals (ARVs) HIV.D.DE550 Antiparasitics Client is currently taking antiparasitics HIV.D.DE551 Antivirals Antiviral medication HIV.D.DE552 Buprenorphine Opioid substitution to treat opioid dependence HIV.D.DE553 Co-trimoxazole preventive therapy (CPT) Combination of two antimicrobial drugs (sulfamethoxazole and trimethoprim) that covers a variety of bacterial, fungal and protozoan infections HIV.D.DE554 Hormonal family planning method Hormonal family planning method HIV.D.DE555 Methadone Opioid substitution to treat opioid dependence HIV.D.DE556 PrEP to prevent HIV Pre-exposure prophylaxis (PrEP) medication for preventing the acquisition of HIV HIV.D.DE557 Other antibiotics Other antibiotics not listed above HIV.D.DE558 Other medications Other medications or supplements that are not listed above HIV.D.DE559 Other medications (specify) Other medications or supplements that are not listed above (specify) HIV.D.DE560 Allergies Does the client have any allergies? HIV.D.DE561 No known allergies Client does not have any known allergies HIV.D.DE562 Don't know of any allergies Client does not know whether or not she has allergies HIV.D.DE563 Albendazole Allergy to albendazole HIV.D.DE564 Malaria medication (sulfadoxine-pyrimethamine) Allergy to malaria medication (sulfadoxine-pyrimethamine) HIV.D.DE565 Penicillin Allergy to penicillin HIV.D.DE566 Tenofovir disoproxil fumarate (TDF) Allergy to pre-exposure prophylaxis (PrEP) tenofovir disoproxil fumarate (TDF) HIV.D.DE567 Other allergies Client has other allergies not listed here HIV.D.DE568 Other allergies (specify) Client has other allergies not listed here (specify) HIV.D.DE569 Family planning method used Method the client reports currently using at intake HIV.D.DE570 Copper-bearing intrauterine device (Cu-IUD) A copper-bearing intrauterine device is being used as a family planning method HIV.D.DE571 Levonorgestrel intrauterine device (LNG-IUD) A levonorgestrel intrauterine device (hormone-releasing intrauterine contraceptive device) is being used as a family planning method HIV.D.DE572 Etonogestrel (ETG) one-rod implant An etonogestrel one-rod implant is being used HIV.D.DE573 Levonorgestrel (LNG) two-rod implant A levonorgestrel two-rod implant is being used as a family planning method HIV.D.DE574 DMPA-IM Injectable depot medroxyprogesterone acetate (DMPA), administered intramuscularly, is being used as a family planning method HIV.D.DE575 DMPA-SC Injectable depot medroxyprogesterone acetate (DMPA), administered subcutaneously is being used HIV.D.DE576 NET-EN norethisterone enanthate Injectable norethisterone enanthate (NET-EN) is being used as a family planning method HIV.D.DE577 Progestogen-only pills (POP) Progestogen-only pills (POP) are being used as a family planning method HIV.D.DE578 Combined oral contraceptives (COCs) Combined oral contraceptives (COCs) pills are being used as a family planning method HIV.D.DE579 Combined contraceptive patch Transdermal combined contraceptive patch is being used as a family planning method HIV.D.DE580 Combined contraceptive vaginal ring (CVR) Combined contraceptive vaginal ring (CVR) is being used as a family planning method HIV.D.DE581 Progesterone-releasing vaginal ring (PVR) Progesterone-releasing vaginal ring (PVR) is being used as a family planning method HIV.D.DE582 Lactational amenorrhea method (LAM) Lactational amenorrhea method (LAM) is being used as a family planning method HIV.D.DE583 Emergency contraceptive pills (ECPs) Client uses emergency contraceptive pills (ECPs) HIV.D.DE584 Fertility awareness-based methods (FAB) Client uses fertility awareness-based methods (FAB) HIV.D.DE585 Male condoms Male condoms are being used as a family planning method HIV.D.DE586 Female condoms Female condoms are being used as a family planning method HIV.D.DE587 Withdrawal Client uses withdrawal method HIV.D.DE588 Female relying on male method The female client is relying on her male partner for contraceptive methods (e.g. male condoms, male sterilization, withdrawal) HIV.D.DE589 Male relying on female method The male client is relying on his female partner for contraceptive methods HIV.D.DE590 Male sterilization Male surgical sterilization (a vasectomy) is the family planning method used HIV.D.DE591 Female sterilization Female surgical sterilization procedure is the family planning method used HIV.D.DE592 No method Client is not using any family planning methods HIV.D.DE593 Medication status Current state of the client's taking of the medication HIV.D.DE594 Currently taking The medication is still being taken (active) HIV.D.DE595 Completed The medication is no longer being taken HIV.D.DE596 Entered in error Entered in error HIV.D.DE597 Intended The medication may be taken at some time in the future HIV.D.DE598 Stopped Actions implied by the statement have been permanently halted, before all of them occurred. This should not be used if the statement was entered in error. HIV.D.DE599 On hold The client has temporarily stopped taking the medication, but is expected to continue again later. May also be called 'suspended'. HIV.D.DE600 Unknown The state of the medication use is not currently known HIV.D.DE601 Did not take The client did not take the medication HIV.D.DE602 Hepatitis B negative counselling conducted Hepatitis B negative counselling conducted HIV.D.DE603 Vaccine brand The brand or trade name used to refer to the vaccine received HIV.D.DE604 Vaccine type Type of vaccine received (such as IPV, OPV) HIV.D.DE605 Date and time of vaccination Represents the visit/encounter date, which is the date and time when the vaccine was administered to the client HIV.D.DE606 Vaccination location The service delivery location where the vaccine adminstration occurred HIV.D.DE607 Dose number Vaccine dose number within series HIV.D.DE608 Dose quantity The quantity of vaccine product that was administered HIV.D.DE609 Total doses in series The recommended number of vaccine doses for immunity according to national protocol HIV.D.DE610 Disease targeted Vaccine preventable disease being targeted by vaccine administered HIV.D.DE611 Hepatitis A The client is receiving vaccination to prevent against hepatitis A HIV.D.DE612 Hepatitis B The client is receiving vaccination to prevent against hepatitis B HIV.D.DE613 Tetanus The client is receiving vaccination to prevent against tetanus HIV.D.DE614 COVID-19 The client is receiving vaccination to prevent against COVID-19 due to SARS-CoV-2 HIV.D.DE615 Influenza due to influenza B virus The client is receiving vaccination to prevent against influenza due to influenza B virus HIV.D.DE616 Tuberculosis The client is receiving vaccination to prevent against tuberculosis (e.g. BCG vaccine) HIV.D.DE617 Acute poliomyelitis The client is receiving vaccination to prevent against acute poliomyelitis (polio) HIV.D.DE618 Measles The client is receiving vaccination to prevent against measles HIV.D.DE619 Diptheria The client is receiving vaccination to prevent against diptheria HIV.D.DE620 Rabies The client is receiving vaccination to prevent against rabies HIV.D.DE621 Cholera The client is receiving vaccination to prevent against cholera HIV.D.DE622 Mumps The client is receiving vaccination to prevent against mumps HIV.D.DE623 HPV infection The client is receiving vaccination to prevent against human papilloma virus (HPV) infection HIV.D.DE624 Haemophilus influenzae type B The client is receiving vaccination to prevent against Haemophilus influenzae type B (Hib) HIV.D.DE625 Varicella The client is receiving vaccination to prevent against varicella HIV.D.DE626 Dengue The client is receiving vaccination to prevent against dengue HIV.D.DE627 Yellow fever The client is receiving vaccination to prevent against yellow fever HIV.D.DE628 Japanese Encephalitis The client is receiving vaccination to prevent against Japanese encephalitis HIV.D.DE629 Rubella The client is receiving vaccination to prevent against rubella HIV.D.DE630 Pertussis The client is receiving vaccination to prevent against pertussis HIV.D.DE631 Enteritis due to rotavirus The client is receiving vaccination to prevent against enteritis due to rotavirus HIV.D.DE632 Pneumococcal disease The client is receiving vaccination to prevent against pneumococcal disease HIV.D.DE633 Meningococcal disease The client is receiving vaccination to prevent against meningococcal disease HIV.D.DE634 Tick-borne encephalitis The client is receiving vaccination to prevent against tick-borne encephalitis HIV.D.DE635 Typhoid The client is receiving vaccination to prevent against typhoid HIV.D.DE636 Reason immunization was not provided Reason the vaccine dose was not given HIV.D.DE637 Stock-out Stock-out of vaccine HIV.D.DE638 Client is ill Client is ill HIV.D.DE639 Client refused Client refused vaccine HIV.D.DE640 Allergy to vaccine Client has an allergy to the vaccine HIV.D.DE641 Other reason immunization not provided Other reason why the immunization was not provided HIV.D.DE642 Other reason immunization not provided (specify) Other reason why the immunization was not provided (specify) HIV.D.DE643 Malaria prophylaxis Whether malaria prophylaxis was given HIV.D.DE644 IPTp-SP dose number provided IPTp-SP dose number that was provided HIV.D.DE645 Date IPTp-SP dose provided Date on which the IPTp-SP dose was provided HIV.D.DE646 Reason malaria prophylaxis not provided Reason why the treatment was not given HIV.D.DE647 Client was referred Client was referred to another provider/facility HIV.D.DE648 Stock out There was a stock out of malaria prophylaxis HIV.D.DE649 Expired Malaria prophylaxis in stock was expired HIV.D.DE650 Other reason not provided Other reason why the prophylaxis was not provided HIV.D.DE651 Other reason not provided (specify) Other reason why the prophylaxis was not provided HIV.D.DE652 >28 days since last missed appointment More than 28 days have passed since client's last missed appointment HIV.D.DE653 AIDS-related death Death of client was AIDS-related HIV.D.DE654 Date of first AIDS diagnosis Date of client's first AIDS diagnosis HIV.D.DE655 Age at final HPV vaccination dose received Client's age at date received final HPV vaccination dose HIV.D.DE656 Date of cervical cancer screening test Date of cervical cancer screening test HIV.D.DE657 Lifetime screening test number Client's lifetime number of screenings for cervical cancer HIV.D.DE658 Cervical cancer primary screening test type Type of cervical cancer screening test used in primary screening HIV.D.DE659 HPV-DNA Screened for cervical cancer using HPV-DNA test HIV.D.DE660 VIA Screened for cervical cancer using visual inspection with acetic acid (VIA) HIV.D.DE661 Cervical cytology Screened for cervical cancer using cervical cytology HIV.D.DE662 Other Screened for cervical cancer using other method HIV.D.DE663 Other (specify) Screened for cervical cancer using other method (specify) HIV.D.DE664 HPV-DNA cervical cancer screening test result HPV-DNA cervical cancer screening test result HIV.D.DE665 Negative HPV-DNA screening test was negative HIV.D.DE666 Positive HPV-DNA screening test was positive HIV.D.DE667 Invalid HPV-DNA screening test was invalid HIV.D.DE668 VIA cervical cancer screening test result Screening test result for VIA HIV.D.DE669 Negative Screening result is negative HIV.D.DE670 Positive Screening result is positive HIV.D.DE671 Suspected cancer Screening result is suspected cancer HIV.D.DE672 Invalid Screening result is invalid HIV.D.DE673 Cervical cytology screening test result Screening result for cervical cytology HIV.D.DE674 NILM Negative for Intraepithelial Lesion Malignancy (NILM) HIV.D.DE675 ASCUS Atypical squamous cells of undetermined significance (ASCUS) HIV.D.DE676 LSIL Low grade squamous intraepithelial lesion (LSIL) HIV.D.DE677 HSIL High grade squamous intraepithelial lesion (HSIL) HIV.D.DE678 Cancer Result was positive for cancer HIV.D.DE679 Invalid/inadequate Screening result was invalid or inadequate HIV.D.DE680 Cervical cancer triage test date Date of triage test for cervical cancer HIV.D.DE681 Cervical cancer triage test type Type of triage test for cervical cancer HIV.D.DE682 VIA Triage test for cervical cancer using visual inspection with acetic acid (VIA) HIV.D.DE683 Colposcopy Triage test for cervical cancer using colposcopy HIV.D.DE684 Cervical cytology Triage test for cervical cancer using cervical cytology HIV.D.DE685 HPV16/18 Triage test for cervical cancer using test for HPV16/18 HIV.D.DE686 Other Triage test for cervical cancer using another test HIV.D.DE687 Other (specify) Triage test for cervical cancer using another test (specify) HIV.D.DE688 HPV16/18 test result Test result from HPV16/18 test HIV.D.DE689 Positive Test is positive for HPV16/18 HIV.D.DE690 Negative Test is negative for HPV16/18 HIV.D.DE691 Cervical cancer colposcopy result Result of cervical cancer colposcopy HIV.D.DE692 Normal colposcopic findings Colposcopy has normal colposcopic findings HIV.D.DE693 Abnormal colposcopic findings Colposcopy has abnormal colposcopic findings HIV.D.DE694 Suspicious for invasive cervical cancer Colposcopy is suspicious for invasive cervical cancer HIV.D.DE695 Miscellaneous findings Colposcopy has miscellaneous findings HIV.D.DE696 Inadequate Colposcopy exam is inadequate HIV.D.DE697 Cervical cancer histopathology result Result of cervical cancer histopathology HIV.D.DE698 Normal Result of cervical cancer histopathology was normal HIV.D.DE699 LSIL (inclusive of LSIL-CIN1) Result of cervical cancer histopathology was low-grade squamous intraepithelial lesion (LSIL) HIV.D.DE700 HSIL (inclusive of HSIL-CIN2 or HSIL-CIN3) Result of cervical cancer histopathology was high-grade squamous intraepithelial lesion (HSIL) HIV.D.DE701 Invasive cervical cancer Result of cervical cancer histopathology is invasive cervical cancer HIV.D.DE702 Date of additional cervical cancer triage test Date of tertiary cervical cancer screening test HIV.D.DE703 Additional cervical cancer triage test type (specify) Additional cervical cancer triage test type (specify) HIV.D.DE704 Additional cervical cancer triage test result (specify) Additional cervical cancer triage test result (specify) HIV.D.DE705 Date of diagnosis of cervical precancer lesions or invasive cervical cancer Date of diagnosis of cervical precancer lesions or invasive cervical cancer HIV.D.DE706 Cervical cancer screening outcome Client's screening outcome for cervical cancer HIV.D.DE707 Positive for cervical precancer lesions Screening outcome for cervical precancer lesions is positive HIV.D.DE708 Negative for cervical precancer lesions Screening outcome for cervical precancer lesions is negative HIV.D.DE709 Cervical cancer diagnosis Type of cervical cancer diagnosis HIV.D.DE710 Cervical precancer lesions Client is diagnosed with cervical precancer lesions HIV.D.DE711 Invasive cervical cancer Client is diagnosed with invasive cervical cancer disease HIV.D.DE712 Cervical cancer stage at diagnosis Cervical cancer stage at diagnosis of cervical cancer HIV.D.DE713 Stage 0 Stage 0 cervical cancer at diagnosis of cervical cancer HIV.D.DE714 Stage I Stage I cervical cancer at diagnosis of cervical cancer HIV.D.DE715 Stage II Stage II cervical cancer at diagnosis of cervical cancer HIV.D.DE716 Stage III Stage III cervical cancer at diagnosis of cervical cancer HIV.D.DE717 Stage IV Stage IV cervical cancer at diagnosis of cervical cancer HIV.D.DE718 Date of treatment for cervical precancer lesions Date of treatment for cervical precancer lesions HIV.D.DE719 Treatment method for cervical precancer lesions Treatment method for cervical precancer lesions HIV.D.DE720 Cryotherapy Treatment for cervical precancer lesions is cryotherapy HIV.D.DE721 Thermal ablation Treatment for cervical precancer lesions is Thermal ablation HIV.D.DE722 Laser ablation Treatment for cervical precancer lesions is Laser ablation HIV.D.DE723 CKC Treatment for cervical precancer lesions is Cold knife conization (CKC) HIV.D.DE724 Laser cone biopsy Treatment for cervical precancer lesions is Laser cone biopsy HIV.D.DE725 LLETZ/LEEP Treatment for cervical precancer lesions is large loop excision of the transformation zone (LLETZ)/loop electrosurgical excision procedure (LEEP) HIV.D.DE726 Other Treatment for cervical precancer lesions is not listed HIV.D.DE727 Other (specify) Treatment for cervical precancer lesions is not listed (specify) HIV.D.DE728 Date of follow-up for treatment for cervical precancer lesions Date of follow-up for treatment for cervical precancer lesions HIV.D.DE729 Date of start of invasive cancer treatment Date of start of invasive cancer treatment HIV.D.DE730 Invasive cervical cancer treatment episode Client's lifetime number of treatments for invasive cervical cancer HIV.D.DE731 Invasive cervical cancer treatment method Invasive cervical cancer treatment method HIV.D.DE732 Conization Invasive cervical cancer treatment method is a conization HIV.D.DE733 Trachelectomy Invasive cervical cancer treatment method is a trachelectomy HIV.D.DE734 Hysterectomy Invasive cervical cancer treatment method is a hysterectomy HIV.D.DE735 Management of invasive cervical cancer Invasive cervical cancer treatment method is management of invasive cervical cancer HIV.D.DE736 Radiotherapy Invasive cervical cancer treatment method is a radiotherapy HIV.D.DE737 Chemotherapy Invasive cervical cancer treatment method is a chemotherapy HIV.D.DE738 Chemoradiation Invasive cervical cancer treatment method is a chemoradiation HIV.D.DE739 Other Invasive cervical cancer treatment method is a not in list HIV.D.DE740 Other (specify) Invasive cervical cancer treatment method is a not in list (specify) HIV.D.DE741 Treatment outcome Treatment outcome from cervical pre-cancerous lesion treatment or invasive cancer treatment (specify) HIV.D.DE742 Secondary/other cancers diagnosed Secondary and other cancers that client is diagnosed with (specify) HIV.D.DE743 Cancers at other sites (HPV- and non-HPV related) Cancers at other sites that client has (specify) HIV.D.DE744 Date of death If deceased, the date that the client died HIV.D.DE745 Cervical cancer screening interval amongst WLHIV Country-specific interval between cancer screenings amongst women living with HIV (typically 3 or 5 years) HIV.D.DE746 Entry point for facility-level testing Specific point where testing is happening at a facility HIV.D.DE747 Provider-initiated tested in a clinic or emergency facility The client tested though provider-initiated HIV testing & counselling, which could be at an emergency facility HIV.D.DE748 Antenatal care clinic The client tested at an antenatal care clinic, including labour and delivery HIV.D.DE749 Voluntary counselling and testing (within a health facility setting) The client tested through voluntary counselling and testing (within a health facility setting) HIV.D.DE750 Family planning clinic The client tested at a family planning clinic HIV.D.DE751 Other facility-level testing The client tested at another type of facility HIV.D.DE752 Tuberculosis (TB) clinic The client tested at a TB clinic HIV.D.DE753 Offer other clinical services Other clinical services offered or referrals given to the client HIV.D.DE754 Assessment and provision of vaccinations Assessment and provision of vaccinations, such as for people from Key population member type, pregnant women and infants; and, where appropriate, tetanus vaccination for adolescent boys and men receiving VMMC HIV.D.DE755 Hepatitis B (HBV) and hepatitis C virus (HCV) testing and treatment Offer or refer for HBV and/or HCV testing and treatment HIV.D.DE756 Co-trimoxazole chemoprophylaxis to prevent pneumocystis carinii pneumonia Offer or refer for co-trimoxazole chemoprophylaxis to prevent pneumocystis carinii pneumonia HIV.D.DE757 Intensified TB case finding and linkage to TB treatment Offer or refer for intensified TB case finding and linkage to TB treatment HIV.D.DE758 Provision of isoniazid preventive therapy if person does not have TB Offer or refer for provision of isoniazid preventive therapy if person does not have TB HIV.D.DE759 Malaria prevention (such as bed nets and prophylaxis), depending on epidemiology Offer or refer for malaria prevention (such as bed nets and prophylaxis), depending on epidemiology HIV.D.DE760 Eligible for DSD ART Client is eligible for differentiated service delivery (DSD) for ART HIV.D.DE761 Date DSD ART eligibility assessed Date client was assessed for eligibility for differentiated service delivery (DSD) for ART HIV.D.DE762 Currently enrolled in DSD ART model Client currently enrolled in differentiated service delivery (DSD) ART model HIV.D.DE763 DSD ART start date Date client started on differentiated service delivery (DSD) for ART HIV.D.DE764 DSD ART model(s) Type of DSD ART model client is enrolled in (country-specific) HIV.D.DE765 Fast track ART refill Client is enrolled in fast track ART refill (DSD ART model) HIV.D.DE766 Facility adherence club Client is enrolled in facility adherence club (DSD ART model) HIV.D.DE767 Community ART distribution point Client is enrolled in community ART distribution point (DSD ART model) HIV.D.DE768 CHW/peer educator community ART group Client is enrolled in community health worker/peer educator community ART group (DSD ART model) HIV.D.DE769 Patient/client community ART group Client is enrolled in patient/client community ART group (DSD ART model) HIV.D.DE770 Other DSD ART model Client is enrolled in another DSD ART model HIV.D.DE771 Other DSD ART model (specify) Client is enrolled in another DSD ART model (specify) HIV.D.DE772 Partner testing offered Whether client was offered partner testing HIV.D.DE773 Partner testing accepted Whether partner testing was accepted HIV.D.DE774 Date partner contacted for index testing Date on which client's partner was contacted for index testing HIV.D.DE775 Date partner tested for HIV Date on which client's partner was tested for HIV HIV.D.DE776 Date of next scheduled follow-up appointment Date of client's next scheduled follow-up appointment HIV.D.DE777 Type of next follow-up appointment Type of client's next follow-up appointment (specify) HIV.D.DE778 Syndrome/STI diagnosed Syndrome or STI for which client is diagnosed HIV.D.DE779 Urethral discharge syndrome Client diagnosed with urethral discharge syndrome HIV.D.DE780 Vaginal discharge syndrome Client diagnosed with vaginal discharge syndrome HIV.D.DE781 Lower Abdominal pain Client diagnosed with lower abdominal pain HIV.D.DE782 Genital ulcer disease syndrome Client diagnosed with genital ulcer disease syndrome HIV.D.DE783 Anorectal discharge Client diagnosed with anorectal discharge HIV.D.DE784 Sent for testing Specimen sent for testing HIV.D.DE785 Other Other syndrome/STI diagnosed HIV.D.DE786 Other (specify) Other syndrome/STI diagnosed (specify) HIV.D.DE787 Any STI syndrome diagnosed Was the client diagnosed with any of the five STI syndromes during this visit? HIV.D.DE788 Date of STI test Date on which the STI test was conducted HIV.D.DE789 STI tested for STI for which the client was tested HIV.D.DE790 Neisseria gonorrhoeae Client tested for Neisseria gonorrhoeae HIV.D.DE791 Chlamydia trachomatis Client tested for Chlamydia trachomatis HIV.D.DE792 Trichomonas vaginalis Client tested for Trichomonas vaginalis HIV.D.DE793 Syphilis (Treponema pallidum) Client tested for Syphilis (treponema pallidum) HIV.D.DE794 Herpes simplex virus (HSV1, HSV2) Client tested for herpes simplex virus (HSV1, HSV2) HIV.D.DE795 Mycoplasma genitalium Client tested for Mycoplasma genitalium HIV.D.DE796 Mpox Client tested for Mpox HIV.D.DE797 Hepatitis B Client tested for Hepatitis B HIV.D.DE798 Hepatitis C Client tested for Hepatitis C HIV.D.DE799 Other Client tested for other STI HIV.D.DE800 Other (specify) Client tested for other STI (specify) HIV.D.DE801 Syphilis test date Date of syphilis test HIV.D.DE802 Syphilis test result Result from syphilis test HIV.D.DE803 Positive Test result is positive for syphilis HIV.D.DE804 Negative Test result is negative for syphilis HIV.D.DE805 Inconclusive Test result is inconclusive HIV.D.DE806 Syphilis treatment start date Date of initiation of syphilis treatment HIV.D.DE807 Gonorrhoea test date Date of Gonorrhoea test HIV.D.DE808 Gonorrhoea test result Result from Gonorrhoea test HIV.D.DE809 Positive Test result is positive for Neisseria gonorrhoeae HIV.D.DE810 Negative Test result is negative for Neisseria gonorrhoeae HIV.D.DE811 Inconclusive Test result is inconclusive HIV.D.DE812 Gonorrhoea treatment start date Date of initiation of Gonorrhoea treatment HIV.D.DE813 Type of specimen Type of specimen to be collected HIV.D.DE814 Blood Blood specimen to be collected HIV.D.DE815 Urine Urine specimen to be collected HIV.D.DE816 Cervical or vaginal swab Cervical or vaginal swab to be collected HIV.D.DE817 Urethral or penile swab Urethral or penile swab to be collected HIV.D.DE818 Rectal swab Rectal swab to be collected HIV.D.DE819 Other Other specimen type to be collected HIV.D.DE820 Other type of specimen (specify) Other specimen type to be collected (specify) HIV.D.DE821 Syphilis test type Type of diagnostic test used for syphilis (Treponema pallidum) HIV.D.DE822 Treponemal Treponemal test used HIV.D.DE823 Non-treponemal Non-treponemal test used HIV.D.DE824 POC Test Point-of-care (POC) test used HIV.D.DE825 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.D.DE826 Other Other test used HIV.D.DE827 Other syphilis test type (specify) Other test used (specify) HIV.D.DE828 Neisseria gonorrhoeae test type Type of diagnostic test used for Neisseria gonorrhoeae HIV.D.DE829 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.D.DE830 POC Test Point-of-care (POC) test used HIV.D.DE831 Culture Culture test used HIV.D.DE832 Microscopy Microscopy test used HIV.D.DE833 Other Other type of test used HIV.D.DE834 Other (specify) Other type of test used (specify) HIV.D.DE835 POC Test for Neisseria gonorrhoeae (specify) Point-of-care (POC) test used for Neisseria gonorrhoeae (specify) HIV.D.DE836 Chlamydia trachomatis test type Type of diagnostic test used for Chlamydia trachomatis HIV.D.DE837 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.D.DE838 POC Test Point-of-care (POC) test used HIV.D.DE839 Culture Culture test used HIV.D.DE840 ELISA ELISA test used HIV.D.DE841 Microscopy Microscopy test used HIV.D.DE842 Other Other type of test used HIV.D.DE843 Other test for Chlamydia (specify) Other type of test used for Chlaymdia (specify) HIV.D.DE844 POC Test type for Chlamydia test (specify) Point-of-care (POC) test used for Chlamydia (specify) HIV.D.DE845 Trichomonas vaginalis test type Type of diagnostic test used for Trichomonas vaginalis HIV.D.DE846 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.D.DE847 POC Test Point-of-care (POC) test used HIV.D.DE848 Culture Culture test used HIV.D.DE849 Microscopy Microscopy test used HIV.D.DE850 Other Other type of test used HIV.D.DE851 Other (specify) Other type of test used (specify) HIV.D.DE852 POC Test type for Trichomonas vaginalis test (specify) Point-of-care (POC) test used (specify) HIV.D.DE853 Herpes simplex virus (HSV) test type Type of diagnostic test used for Herpes simplex virus (HSV) HIV.D.DE854 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.D.DE855 Antibody test Antibody test used HIV.D.DE856 Other Other type of test used HIV.D.DE857 Other (specify) Other type of test used for Herpes simplex virus (HSV) test (specify) HIV.D.DE858 Mycoplasma genitalium test type Type of diagnostic test used for Mycoplasma genitalium HIV.D.DE859 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.D.DE860 Microscopy Microscopy test used HIV.D.DE861 Other Other type of test used HIV.D.DE862 Other (specify) Other type of test used for Mycoplasma genitalium test (specify) HIV.D.DE863 Test type for other STI tested for (specify) Test type used for the other specified STI HIV.D.DE864 STI test result Result from STI test HIV.D.DE865 Positive Test result is positive HIV.D.DE866 Negative Test result is negative HIV.D.DE867 Inconclusive Test result is inconclusive HIV.D.DE868 Date of STI confirmatory test Date of STI confirmatory test HIV.D.DE869 Confirmatory syphilis test type Type of test ued for confirmatory syphilis test HIV.D.DE870 Treponemal Treponemal test used HIV.D.DE871 Non-treponemal Non-treponemal test used HIV.D.DE872 POC Test Point-of-care (POC) test used HIV.D.DE873 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.D.DE874 Other Other test used HIV.D.DE875 Other (specify) Other test used for confirmatory syphilis test (specify) HIV.D.DE876 Confirmatory test type for other STI (specify) Confirmatory test type for other STI HIV.D.DE877 Confirmatory STI test result Result from confirmatory STI test HIV.D.DE878 Positive Test result is positive HIV.D.DE879 Negative Test result is negative HIV.D.DE880 Inconclusive Test result is inconclusive HIV.D.DE881 Date STI treatment prescribed Date STI treatment was prescribed to the client HIV.D.DE882 Date STI treatment dispensed Date STI treatment dispensed to the client HIV.D.DE883 STI treatment dispensed (specify) STI treatment dispensed to the client HIV.D.DE884 Mid-upper arm circumference (MUAC) Client's mid-upper arm circumference (MUAC) HIV.D.DE885 Date of start of fluconazole prophylaxis Date of client's start of fluconazole prophylaxis HIV.D.DE886 Fluconazole prophylaxis Client provided with fluconazole prophylaxis HIV.D.DE887 Date started cryptococcal meningitis treatment induction regimen Date client started cryptococcal meningitis treatment induction regimen HIV.D.DE888 Date completed cryptococcal meningitis treatment induction regimen Date client completed cryptococcal meningitis treatment induction regimen HIV.D.DE889 Date started cryptococcal meningitis treatment maintenance regimen Date client started cryptococcal meningitis treatment maintenance regimen HIV.D.DE890 Date completed cryptococcal meningitis treatment maintenance regimen Date client completed cryptococcal meningitis treatment maintenance regimen HIV.D.DE891 Date started cryptococcal meningitis treatment consolidation regimen Date client started cryptococcal meningitis treatment consolidation regimen HIV.D.DE892 Date completed cryptococcal meningitis treatment consolidation regimen Date client completed cryptococcal meningitis treatment consolidation regimen HIV.D.DE893 Staging of liver disease Staging of liver disease in client HIV.D.DE894 F0-4, fibrosis staging Fibrosis staging of liver disease HIV.D.DE895 F4 or cirrhosis, presence of cirrhosis Presence of cirrhosis HIV.D.DE896 Advanced HIV disease Client has Advanced HIV disease (AHD) HIV.D.DE897 WHO functional status Functional status of people with advanced HIV disease HIV.D.DE898 Working, able to perform usual work inside and outside the home Client is able to perform usual work inside and outside the home (working) HIV.D.DE899 Ambulatory, able to perform activity of daily living (ADL), not able to work Client is able to perform activity of daily living (ADL), not able to work (ambulatory) HIV.D.DE900 Bedridden not able to perform ADL Client is dedridden not able to perform ADL HIV.D.DE901 Tailored adherence counselling for advanced HIV disease Client provided with tailored adherence counselling for advanced HIV disease HIV.D.DE902 Date(s) of tracing interventions Date tracing interventions to support reengagement into HIV care conducted HIV.D.DE903 Medication/drug Current or considered medication/drug, for the purpose of determining drug interactions HIV.D.DE904 Rifampicin Rifampicin currently being taken by, or considered for, client HIV.D.DE905 Halofantrine Halofantrine currently being taken by, or considered for, client HIV.D.DE906 Lovastatin Lovastatin currently being taken by, or considered for, client HIV.D.DE907 Simvastatin Simvastatin currently being taken by, or considered for, client HIV.D.DE908 Hormonal contraception Hormonal contraception currently being taken by, or considered for, client HIV.D.DE909 Metformin Metformin currently being taken by, or considered for, client HIV.D.DE910 Astemizole Astemizole currently being taken by, or considered for, client HIV.D.DE911 Terfenadine Terfenadine currently being taken by, or considered for, client HIV.D.DE912 TDF TDF currently being taken by, or considered for, client HIV.D.DE913 Simeprevir Simeprevir currently being taken by, or considered for, client HIV.D.DE914 Ombitasvir + paritaprevir/ritonavir + dasabuvir Ombitasvir + paritaprevir/ritonavir + dasabuvir currently being taken by, or considered for, client HIV.D.DE915 Methadone Methadone currently being taken by, or considered for, client HIV.D.DE916 Buprenorphine Buprenorphine currently being taken by, or considered for, client HIV.D.DE917 Dofetilide Dofetilide currently being taken by, or considered for, client HIV.D.DE918 Carbamazepine Carbamazepine currently being taken by, or considered for, client HIV.D.DE919 Phenobarbital Phenobarbital currently being taken by, or considered for, client HIV.D.DE920 Phenytoin Phenytoin currently being taken by, or considered for, client HIV.D.DE921 Polyvalent cation products containing Mg, Al, Fe, Ca and Zn Polyvalent cation products containing Mg, Al, Fe, Ca and Zn currently being taken by, or considered for, client HIV.D.DE922 Amodiaquine Amodiaquine currently being taken by, or considered for, client HIV.D.DE923 Cisapride Cisapride currently being taken by, or considered for, client HIV.D.DE924 Ergotamine Ergotamine currently being taken by, or considered for, client HIV.D.DE925 Dihydroergotamine Dihydroergotamine currently being taken by, or considered for, client HIV.D.DE926 Midazolam Midazolam currently being taken by, or considered for, client HIV.D.DE927 Triazolam Triazolam currently being taken by, or considered for, client HIV.D.DE928 Estrogen-based hormonal contraception Estrogen-based hormonal contraception currently being taken by, or considered for, client HIV.D.DE929 Ribavirin Ribavirin currently being taken by, or considered for, client HIV.D.DE930 Peginterferon alfa-2a Peginterferon alfa-2a currently being taken by, or considered for, client HIV.D.DE931 Other Other medication currently being taken by, or considered for, client HIV.D.DE932 Other (specify) Other medication currently being taken by, or considered for, client (specify) HIV.D.DE933 Medication change recommended A medication change is recommended for the client based upon current or considered medications HIV.D.DE934 WHO HIV clinical stage condition or symptom New or recurrent clinical events used to categorize HIV disease severity based at baseline and follow up HIV.D.DE935 Pulmonary TB Client's symptoms include pulmonary TB HIV.D.DE936 Lymph node TB Client's symptoms include lymph node TB HIV.D.DE937 Extrapulmonary TB Client's symptoms include extrapulmonary tuberculosis (TB) HIV.D.DE938 TB disease Whether the client has tuberculosis (TB) disease. Sometimes known as active TB HIV.D.DE939 TB diagnosis result Final result of the TB investigation (bacteriological and/or clinical) HIV.D.DE940 Diagnosed TB Client is diagnosed with TB disease HIV.D.DE941 TB excluded Client is not diagnosed with TB HIV.D.DE942 Method of TB diagnosis Method used to set the TB diagnosis HIV.D.DE943 Bacteriologically confirmed A person from whom a biological specimen is positive by smear microscopy, culture or a WHO-recommended rapid diagnostic HIV.D.DE944 Clinically diagnosed A person who does not fulfil the criteria for bacteriological confirmation but has been diagnosed with TB disease by a medical practitioner who has decided to give the person a full course of TB treatment HIV.D.DE945 Presumptive TB Client has signs or symptoms of tuberculosis (TB) without laboratory confirmation HIV.D.DE946 Presumptive TB registration date Date client is registered as having signs or symptoms of tuberculosis (TB) without laboratory confirmation HIV.D.DE947 TB treatment history History of previous TB treatment HIV.D.DE948 New A person with TB disease who has never been treated for TB before or has only previously ever taken TB drugs for less than 1 month HIV.D.DE949 Recurrent A person with TB disease who was previously treated for TB, was declared cured or treatment completed at the end of their most recent course of TB treatment and is now diagnosed with a new episode of TB. HIV.D.DE950 Re-registered A person with TB disease who had been notified previously as a TB case, but was not declared cured or treatment completed, and is now being registered for a new course of TB treatment. HIV.D.DE951 Unknown A person with TB disease who has undocumented history of TB treatment HIV.D.DE952 Date of TB diagnosis The date when the diagnosis was established HIV.D.DE953 Currently on TB preventive treatment (TPT) Client is currently taking TPT HIV.D.DE954 TB preventive treatment (TPT) start date The date on which the client began taking TPT HIV.D.DE955 TB preventive treatment (TPT) completion date The date on which the client completed TPT HIV.D.DE956 TB screening algorithm Screening algorithm selected for screening activities HIV.D.DE957 Screening with cough Client screened for TB based on cough symptom HIV.D.DE958 Screening with any TB symptom Client screened for TB based on any TB symptom HIV.D.DE959 W4SS single screening algorithm Client screened for TB based on the WHO-recommended four-symptom screen HIV.D.DE960 CRP single screening algorithm Client screened for TB based on C-reactive protein (CRP) testing HIV.D.DE961 CXR single screening algorithm Client screened for TB with a chest radiography (CXR) HIV.D.DE962 Parallel screening algorithm with W4SS and CRP Client screened for TB using parallel screening with WHO-recommended four-symptom screen and C-reactive protein (CRP) testing HIV.D.DE963 Sequential positive screening algorithm with W4SS and CRP Client screened for TB using sequential positive screening with WHO-recommended four-symptom screen and C-reactive protein (CRP) testing. HIV.D.DE964 Sequential negative screening algorithm with W4SS and CRP Client screened for TB using sequential negative screening with WHO-recommended four-symptom screen and C-reactive protein (CRP) testing HIV.D.DE965 Parallel screening algorithm with W4SS and CXR Client screened for TB using the parallel screening algorithm with W4SS and CXR HIV.D.DE966 Sequential positive screening algorithm with W4SS and CXR Client screened for TB using sequential positive screening with WHO-recommended four-symptom screen and chest radiography HIV.D.DE967 Sequential negative screening algorithm with W4SS and CXR Client screened for TB using sequential negative screening with WHO-recommended four-symptom screen and chest radiography HIV.D.DE968 Screening with mWRD Client screened for TB with a molecular WHO-recommended rapid diagnostic test (mWRD), such as an Xpert MTB/RIF test to detect Mycobacterium tuberculosis (MTB) HIV.D.DE969 Clinical assessment Client screened for with a clinical evaluation for tuberculosis (TB) based on national guidelines. Clinical assessment may be used as an eligibility evaluation for testing with LF-LAM or for empiric TB treatment. HIV.D.DE970 Other TB screening algorithm Client screened for tuberculosis (TB) with a different screening method not listed HIV.D.DE971 Other TB screening algorithm (specify) Client screened for tuberculosis (TB) with a different screening method not listed (specify) HIV.D.DE972 TB screening conducted A screening for tuberculosis (TB) was performed HIV.D.DE973 Symptoms of TB Symptoms that may indicate TB disease in clients living with HIV, based on a clinical algorithm HIV.D.DE974 Current cough Client has a cough regardless of duration HIV.D.DE975 Prolonged cough (>=2w) Client has a prolonged cough of 2 weeks or more HIV.D.DE976 Fever of 39 °C or greater Client has a fever with a measured temperature of 102.2 °F/39 °C or greater HIV.D.DE977 Weight loss (reported) Unexplained weight loss HIV.D.DE978 Night sweats Client reports experiencing night sweats HIV.D.DE979 Poor weight gain Client reports poor weight gain of child or infant or growth curve flattening or weight for age <-2 Z-scores. HIV.D.DE980 Reduced playfulness Client reports reduced playfulness of child HIV.D.DE981 Chest pain Client reports chest pain HIV.D.DE982 Haemoptysis Client reports experiencing haemoptysis HIV.D.DE983 Lethargy Client reports lethargy HIV.D.DE984 No symptoms of TB identified HIV.D.DE985 History of contact with a person with TB Client had a history of a contact with a person with TB HIV.D.DE986 TB screening result Record the result of the tuberculosis (TB) screening HIV.D.DE987 Screen positive for TB Screening result was positive for tuberculosis (TB) HIV.D.DE988 Screen negative for TB Screening result was negative for tuberculosis (TB) HIV.D.DE989 Inconclusive Screening result was inconclusive for tuberculosis (TB) HIV.D.DE990 TB screening date Date the TB screening was conducted HIV.D.DE991 TB screening result date The date when the result of TB screening is available HIV.D.DE992 TB diagnostic test category The type of diagnostic test performed to detect tuberculosis (TB) disease HIV.D.DE993 LF-LAM Client tested for tuberculosis with a lateral flow urine lipoarabinomannan assay HIV.D.DE994 mWRD test for TB Client tested with a WHO-recommended molecular diagnostic test to detect Mycobacterium tuberculosis (MTB) HIV.D.DE995 Microscopy - Sputum acid-fast bacilli (AFB) Client tested for tuberculosis with a sputum acid-fast bacilli (AFB) HIV.D.DE996 TB Culture Client tested for tuberculosis (TB) with a culture HIV.D.DE997 TB diagnostic test date The date when TB diagnostic test was performed HIV.D.DE998 Test sample collection date The date when the test sample was collected from the client HIV.D.DE999 TB diagnostic test result date The date when the result of the TB diagnostic test is available HIV.D.DE1000 TB treatment started Indicates if TB treatment was started HIV.D.DE1001 TB treatment start date The date on which the client start or restarted tuberculosis (TB) treatment HIV.D.DE1002 TB treatment outcome Indicates patient's TB treatment outcome HIV.D.DE1003 Treatment failed The treatment regimen terminated or permanently changed to a new regimen or treatment strategy. Reasons for the change include: no clinical response or no bacteriological response, or both (see note; adverse drug reaction; or evidence of additional drug-resistance to medicines in the regimen. HIV.D.DE1004 Cured Client with pulmonary TB with bacteriologically confirmed TB at the beginning of treatment who completed treatment as recommended by the national policy, with evidence of bacteriological response and no evidence of failure. HIV.D.DE1005 Treatment completed Patient completed treatment as recommended by the national policy but the outcome does not meet the definition for cure or treatment failure HIV.D.DE1006 Died Client died before starting treatment or during the course of treatment HIV.D.DE1007 Lost to follow-up Client was lost to follow-up HIV.D.DE1008 Not evaluated No treatment outcome was assigned. This includes cases 'transferred out' to another treatment unit and whose treatment outcome is unknown; however, it excludes those lost to follow-up. HIV.D.DE1009 TB treatment completion date Date client completes TB treatment HIV.D.DE1010 TB treatment regimen composition TB drugs currently being taken by the client HIV.D.DE1011 Isoniazid Client is currently taking isoniazid HIV.D.DE1012 Rifampicin Client is currently taking rifampicin HIV.D.DE1013 Rifabutin Client is currently taking rifabutin HIV.D.DE1014 Ethambutol Client is currently taking ethambutol HIV.D.DE1015 Levofloxacin Client is currently taking levofloxacin HIV.D.DE1016 Pyrazinamide Client is currently taking pyrazinamide, a first-line anti-tuberculosis drug HIV.D.DE1017 Eligible for TB preventive treatment Client is eligible for tuberculosis preventive treatment (TPT) HIV.D.DE1018 Date when eligibility for TB preventive treatment (TPT) was determined Date when a determination of the client's eligibility for TPT was made HIV.D.DE1019 TB status at ART start Client's tuberculosis (TB) status when antiretroviral therapy (ART) is started HIV.D.DE1020 Symptomatic for TB Signs or symptoms of tuberculosis (TB) without laboratory confirmation HIV.D.DE1021 Diagnosed TB Laboratory confirmed tuberculosis (TB) diagnosis HIV.D.DE1022 Client has no signs or symptoms of tuberculosis (TB) and is not diagnosed with tuberculosis (TB) HIV.D.DE1023 TB prevention services accepted Indicates if the client accepts to be evaluated for TB infection and to take the treatment in case he/she is eligible HIV.D.DE1024 TB meningitis Type of extrapulmonary TB identified for the client is TB meningitis HIV.D.DE1025 C reactive protein test date The date on which the client has a test for C reactive protein HIV.D.DE1026 C reactive protein test result Test result of the client's C reactive protein test result in mg/L HIV.D.DE1027 C reactive protein test result date The date when the client's test result for C reactive protein is available HIV.D.DE1028 TPT regimen type Type of TPT regimen the client is currently on HIV.D.DE1029 3HP The client's current TPT regimen is 3HP HIV.D.DE1030 1HP The client's current TPT regimen is 1HP HIV.D.DE1031 6H The client's current TPT regimen is 6H HIV.D.DE1032 Six months of levofloxacin daily The client's current TPT regimen is six months of levofloxacin daily HIV.D.DE1033 Other TB preventive treatment (TPT) regimen The client's current TPT regimen is another regimen than those listed above HIV.D.DE1034 TB preventive treatment (TPT) status Indicates the current status of TB preventive treatment (TPT) HIV.D.DE1035 Not started The client did not start the TB preventive treatment (TPT) HIV.D.DE1036 On TPT The client started the TB preventive treatment (TPT) and is currently taking the medication, without treatment interruptions HIV.D.DE1037 On TPT with interruptions The client started the TB preventive treatment (TPT) and is currently taking the medication, with treatment interruptions HIV.D.DE1038 On hold The health care worker has temporarily stopped the TB preventive treatment (TPT), but TPT is expected to continue again later. May also be called 'suspended'. HIV.D.DE1039 Completed TB preventive treatment (TPT) was completed HIV.E.DE1 Pregnant woman's first name Pregnant woman's first or given name HIV.E.DE2 Pregnant woman's surname Pregnant woman's family name or last name HIV.E.DE3 Pregnant woman's unique ID Unique identifier generated for new clients or a universal ID, if used in the country HIV.E.DE4 Antenatal care number Identification number assigned to woman at first visit to the ANC based on national system HIV.E.DE5 Gestational age Gestational age in weeks and/or days depending on the source of gestational age HIV.E.DE6 Source of gestational age Gestational age can be calculated multiple ways. This data element describes where the gestational age above has been calculated from. HIV.E.DE7 Last menstrual period (LMP) Gestational age (GA) calculated from LMP HIV.E.DE8 Ultrasound Woman's gestational age today calculated field using ultrasound GA and ultrasound date HIV.E.DE9 Symphysis fundal height (SFH) or abdominal palpation If LMP is unknown and either ultrasound wasn't done or it wasn't done early enough, then show the option for health worker to enter GA in weeks based on Symphysis Fundal Height (SFH) or abdominal palpation. HIV.E.DE10 Expected date of delivery (EDD) Expected date of delivery based on gestational age HIV.E.DE11 Number of pregnancies (gravida) Total number of times the woman has been pregnant (including this pregnancy). Also referred to as gravida. HIV.E.DE12 Number of previous pregnancies This calculates the total number of all previous pregnancies (i.e. not including this current pregnancy). This is done for easier obstetric history calculations. HIV.E.DE13 Number of miscarriages and/or abortions Total number of pregnancies lost or ended due to miscarriages and/or abortions before 22 weeks / 5 months HIV.E.DE14 Number of live births Total number of live births after 22 weeks HIV.E.DE15 Number of caesarian sections Total number of caesarean sections HIV.E.DE16 Number of stillbirths Total number of stillbirths after 22 weeks HIV.E.DE17 Past pregnancy complications Whether the woman has had any complications or problems in any previous pregnancy HIV.E.DE18 No past pregnancy complications No known past pregnancy problems HIV.E.DE19 Does not know of any past pregnancy complications Don't know if there were any problems during past pregnancies HIV.E.DE20 Pre-eclampsia A condition specific to pregnancy, arising after the 20th week of gestation, characterized by hypertension and proteinuria. Oedema may also be present, but is no longer considered a cardinal sign because it is present to some extent in most pregnancies. If not controlled, pre-eclampsia will lead to eclampsia which is characterized by fits, followed by coma, and has a high mortality rate. HIV.E.DE21 Eclampsia A condition peculiar to pregnancy or a newly delivered woman, characterized by fits followed coma. The woman usually has hypertension and proteinuria. The fits may occur in the antepartum, intrapartum or early postpartum periods. HIV.E.DE22 Alcohol use Alcohol intake HIV.E.DE23 Baby died within 24 hours of birth The woman's baby died within 24 hours of childbirth HIV.E.DE24 Prolonged labour The woman's experienced prolonged labour HIV.E.DE25 Convulsions Woman had convulsions during her past pregnancy HIV.E.DE26 Forceps Woman required forceps delivery HIV.E.DE27 Gestational diabetes mellitus Hyperglycaemia first detected at any time during pregnancy HIV.E.DE28 Heavy bleeding (during or after delivery) Woman was bleeding heavily during or after giving birth during previous pregnancy/pregnancies HIV.E.DE29 Macrosomia Fetus large for gestational age HIV.E.DE30 Perineal tear (3rd or 4th degree) Woman experienced 3rd or 4th degree perineal tear HIV.E.DE31 Substance use Illicit drug use (e.g. cannabis, amphetamines, prescription stimulants, opioids, opiates, ecstasy, cocaine) HIV.E.DE32 Tobacco use Use of tobacco products, in any form HIV.E.DE33 Vacuum delivery Woman required vacuum delivery HIV.E.DE34 Other past pregnancy problems Woman experienced other past pregnancy problems not described above HIV.E.DE35 Other past pregnancy problems (specify) Woman experienced other past pregnancy problems not described above (specify) HIV.E.DE36 Parity Total number of live and stillbirths (calculated) HIV.E.DE37 Pregnancy in HIV-infected woman Any HIV diagnosis in a pregnant woman as determined by the national HIV testing algorithm, or a pregnancy in a woman previously diagnosed with HIV HIV.E.DE38 Date new pregnancy of HIV-positive woman identified Earliest date when a new pregnancy of an HIV-positive woman is recorded HIV.E.DE39 ANC contact during pregnancy Whether the mother had at least one ANC contact (visit) HIV.E.DE40 Date of first ANC visit Date of the pregnant woman's first ANC visit HIV.E.DE41 Timing of ART initiation When the pregnant woman or mother initiated ART, for women living with HIV. HIV.E.DE42 Already on ART at first antenatal care visit The pregnant woman was already on antiretroviral therapy (ART) at first antenatal care visit HIV.E.DE43 Newly on ART during pregnancy The pregnant woman started ART during her pregnancy HIV.E.DE44 Newly on ART during labour and delivery The woman started ART during labour and delivery HIV.E.DE45 Maternal use of recommended ART regimen Whether the mother is taking a recommended ART regimen HIV.E.DE46 Delivery date Date on which the woman delivered HIV.E.DE47 Pregnancy outcome Outcome of current pregnancy HIV.E.DE48 Live birth Outcome of pregnancy was a live birth HIV.E.DE49 Early fetal loss/miscarriage Outcome of pregnancy was early fetal loss/miscarriage HIV.E.DE50 Induced abortion Outcome of pregnancy was induced abortion HIV.E.DE51 Stillbirth Outcome of pregnancy was stillbirth HIV.E.DE52 Delivery mode Mode of delivery for current pregnancy HIV.E.DE53 Spontaneous vaginal delivery Mode of delivery for current pregnancy spontaneous vaginal delivery (SVD) HIV.E.DE54 Assisted vaginal delivery Mode of delivery for current pregnancy was assisted vaginal delivery HIV.E.DE55 Caesarian section (C/S, operative delivery) Mode of delivery for current pregnancy was caesarian section (C/S; operative delivery) HIV.E.DE56 Indications for caesarian section (C/S) Indications for caesarian section HIV.E.DE57 Obstetric complications Serious or life-threatening obstetric complications during pregnancy, delivery or postpartum experienced by mother or her newborn HIV.E.DE58 Live birth The woman had a live birth HIV.E.DE59 Live birth to an HIV-positive woman A woman living with HIV had a live birth HIV.E.DE60 Gestational age at birth Best estimate of gestational age in completed weeks when infant was born (an indication of prematurity, preterm and extreme preterm) HIV.E.DE61 Small for gestational age (SGA) Whether the infant was small for gestational age (SGA) at birth (<10th percentile) HIV.E.DE62 Preterm birth status The woman gave birth when the gestational age is less than 37 weeks HIV.E.DE63 Not preterm The birth was not preterm HIV.E.DE64 Preterm (<37 weeks gestation) Gestational age at birth was <37 weeks HIV.E.DE65 Very preterm (<32 weeks gestation) Gestational age at birth was <32 weeks HIV.E.DE66 Maternal ART start date The date on which the infant was started or restarted on ART HIV.E.DE67 Place of delivery The type of place where the woman delivered HIV.E.DE68 Health facility The woman delivered at a health facility HIV.E.DE69 Home The woman delivered at home HIV.E.DE70 Other The woman delivered at another location that is not at home or at a health facility HIV.E.DE71 Other (specify) The woman delivered at another location that is not at home or at a health facility (specify) HIV.E.DE72 Delivery facility Facility where the infant or child was born HIV.E.DE73 Date of miscarriage or abortion Date of the miscarriage/abortion HIV.E.DE74 Date of death of mother Date that the woman died HIV.E.DE75 Cause of death of mother The woman's cause of death HIV.E.DE76 Infant's first name Infant's first or given name HIV.E.DE77 Infant's surname Infant's family name or last name HIV.E.DE78 Infant's unique ID Unique identifier generated for new clients or a universal ID, if used in the country HIV.E.DE79 Mother's first name Biological mother's first or given name HIV.E.DE80 Mother's surname Biological mother's family name or last name HIV.E.DE81 Mother's unique ID Unique identifier generated for new clients or a universal ID, if used in the country HIV.E.DE82 Caregiver's first name Caregiver's first or given name HIV.E.DE83 Caregiver's surname Caregiver's family name or last name HIV.E.DE84 Caregiver's unique identifier Unique identifier generated for new clients or a universal ID, if used in the country HIV.E.DE85 ANC contact date The date and time of the client's ANC contact (in the ANC DAK this is called 'Contact date') HIV.E.DE86 Referral If infant was referred for care HIV.E.DE87 Infant date of birth The infant's date of birth (DOB) if known HIV.E.DE88 Date of birth of infant unknown Is the client's DOB unknown? HIV.E.DE89 Estimated age of infant If DOB is unknown, enter the client's estimated age. Display client's age in number of years HIV.E.DE90 Age of infant Infant age calculated using date of birth HIV.E.DE91 Gender of infant Gender of the infant HIV.E.DE92 Female Client identifies as female HIV.E.DE93 Male Client identifies as male HIV.E.DE94 Other Client identifies in a non-binary way HIV.E.DE95 Infant height The infant's height in centimetres HIV.E.DE96 Infant weight The infant's current weight in kilograms HIV.E.DE97 Birth weight Birth weight in kg of the baby HIV.E.DE98 Low birth weight Note if infant </¬¨‚â•2500 g at birth HIV.E.DE99 Length of infant Length of infant at birth in cm HIV.E.DE100 Head circumference Head circumference of infant at birth in cm HIV.E.DE101 Mother HIV test conducted Whether an HIV test of the mother was conducted HIV.E.DE102 Mother HIV test ordered Whether an HIV test of the mother was ordered HIV.E.DE103 Mother HIV test date Date when a mother's HIV test was conducted HIV.E.DE104 Maternal HIV test result Test result for mother after applying the testing strategy HIV.E.DE105 HIV-positive Test result is HIV-positive HIV.E.DE106 HIV-negative Test result is HIV-negative HIV.E.DE107 HIV-inconclusive Test result is HIV-inconclusive HIV.E.DE108 Infant or child exposure to HIV Whether the infant or child was determined to have had HIV exposure through mother HIV.E.DE109 Not exposed Infant or child is not known to have been exposed to HIV HIV.E.DE110 HIV-exposed Infant had known exposure to HIV HIV.E.DE111 Unknown HIV exposure Don't know whether infant or child was exposed to HIV, such as if mother's HIV status is unknown HIV.E.DE112 HIV-exposed infant or child Whether the infant or child was determined to have had HIV exposure HIV.E.DE113 Key population member Mother is a member of a key population which has an increased risk of HIV HIV.E.DE114 Key population member type The type of key population that the infant's mother is included in HIV.E.DE115 Sex worker Infant's mother is a sex worker HIV.E.DE116 People who inject drugs Infant's mother is a person who injects drugs HIV.E.DE117 Trans and gender-diverse people Infant's mother identifies as trans and gender-diverse HIV.E.DE118 People living in prisons and other closed setting Infant's mother is in a prison or closed setting HIV.E.DE119 Postpartum family planning counselling conducted Provide family planning and contraception counselling HIV.E.DE120 Age of infant on HIV test date Infant's age when an HIV test is performed in months and years (calculated from date of birth) HIV.E.DE121 ARV adherence counselling Counselling was carried out during visit HIV.E.DE122 Infant feeding counselling provided Support on infant and child feeding to mother or caregiver provided HIV.E.DE123 Date infant feeding counselling provided Date support on infant and child feeding to mother or caregiver provided HIV.E.DE124 Malaria prevention counselling conducted Counselling provided on how to prevent malaria HIV.E.DE125 Insecticide treated bednet (ITN) provided or referred An insecticide treated bednet (ITN) was provided or the client was referred HIV.E.DE126 Maternal syphilis treatment Whether or not mother was treated for syphilis HIV.E.DE127 Infant feeding practice Infant feeding practice HIV.E.DE128 Exclusively breastfeeding Specifies whether the infant is exclusively being breastfed by the mother HIV.E.DE129 Replacement feeding Infant is not receiving any breast milk with a diet that provides all the nutrients needed until they can be fully fed on family foods HIV.E.DE130 Mixed feeding Infant younger than 6 months of age is given other liquids and/or foods together with breast milk. This could be water, other types of milk or any type of solid food. HIV.E.DE131 Infant feeding practice recorded date Date on which infant feeding practice was recorded HIV.E.DE132 Stopped breastfeeding The mother has fully stopped breastfeeding the infant or child HIV.E.DE133 Date stopped breastfeeding The date on which the mother stopped breastfeeding the infant HIV.E.DE134 Taking iron and folic acid (IFA) tablets Is client taking her iron and folic acid (IFA) tablets? Select whether the woman is continuing to take IFA supplements HIV.E.DE135 Amount of iron prescribed Amount of iron supplements prescribed in milligrams for intake HIV.E.DE136 Type of iron supplement dosage provided Whether the amount of iron prescribed is for daily or weekly intake HIV.E.DE137 Daily Iron supplements prescribed for daily intake HIV.E.DE138 Weekly Iron supplements prescribed for daily intake HIV.E.DE139 Amount of daily dose of folic acid prescribed Amount of folic acid supplements prescribed in milligrams for daily intake HIV.E.DE140 Date infant ARV prophylaxis dispensed (or started) Date HIV-exposed infant received ARV prophylaxis (for the first time) HIV.E.DE141 Maternal HIV status The HIV status of the infant's mother HIV.E.DE142 HIV-positive Infant's mother is HIV-positive HIV.E.DE143 HIV-negative Infant's mother is HIV-negative HIV.E.DE144 Unknown Don't know HIV status - client does not know partner's HIV status HIV.E.DE145 Maternal HIV status at first ANC visit The HIV status of the infant's mother at first ANC visit HIV.E.DE146 HIV-positive Infant's mother is HIV-positive HIV.E.DE147 HIV-negative Infant's mother is HIV-negative HIV.E.DE148 Unknown Don't know HIV status - client does not know partner's HIV status HIV.E.DE149 Maternal syphilis test result Result from maternal syphilis test HIV.E.DE150 Positive Test result is positive for syphilis HIV.E.DE151 Negative Test result is negative for syphilis HIV.E.DE152 Inconclusive Test result is inconclusive HIV.E.DE153 Hypertension Whether the client has developed hypertension associated with pregnancy HIV.E.DE154 Pre-eclampsia Whether the client has pre-eclampsia HIV.E.DE155 Signs of substantial risk of HIV infection Signs the client is at a substantial risk of HIV infection HIV.E.DE156 No condom use during sex with more than one partner in the past 6 months Recent vaginal or anal sexual intercourse without a condom with more than one partner HIV.E.DE157 STI in the past 6 months A recent history (in the last 6 months) of a sexually transmitted infection (STI) by laboratory testing or self-report of syndromic STI treatment HIV.E.DE158 A sexual partner in the past 6 months had one or more HIV risk factors A recent sex partner of the client had HIV risk factors HIV.E.DE159 PrEP requested by client Client is requesting PrEP, reflecting a decision-making process has already taken place and suggesting of substantial risk of HIV HIV.E.DE160 Serodiscordant partner Mother's HIV status is different from a current partner's HIV status HIV.E.DE161 Date woman received counselling for CPT Date woman received counselling for co-trimoxazole preventive therapy (CPT) HIV.E.DE162 Date woman received counselling for TPT Date woman received counselling for TB preventive therapy HIV.E.DE163 Infant's co-trimoxazole prophylaxis start date Start date of co-trimoxazole prophylaxis HIV.E.DE164 Infant's age when co-trimoxazole prophylaxis was started The number of weeks or months infant was when started on co-trimoxazole (CTX) prophylaxis preventive therapy HIV.E.DE165 Presumptive clinical diagnosis of severe HIV infection in infants Presumptive clinical diagnosis of severe HIV infection in infants HIV.E.DE166 Infant ARV prophylaxis Infant is taking an antiretroviral prophylaxis to prevent infection from HIV exposure HIV.E.DE167 Infant ARV prophylaxis start date The date on which the infant was started on an antiretroviral prophylaxis HIV.E.DE168 HIV test type Type of HIV test HIV.E.DE169 Rapid diagnostic test for HIV Antibody test for HIV performed with a rapid diagnostic (RDT) HIV.E.DE170 Enzyme immunoassay for HIV Antibody test for HIV performed with an enzyme immunoassay (EIA) HIV.E.DE171 Nucleic acid test for HIV Virological test, which includes testing for early infant diagnosis HIV.E.DE172 Dual HIV/syphilis rapid diagnostic test Antibody test for HIV and syphilis performed with a rapid diagnostic HIV.E.DE173 Maternal and child health service visit Maternal and child health service visit attended by an HIV-exposed infant HIV.E.DE174 12-month visit HIV-exposed infant attending MCH services for a 12-month visit HIV.E.DE175 24-month visit HIV-exposed infants attending MCH services for a 24-month visit HIV.E.DE176 First visit after the end of breastfeeding HIV-exposed infant attending MCH services for a first visit after the end of breastfeeding HIV.E.DE177 Weeks postpartum Number of weeks postpartum on this visit date HIV.E.DE178 Birth cohort Month and year of infant's birth, which the infant is registered into. The cohort is a group of infants born in the same month, whose status is followed over time. HIV.E.DE179 Registered in birth cohort Whether the infant has been registered in a birth cohort HIV.E.DE180 EID sample number Early infant diagnosis (EID) sample number HIV.E.DE181 EID sample 1 First sample used to test an infant for HIV HIV.E.DE182 EID sample 2 Second sample used to test an infant for HIV HIV.E.DE183 EID test number Early infant diagnosis (EID) HIV test number using the same sample HIV.E.DE184 EID test number 1 First test on a sample to test an infant for HIV HIV.E.DE185 EID test number 2 Second test on a sample to test an infant for HIV HIV.E.DE186 EID test number 1 test result Early infant diagnosis test number 1 test result HIV.E.DE187 Positive Positive HIV test result from the nucleic acid test HIV.E.DE188 Negative Negative HIV test result from the nucleic acid test HIV.E.DE189 Indeterminate Indeterminate HIV test result from the nucleic acid test HIV.E.DE190 EID test number 2 test result Early infant diagnosis test number 2 test result HIV.E.DE191 Positive Positive HIV test result from the nucleic acid test HIV.E.DE192 Negative Negative HIV test result from the nucleic acid test HIV.E.DE193 Indeterminate Indeterminate HIV test result from the nucleic acid test HIV.E.DE194 Assay number in testing strategy The number of the assay (test kit) in the HIV testing strategy HIV.E.DE195 Assay 0 A community outreach test-for-triage or self-test which is not included in the HIV testing strategy HIV.E.DE196 Assay 1 The first test in the HIV testing strategy HIV.E.DE197 Assay 2 The second test in the HIV testing strategy HIV.E.DE198 Assay 3 The third test in the HIV testing strategy HIV.E.DE199 Assay 1 repeated The first test in the HIV testing strategy HIV.E.DE200 Test result of HIV assay 1 The result of the first HIV assay in the testing strategy HIV.E.DE201 Reactive The result of the HIV assay in the testing strategy was reactive HIV.E.DE202 Non-reactive The result of the HIV assay in the testing strategy was non-reactive HIV.E.DE203 Invalid The result of the HIV assay in the testing strategy was invalid HIV.E.DE204 Test result of HIV assay 2 The result of the second HIV assay in the testing strategy HIV.E.DE205 Reactive The result of the HIV assay in the testing strategy was reactive HIV.E.DE206 Non-reactive The result of the HIV assay in the testing strategy was non-reactive HIV.E.DE207 Invalid The result of the HIV assay in the testing strategy was invalid HIV.E.DE208 Test result of HIV assay 3 The result of the third HIV assay in the testing strategy HIV.E.DE209 Reactive The result of the HIV assay in the testing strategy was reactive HIV.E.DE210 Non-reactive The result of the HIV assay in the testing strategy was non-reactive HIV.E.DE211 Invalid The result of the HIV assay in the testing strategy was invalid HIV.E.DE212 Test result of HIV assay 1 repeated The result of the repeated first HIV assay in the testing strategy HIV.E.DE213 Reactive The result of the HIV assay in the testing strategy was reactive HIV.E.DE214 Non-reactive The result of the HIV assay in the testing strategy was non-reactive HIV.E.DE215 Invalid The result of the HIV assay in the testing strategy was invalid HIV.E.DE216 Test result of syphilis assay 1 The result of the first syphilis assay in the testing strategy HIV.E.DE217 Reactive The result of the first syphilis assay in the testing strategy was reactive HIV.E.DE218 Non-reactive The result of the first syphilis assay in the testing strategy was non-reactive HIV.E.DE219 Invalid The result of the HIV assay in the testing strategy was invalid HIV.E.DE220 Test result of syphilis assay 1 repeated The result of the first syphilis assay repeated in the testing strategy HIV.E.DE221 Reactive The result of the first syphilis assay repeated in the testing strategy was reactive HIV.E.DE222 Non-reactive The result of the first syphilis assay repeated in the testing strategy was non-reactive HIV.E.DE223 Invalid The result of the first syphilis assay repeated in the testing strategy was invalid HIV.E.DE224 HIV test date Date of the HIV test HIV.E.DE225 Infant HIV status HIV status reported after applying the HIV testing algorithm. No single HIV test can provide an HIV-positive diagnosis. HIV.E.DE226 HIV-positive Infant is HIV-positive HIV.E.DE227 HIV-negative Infant is HIV-negative HIV.E.DE228 Unknown Infant has unknown HIV status HIV.E.DE229 Infant ART start date The date on which the infant was started or restarted on antiretroviral therapy (ART) HIV.E.DE230 Final diagnosis of HIV-exposed infant HIV-exposed infant final status at 18 months or 3 months after cessation of breastfeeding (whichever is later). HIV.E.DE231 HIV-positive The infant is HIV-positive HIV.E.DE232 HIV-negative and no longer breastfeeding The infant is HIV-negative and the mother has quit breastfeeding HIV.E.DE233 HIV status unknown The final HIV status of the child is unknown because the infant died, was lost to follow-up or transferred out without ever having an HIV-positive diagnosis or is active in care but was not tested at 18 months HIV.E.DE234 HIV-exposed infant reason for unknown final status The outcome for the infant does not have a final outcome, which may because of death, stopped treatment or lost to follow-up. HIV.E.DE235 Lost to follow-up Twenty-eight days or more since last missed appointment HIV.E.DE236 Transferred out The client transferred to another facility HIV.E.DE237 Death (documented) People living with HIV previously on ART who are confirmed to have died from any cause HIV.E.DE238 Refused (stopped) treatment Client was contacted and confirmed to have stopped ART HIV.E.DE239 Date of death of infant Date that the infant died HIV.E.DE240 Cause of death of infant The infant's cause of death HIV.E.DE241 Infant died within 24 hours of childbirth The infant died within 24 hours of childbirth HIV.E.DE242 Action(s) needed during infant follow-up visit Any actions needed during infant follow-up visit HIV.E.DE243 Timing of additional infant HIV test Age in months when additional infant HIV test is performed HIV.E.DE244 Date of sample collection of additional infant HIV test Date of sample collection of additional infant HIV test HIV.E.DE245 Haemoglobin (Hb) result Result of woman's haemoglobin test during ANC, labour or delivery. Full blood count testing is recommended, and if not available, use of haemoglobinometer over haemoglobin colour scale. HIV.E.DE246 Blood group and Rh factor Mother's blood type and blood Rh factor HIV.E.DE247 A+ Mother's blood type and blood Rh factor is A+ HIV.E.DE248 A- Mother's blood type and blood Rh factor is A- HIV.E.DE249 B+ Mother's blood type and blood Rh factor is B+ HIV.E.DE250 B- Mother's blood type and blood Rh factor is B- HIV.E.DE251 O+ Mother's blood type and blood Rh factor is O+ HIV.E.DE252 O- Mother's blood type and blood Rh factor is O- HIV.E.DE253 AB+ Mother's blood type and blood Rh factor is AB+ HIV.E.DE254 AB- Mother's blood type and blood Rh factor is AB- HIV.E.DE255 Asymptomatic bacteriuria (ASB) test result Result of urine culture (or urine Gram-staining if not available over dipstick tests) for diagnosing asymptomatic bacteriuria HIV.E.DE256 Positive Result of test for asymptomatic bacteriuria is positive HIV.E.DE257 Negative Result of test for asymptomatic bacteriuria is negative HIV.E.DE258 Unknown Result of test for asymptomatic bacteriuria is unknown HIV.E.DE259 Urine protein test result Results of urine protein test of mother during ANC visit HIV.E.DE260 0 Result of urine protein test of mother during ANC visit is '0' HIV.E.DE261 + Result of urine protein test of mother during ANC visit is '+' HIV.E.DE262 ++ Result of urine protein test of mother during ANC visit is '++' HIV.E.DE263 +++ Result of urine protein test of mother during ANC visit is '+++' HIV.E.DE264 Type of hypertensive disorder Type of hypertensive disorder of the mother HIV.E.DE265 Chronic hypertension Hypertension detected pre-pregnancy or before 20 weeks' gestation HIV.E.DE266 Essential Hypertension without a known secondary cause (pre-pregnancy or at less than 20 weeks) HIV.E.DE267 Secondary Hypertension with a known secondary cause (e.g. renal disease; detected pre-pregnancy or at less than 20 weeks) HIV.E.DE268 White-coat hypertension sBP greater than or equal to 140 and/or dBP greater than or equal to 90 mmHg when measured in the office or clinic, and BP less than 135/85 mmHg using HBPM or ABPM readings (pre-pregnancy or at less than 20 weeks) HIV.E.DE269 Masked hypertension BP that is less than 140/90 mmHg at a clinic/office visit, but greater then or equal to 135/85 mmHg at other times outside the clinic/ office (pre-pregnancy or at less than 20 weeks) HIV.E.DE270 Gestational hypertension Hypertension arising de novo at greater than or equal to 20 weeks' gestation in the absence of proteinuria or other findings suggestive of pre-eclampsia HIV.E.DE271 Transient gestational hypertension Hypertension arising at greater than or equal to 20 weeks' gestation in the clinic, which resolves with repeated BP readings HIV.E.DE272 Pre-eclampsia Pre-eclampsia HIV.E.DE273 Superimposed on chronic hypertension Among women with chronic hypertension, development of new proteinuria, another maternal organ dysfunction(s), or evidence of uteroplacental dysfunction. HIV.G.DE1 CD4 count CD4 cell count in cells/mm^3 HIV.G.DE2 CD4 cell percentage CD4 cell percentage HIV.G.DE3 Baseline CD4 count CD4 count performed at HIV diagnosis HIV.G.DE4 Date of baseline CD4 count sample collection Date and time when baseline CD4 count test sample was collected HIV.G.DE5 Late ART initiation The client's first CD4 count from baseline CD4 test performed (such as at HIV diagnosis) was a count of <200 cells/mm3 HIV.G.DE6 Date of CD4 sample collection Date sample to be used for CD4 count was collected HIV.G.DE7 Viral load test conducted A viral load test was performed HIV.G.DE8 Date of viral load sample collection Date and time when the sample was collected to test the client's HIV viral load HIV.G.DE9 Date of first viral load sample collection Date and time when the sample was collected to test the client's HIV viral load for the first time HIV.G.DE10 Date viral load sample sent Date viral load sample sent to the lab HIV.G.DE11 First viral load test result Result from the initial viral load test in number of copies/mL HIV.G.DE12 Viral load test result Result from the viral load test in number of copies/mL HIV.G.DE13 HIV viral load specimen type The type of specimen to be used to test viral load HIV.G.DE14 Liquid plasma specimen for viral load testing Liquid plasma and using ethylenediaminetetraacetic acid (EDTA) or plasma preparation tubes for viral load test HIV.G.DE15 Dried blood spot specimen Dried blood spot specimen (DBS) for viral load test HIV.G.DE16 Dried plasma spot from a plasma separation card Dried plasma spot from a plasma separation card for viral load test HIV.G.DE17 HBsAg test date Date client was tested for hepatitis B virus (HBV) HIV.G.DE18 HBsAg test result Hepatitis B virus test result (HBsAg) HIV.G.DE19 Positive HBsAg test result was positive HIV.G.DE20 Negative HBsAg test result was negative HIV.G.DE21 Indeterminate HBsAg test result was indeterminate HIV.G.DE22 Reason Hepatitis B test not conducted Reason why a hepatitis B test was not done HIV.G.DE23 Test delayed to next contact or referred Test has been delayed to the next contact or client was referred to another provider/facility HIV.G.DE24 Stock-out or expired Test out of stock or stock present but expired HIV.G.DE25 Machine or technician not available or machine not functioning Test machine or technician is unavailable, or machine is not functioning HIV.G.DE26 Client declined / refused test Client declined or refused test being undertaken HIV.G.DE27 Other Other reason test not performed HIV.G.DE28 Other (specify) Other reason test not performed (specify) HIV.G.DE29 Hepatitis B diagnosis Client's hepatitis B diagnosis HIV.G.DE30 Hepatitis B positive Client is positive for Hepatitis B HIV.G.DE31 Hepatitis B negative Client is negative for Hepatitis B HIV.G.DE32 Hepatitis C screening date Date when client was screened for HCV HIV.G.DE33 Hepatitis C test ordered Hepatitis C test has been ordered HIV.G.DE34 Hepatitis C test conducted Whether a hepatitis C test was conducted HIV.G.DE35 Reason Hepatitis C test not done Reason why a hepatitis C test was not done HIV.G.DE36 Test delayed to next contact or referred Test has been delayed to the next contact or client was referred to another provider/facility HIV.G.DE37 Stock-out or expired Test out of stock or stock present but expired HIV.G.DE38 Machine or technician not available or machine not functioning Test machine or technician is unavailable, or machine is not functioning HIV.G.DE39 Client declined / refused test Client declined or refused test being undertaken HIV.G.DE40 Other Other reason test not performed HIV.G.DE41 Other (specify) Other reason test not performed (specify) HIV.G.DE42 HCV test date Date client was tested for hepatitis C virus (HCV antibody, HCV RNA or HCV core antigen) HIV.G.DE43 HCV test result Hepatitis C virus test result (HCV antibody, HCV RNA or HCV core antigen) HIV.G.DE44 Positive HCV test result was positive HIV.G.DE45 Negative HCV test result was negative HIV.G.DE46 Indeterminate HCV test result was indeterminate HIV.G.DE47 HCV viral load test date Hepatitis C viral load test date HIV.G.DE48 HCV viral load test result Hepatitis C viral load test result (qualitative) HIV.G.DE49 Detected HCV was detected HIV.G.DE50 Not detected HCV was not detected HIV.G.DE51 Hepatitis C diagnosis Client's hepatitis C diagnosis HIV.G.DE52 Hepatitis C positive Client is positive for hepatitis C HIV.G.DE53 Hepatitis C negative Client is negative for hepatitis C HIV.G.DE54 Syphilis test required Syphilis test is required HIV.G.DE55 Syphilis test type Type of diagnostic test used for syphilis (treponema pallidum) HIV.G.DE56 Treponemal Treponemal test used HIV.G.DE57 Non-treponemal Non-treponemal test used HIV.G.DE58 POC Test Point-of-care (POC) test used HIV.G.DE59 NAAT Nucleic Acid Amplification Test (NAAT) used HIV.G.DE60 Other Other test used HIV.G.DE61 Other syphilis test type (specify) Other test used (specify) HIV.G.DE62 Reason syphilis test not done Reason why a syphilis test was not done HIV.G.DE63 Test delayed to next contact or referred Test has been delayed to the next contact or client was referred to another provider/facility HIV.G.DE64 Stock-out or expired Test out of stock or stock present but expired HIV.G.DE65 Machine or technician not available or machine not functioning Test machine or technician is unavailable, or machine is not functioning HIV.G.DE66 Client declined / refused test Client declined or refused test being undertaken HIV.G.DE67 Other Other reason test not performed HIV.G.DE68 Other (specify) Other reason test not performed (specify) HIV.G.DE69 Syphilis test date Date of syphilis test HIV.G.DE70 Syphilis test result Result from syphilis test HIV.G.DE71 Positive Test result is positive for syphilis HIV.G.DE72 Negative Test result is negative for syphilis HIV.G.DE73 Inconclusive Test result is inconclusive HIV.G.DE74 Syphilis diagnosis Client's syphilis diagnosis HIV.G.DE75 Syphilis positive Client is positive for syphilis HIV.G.DE76 Syphilis negative Client is negative for syphilis HIV.G.DE77 Other tests conducted If the health worker performed other tests on the woman that are not explicitly listed in the application, select 'yes' here and fill in the details below. HIV.G.DE78 Other test(s) name Input the name of other test(s) that were done. HIV.G.DE79 Other test(s) date Input the date of other test(s) that were done. HIV.G.DE80 Other test(s) result(s) Input the result from the test(s). HIV.H.DE1 Reason for follow-up The reason why the client is being followed up HIV.H.DE2 Missed care visit Client did not present for a care appointment as scheduled / as expected HIV.H.DE3 Missed medication pickup Client did not pick up medication as scheduled from pharmacy or other drug distribution point HIV.H.DE4 Did not initiate ART Client did not initiate ART at the same time as diagnosis (e.g., because they required additional counselling) and required follow-up for ART initiation HIV.H.DE5 Incomplete visit Client presented for care, but left before services were completed, e.g., due to long wait times or not staying to have labs taken HIV.H.DE6 Inconclusive HIV status Client has not returned for a follow-up test after an inconclusive test result HIV.H.DE7 Test results received Client needs to be informed of test results (e.g., viral load) HIV.H.DE8 Other follow-up reason Client was followed up for another reason HIV.H.DE9 Other follow-up reason (specify) Client was followed up for another reason (specify) HIV.H.DE10 Client contact attempted An attempt to locate the client was made HIV.H.DE11 Date of contact attempt Date of attempt to contact client HIV.H.DE12 Contact attempted by Who attempted to reach out to the client HIV.H.DE13 Contact method Method used to try to reach out to the client HIV.H.DE14 Home visit Contacted client at home HIV.H.DE15 Text message Contacted client by short message service (SMS) text HIV.H.DE16 Phone Contacted client by phone call HIV.H.DE17 Source of information Source of information about the client HIV.H.DE18 Client The client was the source of information HIV.H.DE19 Informed by treatment provider Source of information was a treatment provider of the client HIV.H.DE20 Informed by family or partner Source of information was a family member of partner HIV.H.DE21 Other source of information Information about the client's status was provided by someone else HIV.H.DE22 Other source of information (specify) Information about the client's status was provided by someone else (specify) HIV.H.DE23 Outcome from outreach attempt Detailed outcome from the attempt to locate the client HIV.H.DE24 Returning to clinic Client was located and agreed to return to clinic HIV.H.DE25 Self-transferred out Client transferred to another facility for care (client-initiated transfer, not provider-initiated transfer) HIV.H.DE26 Hospitalized Client was hospitalized HIV.H.DE27 Refused to return Client was found but declined to return to treatment HIV.H.DE28 Not located Attempt was made to locate client, but client was not found HIV.H.DE29 Died (reported) The client was reported as having died HIV.H.DE30 Moved from catchment area The client moved from the catchment area (may be reported from the community level) HIV.H.DE31 Date client moved from catchment area The date on which the client moved from the catchment area, if known HIV.H.DE32 New catchment area New catchment area where the client resides HIV.H.DE33 Partner or contact of index case The client was identified by an index case as a partner or contact HIV.H.DE34 HIV status of partner or contact HIV status of the partner or contact given by the index case HIV.H.DE35 Already knew positive The partner or contact of the index case already knew they are HIV-positive HIV.H.DE36 Newly diagnosed The partner or contact of the index case is newly diagnosed as HIV-positive HIV.H.DE37 Negative The partner or contact of the index case is newly diagnosed is HIV-negative HIV.H.DE38 Date of death If deceased, the date that the client died HIV.H.DE39 Cause of death Cause of death, if known HIV.H.DE40 Place of death Where the client died, if known HIV.H.DE41 HIV treatment outcome The outcome for the client which is used for reporting retention/attrition. HIV.H.DE42 Lost to follow-up Twenty-eight days or more since last missed appointment HIV.H.DE43 Transferred out The client transferred to another facility HIV.H.DE44 Death (documented) People living with HIV previously on ART who are confirmed to have died from any cause HIV.H.DE45 Refused (stopped) treatment Client was contacted and confirmed to have stopped ART (reasons may include stigma and discrimination, faith healing, etc.) HIV.H.DE46 Date patient lost to follow-up Date patient was lost to follow-up (LTFU) HIV.H.DE47 On ART Client is currently taking ART HIV.H.DE48 Date HIV treatment outcome changed The date on which the client's outcome (lost to follow-up, transferred out, death (documented), or refused (stopped) treatment) changed HIV.H.DE49 Transfer confirmed Select if transfer to another facility is confirmed HIV.H.DE50 Transfer to facility Name of health facility client was transferred to HIV.H.DE51 Date of transfer out The date the client transferred out of the facility to be provided with care at another facility HIV.H.DE52 Adherence assessment Whether client is adherent or not to ART regimen per national guidelines (immunological or virological monitoring) HIV.H.DE53 Reason(s) for adherence problem Reason why client is not adherent HIV.H.DE54 Forgot Client reported not being adherent because they forgot HIV.H.DE55 Toxicity/side effects Client reported not being adherent because of toxicity/side effects HIV.H.DE56 Busy Client reported not being adherent because they were busy HIV.H.DE57 Change of routine Client reported not being adherent because of a change of routine HIV.H.DE58 Travel cost Client reported not being adherent because of travel cost HIV.H.DE59 Distance to clinic Client reported not being adherent because of distance to clinic HIV.H.DE60 Client lost/ran out of pills Client reported not being adherent because of client lost/ran out of pills HIV.H.DE61 Stock-out Client reported not being adherent because of a stock-out HIV.H.DE62 Too ill Client reported not being adherent because of being too ill HIV.H.DE63 Pill burden Client reported not being adherent because of the pill burden HIV.H.DE64 Felt well Client reported not being adherent because they felt well HIV.H.DE65 Depression Client reported not being adherent because of depression HIV.H.DE66 Alcohol use Client reported not being adherent because of alcohol use HIV.H.DE67 Substance use Client reported not being adherent because of substance use (i.e., drugs) HIV.H.DE68 Stigma/disclosure concerns Client reported not being adherent because of stigma/disclosure concerns HIV.H.DE69 Lack of food Client reported not being adherent because of a lack of food HIV.H.DE70 Poor palatability Client reported not being adherent because of poor palatability HIV.H.DE71 Other Client reported not being adherent because of other reason HIV.H.DE72 Other (specify) Client reported not being adherent because of other reason (specify) HIV.H.DE73 Date ART stopped Date on which client stopped ART HIV.H.DE74 Reason ART stopped Reason why client intentionally stopped ART HIV.H.DE75 Toxicity/side effects Client stopped ART because of toxicity/side effects HIV.H.DE76 Severe illness, hospitalization Client stopped ART because of severe illness, hospitalization HIV.H.DE77 Drugs out of stock Client stopped ART because of drugs being out of stock HIV.H.DE78 Client lacks finances Client stopped ART because client lacked finances HIV.H.DE79 Excluded HIV infection in infant Client stopped ART because the infant was determined to not have HIV HIV.H.DE80 Other reason for stopping ART Client stopped ART for other reason HIV.H.DE81 Other reason for stopping ART (specify) Client stopped ART for other reason (specify) HIV.I.DE1 Emergency referral Referral for urgent care HIV.I.DE2 Reason for referral Reason why the client is being referred. If diagnosed, this may include the reason for the diagnosis. HIV.I.DE3 Hospital Client's clinical status warrants hospitalization HIV.I.DE4 Referral for screening including diagnostics and lab testing The client is referred because they need a lab test done and/or diagnostics done, but those services are unavailable at the current health facility or providers. This includes referral for TB screening (is symptomatic of TB, has had close contact with confirmed TB case, etc.) and other comorbidities or coinfections. HIV.I.DE5 TB referral Referral for TB care HIV.I.DE6 Antenatal care referral Client was referred because the client is pregnant HIV.I.DE7 Referral for other general services If none of the reasons above apply, this should be selected HIV.I.DE8 Referral for other general services (specify) If none of the reasons above apply, specify the reason(s) HIV.I.DE9 Any treatment given before referral? If client was referred, was any treatment provided before referral? HIV.I.DE10 Date of scheduled referral appointment When the referral is scheduled HIV.I.DE11 Location of scheduled referral appointment Where the client is being referred to HIV.I.DE12 Date referral was made The date the referral was made HIV.I.DE13 Provider who made referral The name of the provider who made the referral HIV.I.DE14 Provider's facility Facility client is being referred from HIV.I.DE15 Provider's telephone number The contact details of the provider making the referral HIV.I.DE16 Referral notes Any additional relevant details of clinical significance for the referral facility to provide quality care HIV.I.DE17 Client history summary With interoperable systems, the provider receiving the referral should be able to access the client's health record digitally. However, in the absence of this, the referral provider should receive a summary of the client's health records that includes the client's history, medications, medications prescribed or dispensed, reported issues and concerns, and any other relevant clinical information the health care provider had already obtained. HIV.PRV.DE1 At elevated risk for HIV acquisition Client is at elevated risk for HIV acquisition, defined according to country/programme context HIV.PRV.DE2 HIV prevention intervention HIV prevention intervention that client accessed HIV.PRV.DE3 PrEP service Client accessed PrEP services HIV.PRV.DE4 OAMT Client accessed opioid agonist maintenance treatment (OAMT) services HIV.PRV.DE5 NSP Client accessed needle-syringe programme (NSP) services HIV.PRV.DE6 STI services Client accessed sexually transmitted infection (STI) services HIV.PRV.DE7 VMMC Client accessed voluntary medical male circumcision (VMMC) services HIV.PRV.DE8 Other Client accessed other HIV prevention services HIV.PRV.DE9 Other (specify) Client accessed other HIV prevention services (specify) HIV.PRV.DE10 Date accessed HIV prevention intervention Date the client accessed HIV prevention intervention HIV.PRV.DE11 HIV status of contact The HIV status of the client's contact HIV.PRV.DE12 HIV-positive Client's contact is HIV-positive HIV.PRV.DE13 HIV-negative Client's contact is HIV-negative HIV.PRV.DE14 Unknown Client does not know contact's HIV status HIV.PRV.DE15 Date injecting equipment provided Date client was provided with injecting equipment HIV.PRV.DE16 Number of needles-syringes provided Number of needles-syringes provided to client HIV.PRV.DE17 Date OAMT initiated Date client initiated opioid agonist maintenance treatment (OAMT) HIV.PRV.DE18 Date OAMT dose received Date client received opioid agonist maintenance treatment (OAMT) dose HIV.PRV.DE19 Date OAMT take-away dose(s) dispensed Date the client was dispensed opioid agonist maintenance treatment (OAMT) take-away dose(s) HIV.PRV.DE20 Currently on OAMT Client is currently on opioid agonist maintenance treatment (OAMT) at reporting date, defined according to country/program to account for medication dispensed and LTFU criterion HIV.PRV.DE21 Retained on OAMT Client is retained on opioid agonist maintenance treatment (OAMT) at reporting date, defined according to country/program to account for medication dispensed and LTFU criterion HIV.PRV.DE22 Client being inducted on OAMT Client is currently being inducted on opioid agonist maintenance treatment (OAMT), defined according to country/program HIV.PRV.DE23 Client on reducing doses of OAMT Client is current on reducing doses of opioid agonist maintenance treatment (OAMT), defined according to country/program HIV.PRV.DE24 Date first maintenance dose received First date on which client received maintenance dose HIV.PRV.DE25 Date of loss to follow-up or OAMT stopped Date of loss to follow-up or opioid agonist maintenance treatment (OAMT) stopped HIV.PRV.DE26 Date medications dispensed Date the client was dispensed medications HIV.PRV.DE27 Date medications prescribed Date the client was prescribed medications HIV.PRV.DE28 Number of days prescribed Days of medication client has been prescribed HIV.Config.DE1 Population prevalence of TB The tuberculosis prevalence in the general population in number of cases per 100 000 persons or greater. HIV.Config.DE2 Population prevalence of soil-transmitted helminth infection The percentage of individuals in the general population infected with at least one species of soil-transmitted helminths HIV.Config.DE3 Population incidence of HIV in the absence of PrEP HIV incidence number of cases per 100 person–years in the absence of PrEP HIV.Config.DE4 Population prevalence of HIV The proportion of the population that are HIV-positive HIV.Config.DE5 Prevalence of pretreatment NNRTI drug resistance Prevalence of pretreatment HIV drug resistance to NNRTIs among people initiating first-line ART HIV.Config.DE6 Malaria-endemic setting Whether the setting is a malaria-endemic setting HIV.Config.DE7 Population prevalence of syphilis The proportion of the population with syphilis HIV.Config.DE8 Population prevalence of hepatitis B The proportion of hepatitis B surface antigen (HBsAg) seroprevalence in the general population HIV.Config.DE9 Population prevalence of hepatitis C The proportion of hepatitis C virus (HCV) antibody seroprevalence in the general population HIV.Config.DE10 Prevalence of HIV in the catchment area The proportion of the population from the health facility's catchment area that are HIV-positive (estimated) HIV.Config.DE11 Ultrasound available at the health facility Whether an ultrasound machine is available and functional in the facility and a trained health worker is available to use it HIV.Config.DE12 HIV burden of the setting HIV burden of the setting (high or low) based on the national HIV prevalence or where the HIV prevalence and/or incidence in a geographical setting is higher than national prevalence and, therefore, needs priority in the HIV response HIV.Config.DE13 High HIV burden setting Settings with >5% national HIV prevalence and subpopulations and geographic settings where HIV prevalence and/or incidence is higher than nationally. HIV.Config.DE14 Low HIV burden setting Settings with <5% HIV national prevalence but where certain populations (primarily key populations and their partners) and geographic settings may have higher HIV prevalence and/or incidence than nationally and, therefore, need priority in the HIV response HIV.Config.DE15 HPV DNA testing operational at the health facility Is HPV DNA testing operational at the health facility for cervical cancer screening? HIV.Config.DE16 Routine viral load testing is available Routine viral load testing is available in the facility HIV.Config.DE17 Health facility ID Unique ID of the health facility that recorded the client. This ID could represent a universal health facility ID, if used in the country. Alternatively this ID can also be generated by the national surveillance system and assigned to reporting facility. HIV.Config.DE18 TB treating facility ID The facility where the client is receiving tuberculosis (TB) treatment HIV.Config.DE19 Other priority populations Other populations of priority of HIV prevention and care in local context (provided during adaptation) HIV.Config.DE20 Reporting period end date End date of the reporting period HIV.Config.DE21 Reporting period start date Start date of the reporting period HIV.Config.DE22 Reporting date Reporting date, for surveys performed on a specific date
This code system defines the concepts used in the World Health Organization SMART HIV DAK
Referred by the community level services
Unique identifier generated for new clients or a universal ID, if used in the country
National unique identifier assigned to the client, if used in the country
National health unique identifier assigned to the client, if used in the country
National programme unique identifier assigned to the client, if used in the country
National health insurance unique identifier assigned to the client, if used in the country
The client's date of birth (DOB) if known
If DOB is unknown, enter the client's estimated age. Display client's age in number of years.
Calculated age (number of years) of the client based on date of birth
Client identifies in non-binary way or as a sexual and gender minority (or minorities)
Client's home address or address which the client is consenting to disclose
Client does not have an active marriage contract
Client has never entered into a marriage contract
Client is divorced, whereby marriage contract has been declared dissolved and inactive
Client does not wish to disclose marital status
Client reports that they are in a domestic partnership
Client's marriage contract has been declared null and to have not existed
Client is legally separated from their spouse
Client is subject to an interlocutory decree
Client's telephone number (a landline or a mobile phone number)
This should be a context-specific list of administrative areas, such as villages, districts, etc. The purpose of this data element is to allow for grouping and flagging of client data to a particular facility's catchment area. This can be input into the system by the end user OR it can be automated in the database based on the end user's attributes.
Indication that client gave consent to be contacted
Whether client wants to receive text or other messages as follow-up for HIV services
How the client would like to receive family planning communications
The client would like to receive communications via Text message/SMS
Client would like to receive communications via voice call
Client's primary email account where the client can be contacted
Name of an alternate contact, which could be next of kin (e.g. partner, husband, mother, sibling, etc.). The alternate contact would be used in the case of an emergency situation.
Alternate contact's home address or address which the client is consenting to disclose
The alternate contact's relationship to the client (e.g. partner, husband, mother, sibling, etc.)
First encounter for screening for human immunodeficiency virus
Retesting for human immunodeficiency virus
Client attending facility for HIV testing services visit
Client reported coming to the facility after receiving a provider-assisted referral or patient referral from a contact or partner
The client is a contact or partner of a person diagnosed with HIV (an index case)
Partner or contact of an HIV testing client (non-index case)
The client is a contact or partner identified through partner or social network services, but is not known to be a partner of an index-case
Type of contact or partner for partner services
Client's relationship to the person that referred the client for partner services or family services
Client is the biological child of the person that referred the client for family services
Client is a drug-injecting partner of the person that referred the client for partner services
Client is a sexual partner of the person that referred the client for partner services
Client is a social contact of the person that referred the client for social-network services
Contact with and (suspected) exposure to HIV
When the client is reported to have had suspected exposure to HIV
Date and time when the client had suspected exposure to HIV
Whether testing is happening in the community or at a facility
Testing is happening in the community, which includes mobile testing
Specific point in the community where testing is happening
Mobile testing (e.g. through vans or temporary testing facilities)
The client tested through mobile testing, such as through vans or temporary testing facilities
Voluntary counselling and testing centres (not within a health facility setting)
The client tested at a voluntary counselling and testing centre (not in a health facility setting)
The client tested through another type of community-based testing
Specific point where testing is happening at a facility
Provider-initiated tested in a clinic or emergency facility
The client tested though provider-initiated HIV testing & counselling, which could be at an emergency facility
The client tested at an antenatal care clinic, including labour and delivery
Voluntary counselling and testing (within a health facility setting)
The client tested through voluntary counselling and testing (within a health facility setting)
The client tested at a family planning clinic
The client tested at another type of facility
Gestational age in weeks and/or days depending on the source of gestational age
Expected date of delivery based on gestational age
Don't know HIV status - client does not know partner's HIV status
Client's partner is a member of a key population, that has an increased risk of HIV
Client's partner is a man who has sex with men
Client's partner identifies as trans and gender-diverse
Client's partner is a person who injects drugs
People living in prisons and other closed settings
Client's partner lives in a prison or other closed setting
Has used an HIV self-test before (reported)
The client reported having used an HIV self-test before
Date when the HIV self-test was conducted
Client is a member of a key population that has an increased risk of HIV
The type of key population that the client is included in
Client identifies as trans and gender-diverse
Client lives in a prison or another closed setting
Calculated field based on age and gender, if client is 10 years or older and under 20 years old
Calculated field based on age and gender, if client is 20 years or older and under 25 years old
Client considered an orphan or vulnerable child
Client has been informed of their HIV test result
Ways in which the client was exposed to HIV
Non-occupational violent exposure to HIV
Exposure to HIV through non-occupational consensual sex
The date on which the client was diagnosed with HIV
The facility where the client received an HIV-positive diagnosis
Date of first positive test indicative of HIV diagnosis
Earliest date of HIV diagnosis determined according to the national HIV testing algorithm
The date on which the client started or restarted antiretroviral therapy (ART)
The client's age (in years) when given an HIV diagnosis
Client's relationship to the contact identified for voluntary partner services or family services
Contact identified for family services is the biological child of the client
Contact identified for partner services is a drug-injecting partner of the client
Contact identified for partner services is a sexual partner of the client
Contact identified for social-network services is a social contact of the client
An HIV test of the client was ordered by the provider
An HIV test was performed on the client during the visit
Antibody test for HIV performed with a rapid diagnostic
Antibody test for HIV performed with an enzyme immunoassay
Virological test, which includes testing for early infant diagnosis
Antibody test for HIV and syphilis performed with a rapid diagnostic
Antibody test for HIV performed by self-tester using a rapid diagnostic
The number of the assay (test kit) in the HIV testing strategy
A community outreach test-for-triage or self-test which is not included in the HIV testing strategy
The first test in the HIV testing strategy
The second test in the HIV testing strategy
The third test in the HIV testing strategy
The result of the first HIV assay in the testing strategy
The result of the HIV assay in the testing strategy was reactive
The result of the HIV assay in the testing strategy was non-reactive
The result of the HIV assay in the testing strategy was invalid
The result of the second HIV assay in the testing strategy
The result of the third HIV assay in the testing strategy
The result of the repeated first HIV assay in the testing strategy
The result from HIV testing after applying the testing algorithm
HIV status reported after applying the national HIV testing algorithm. No single HIV test can provide an HIV-positive diagnosis.
Date patient received positive HIV test confirmation (with written documentation)
Name or identifier of health facility where HIV test was confirmed
Probable route(s) of transmission of HIV to client
Probable route of HIV transmission was through heterosexual sex
Probable route of HIV transmission was through sex between men
Probable route of HIV transmission was through unprotected intercourse during sex work
Injecting drug use with unsterile equipment
Probable route of HIV transmission was through injecting drug use with unsterile equipment
Probable route of HIV transmission was nosocomial
Probable route of HIV transmission to an infant was during pregnancy, labour, delivery and breastfeeding (vertical transmission)
Probable route of HIV transmission was other and may include needle accidents, blood transfusion, blood products or organ/tissue donations, tattoos, piercings, circumcision, or acupuncture.
If the client does not know the HIV status of the client's partner(s), offer to test and add results here
An HIV test for the client's partner has been ordered
The HIV test result of the client's partner
The HIV status of a sexual or drug-injecting partner of the client, based on a confirmed test result
ART and virally suppression status of a partner of the client
Whether counselling was provided to a client during the visit
Whether counselling was provided to a client who has been diagnosed with HIV
Hepatitis B positive counselling conducted
Whether counselling was provided to a client who has been diagnosed with hepatitis B
Hepatitis C positive counselling conducted
Whether counselling was provided to a client who has been diagnosed with hepatitis C
Syphilis counselling, treatment and further testing
Whether counselling and treatment was provided to a client who has been diagnosed with syphilis. Additional testing (RPR test) recommended.
Linked to enrolment in care and ART initiation
Linkage made from HIV testing to enrolment in care following an HIV diagnosis
Whether counselling for voluntary medical male circumcision (VMMC) was provided following an HIV-negative test
Prevention services offered and referrals
Offer male and female condoms and condom-compatible lubricants
Offer pre-exposure prophylaxis (PrEP) for people at elevated risk for HIV acquisition
Offer pre-exposure prophylaxis (PrEP) to people with substantial ongoing risk of HIV infection
Offer post-exposure prophylaxis (PEP) following suspected exposure
Offer or refer client for PEP following suspected exposure
Voluntary medical male circumcision (VMMC)
Harm reduction for people who inject drugs
Offer or refer to harm reduction services for people who inject drugs (needle and syringe programmes, opioid substitution therapy, other drug-dependence treatment and opioid overdose prevention and management)
Behavioural interventions to support risk reduction, particularly for people with HIV and members of key populations
Offer or refer to behavioural interventions to support risk reduction, particularly for people with HIV and members of key populations
HIV testing for partners and biological children
Offer voluntary testing for all partners and biological children of positive cases (includes partner services and index case testing), as welll as partners and social contacts of people from key populations, where appropriate
HIV testing for partners and social contacts of people from key populations, where appropriate
Offer voluntary testing for partners and social contacts of people from key populations, where appropriate
Sexual and reproductive health integrated services
Offer or refer to sexual and reproductive health services
Offer contraception and family planning services
Prevention of mother-to-child transmission counselling
Offer services for prevention of mother-to-child transmission (counselling)
Cervical cancer screening and treatment counselling
Offer cervical cancer screening and treatment counselling and services
Anal cancer screening (for men who have sex with men)
Offer services for anal cancer screening (for men who have sex with men)
Offer sexually transmitted infection (STI) testing and treatment services
Other clinical services offered or referrals given to the client
Assessment and provision of vaccinations
Assessment and provision of vaccinations, such as for people from key populations, pregnant women and infants; and, where appropriate, tetanus vaccination for adolescent boys and men receiving VMMC
Hepatitis B (HBV) and hepatitis C virus (HCV) testing and treatment provided
Offer or refer for HBV and/or HCV testing and treatment
Co-trimoxazole chemoprophylaxis to prevent Pneumocystis carinii pneumonia provided
Offer or refer for co-trimoxazole chemoprophylaxis to prevent pneumocystis carinii pneumonia
Intensified TB case finding and linkage to TB treatment provided
Offer or refer for intensified TB case finding and linkage to TB treatment
Provision of isoniazid preventive therapy if person does not have TB
Offer or refer for provision of isoniazid preventive therapy if person does not have TB
Malaria prevention (such as bed nets and prophylaxis), depending on epidemiology
Offer or refer for malaria prevention (such as bed nets and prophylaxis), depending on epidemiology
Offer or refer for other support services
Offer or refer for mental health services
Psychosocial counselling, support and treatment adherence counselling
Offer or refer for psychosocial counselling, support and treatment adherence counselling
Support for disclosure and partner services
Offer or refer for support for disclosure and partner services
Offer or refer for legal and social services
Services for responding to violence against women
Offer or refer for services for responding to violence against women, including first-line support and psychosocial support, post-rape care and other support services including shelters, legal services and women and child protection services
Clinical enquiry for intimate partner violence (IPV) done
Whether a clinical enquiry for intimate partner violence was conducted
Intimate partner violence enquiry results
Result of medical inquiry for intimate partner violence
Client received treatment and/or counselling as needed
Client was referred to another provider/facility
No additional action was deemed necessary
Other intimate partner violence (IPV) result not described above
Other intimate partner violence (IPV) result not described above (specify)
Whether the client was offered voluntary partner services or family services
Count of contacts or partners given for social network-based/partner services
The quantity of contacts or partners given by a client that accepts social network-based/partner services for follow-up
Offered social network-based/partner services
Whether the client was offered social network-based partner services
Accepted social network-based/partner services
Whether the client accepted social network-based partner services
Contact first name to offer social network-based/partner services
First name of each contact given by the client to offer social network-based/partner services
Contact last name to offer social network-based/partner services
Last or family name of each contact given by the client to offer social network-based/partner services
Type of follow-up appointment for testing services
Other reason for the follow-up appointment
Other reason for the follow-up appointment (specify)
Date the patient is to return for monitoring, re-supply or any other reason
Date when follow-up is recommended based on follow up requirements
Whether a voluntary medical male circumcision procedure was performed
Date on which a voluntary medical male circumcision procedure was performed
Whether an adverse event was reported associated with a voluntary medical male circumcision (VMMC) procedure
Complications from voluntary medical male circumcision (VMMC) procedure resulted in death or hospitalization within 30 days of the procedure or permanent disability
Severity of the adverse event associated with voluntary medical male circumcision (VMMC) procedure
Severity of the adverse event associated with VMMC procedure was moderate
Severity of the adverse event associated with VMMC procedure was severe
When the adverse event associated with VMMC procedure occurred
The adverse event associated with VMMC procedure occurred during the procedure
The adverse event associated with VMMC procedure occurred within the first 30 days after the procedure
Type of adverse event associated with voluntary medical male circumcision (VMMC) procedure
Client experienced excessive skin removal
Client experienced scar or disfigurement
During VMMC procedure there was sharps injury to personnel
Client experienced other adverse VMMC event
Client experienced other adverse VMMC event (specify)
HIV retest prior to starting ART conducted
Client is at elevated risk for HIV acquisition
Syndrome or STI for which client is diagnosed
Client diagnosed with urethral discharge syndrome
Client diagnosed with vaginal discharge syndrome
Client diagnosed with lower abdominal pain
Client diagnosed with genital ulcer disease syndrome
Client diagnosed with anorectal discharge
Was the client diagnosed with any of the five STI syndromes during this visit?
Date on which the STI test was conducted
Client tested for Syphilis (treponema pallidum)
Client tested for herpes simplex virus (HSV1, HSV2)
Date of initiation of syphilis treatment
Test result is positive for Neisseria gonorrhoeae
Test result is negative for Neisseria gonorrhoeae
Date of initiation of Gonorrhoea treatment
Cervical or vaginal swab to be collected
Other specimen type to be collected (specify)
Type of diagnostic test used for syphilis (treponema pallidum)
Nucleic Acid Amplification Test (NAAT) used
Type of diagnostic test used for Neisseria gonorrhoeae
POC Test for Neisseria gonorrhoeae (specify)
Point-of-care (POC) test used for Neisseria gonorrhoeae (specify)
Type of diagnostic test used for Chlamydia trachomatis
Other type of test used for Chlaymdia (specify)
POC Test type for Chlamydia test (specify)
Point-of-care (POC) test used for Chlamydia (specify)
Type of diagnostic test used for Trichomonas vaginalis
POC Test type for Trichomonas vaginalis test (specify)
Type of diagnostic test used for herpes simplex virus (HSV)
Other type of test used for Herpes simplex virus (HSV) test (specify)
Type of diagnostic test used for Mycoplasma genitalium
Other type of test used for Mycoplasma genitalium test (specify)
Test type for other STI tested for (specify)
Test type used for the other specified STI
Type of test ued for confirmatory syphilis test
Other test used for confirmatory syphilis test (specify)
Confirmatory test type for other STI (specify)
Date STI treatment was prescribed to the client
Date STI treatment dispensed to the client
Client's reason for the prevention visit
The client is interested in discussing pre-exposure prophylaxis (PrEP) for the first time
Client is at a follow-up or refill pre-exposure prophylaxis (PrEP) appointment
Client has previously taken pre-exposure prophylaxis (PrEP) and may like to restart taking it
Counselling on post-exposure prophylaxis (PEP)
Patient visit for management of side effects related to PrEP
Client is visiting for the recommended 3-month pre-exposure prophylaxis (PrEP) visit
The client had suspected or known exposure to HIV
When the suspect exposure to HIV took place
The client is currently taking PrEP. Oral pre-exposure prophylaxis (PrEP) of HIV is the use of ARV drugs by people who are not infected with HIV to block the acquisition of HIV.
Way in which pre-exposure prophylaxis (PrEP) is taken (daily or event-driven)
Pre-exposure prophylaxis (PrEP) is taken every day
Event-driven pre-exposure prophylaxis (PrEP) is taken on an even-driven basis (2+1+1)
Used event-driven PrEP for at risk exposures over the past 3 months
Client reports taking ED-PrEP for at risk exposures over a 3-month period
HIV pre-exposure prophylaxis (PrEP) regimen
Treated with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) pre-exposure prophylaxis (PrEP) regimen (oral PrEP)
Treated with single-agent tenofovir disoproxil fumarate (TDF) pre-exposure prophylaxis (PrEP) regimen (oral PrEP)
Treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) pre-exposure prophylaxis (PrEP) regimen (oral PrEP)
Treated with other tenofovir disoproxil fumarate (TDF)-based regimen (oral PrEP)
Dapivirine vaginal ring (DVR) for HIV prevention
The client has never used pre-exposure prophylaxis (PrEP) before (naive)
The client has used PrEP before and is continuing to use PrEP
Restarting following a period of not taking PrEP
The client is restarting PrEP following a period of not taking PrEP
The date on which the client started or restarted pre-exposure prophylaxis (PrEP)
Client stopped taking pre-exposure prophylaxis (PrEP)
Date client stopped taking pre-exposure prophylaxis (PrEP)
The client's history in taking post-exposure prophylaxis (PEP) for HIV prevention
The client has never used post-exposure prophylaxis (PEP) before
The client has used post-exposure prophylaxis (PEP) before
Dates when the client previously used post-exposure prophylaxis (PEP)
Signs of substantial risk of HIV infection
Signs the client is at a substantial risk of HIV infection
No condom use during sex with more than one partner in the past 6 months
Recent vaginal or anal sexual intercourse without a condom with more than one partner
A recent history (in the last 6 months) of a sexually transmitted infection (STI ) by laboratory testing, self-report or syndromic STI treatment
A sexual partner in the past 6 months had one or more HIV risk factors
A recent sex partner of the client had HIV risk factors
Client is requesting PrEP, reflecting a decision-making process has already taken place and suggesting of substantial risk of HIV
Pregnancy intention in serodiscordant partnerships
Client's intention or desire in the next year to either become pregnant or prevent a future pregnancy (in serodiscordant partnerships)
Client is not intending to become pregnant, but would not be adverse to becoming pregnant
Client does not intend to become pregnant
Client is unsure or undecided about her pregnancy intentions
Symptoms that could suggest an acute HIV infection
Client's symptoms include swollen glands
Treatment adherence of client's sex partner for partners that are HIV-positive
Sex partner is HIV-positive and not on ART
Sex partner is HIV-positive and is on ART less than 6 months. ART may take up to 6 months to suppress viral load. In studies of serodiscordant couples, pre-exposure prophylaxis (PrEP) has provided a useful bridge to full viral suppression by the partner during that time.
Partner has suspected low adherence to ART
Sex partner is HIV-positive and is suspected to have low adherence to ART. There have been gaps in the partner's treatment adherence or the couple is not communicating openly about treatment adherence and viral load test results.
Sex partner is HIV-positive and not virally suppressed
Partner is virally suppressed and has been on ART for 6 months or more
Sex partner is HIV-positive and virally suppressed with 6 months or more on ART
After being evaluated as suitable for PrEP, the client was offered PrEP
Screenings and diagnostics for PrEP users
Listing of tests for clients on or starting pre-exposure prophylaxis (PrEP) that may be recommended or should be considered
Test serum creatinine to identify pre-existing renal disease (estimated creatinine clearance less than 60 ml/min)
Other STI screening recommended for client
Review vaccination history recommended for client
Test serum creatinine to identify pre-existing renal disease (estimated creatinine clearance less than 60 ml/min).
Date the client was dispensed medications
Date the client was prescribed medications
Client was prescribed pre-exposure prophylaxis (PrEP) for HIV prevention
Client was prescribed post-exposure prophylaxis (PEP) for HIV prevention
Client was prescribed other medications (specify)
PrEP product that the client was prescribed
Client was prescribed dapivirine vaginal ring (DVR)
Client was prescribed long-acting cabotegravir (CAB-LA)
Client was prescribed other PrEP product
Client was prescribed other PrEP product (specify)
Date client was prescribed PrEP, including initial prescription and repeats
Volume of PrEP product prescribed/dispensed
Volume of PrEP product the client was prescribed or dispensed (for example, number of pills, number of devices)
Preferred backbone containing tenofovir disoproxil fumarate and lamivudine
Preferred backbone containing tenofovir disoproxil fumarate and emtricitabine
Preferred backbone containing zidovudine and lamivudine
Alternative backbone containing abacavir and lamivudine
Alternative backbone containing tenofovir disoproxil fumarate and lamivudine
Alternative backbone containing tenofovir disoproxil fumarate and emtricitabine
Alternative third drug of atazanavir/ritonavir (ATV/r)
Alternative third drug of darunavir/ritonavir (DRV/r)
Alternative third drug of lopinavir/ritonavir (LPV/r)
Alternative third drug of raltegravir (RAL)
Estimated creatinine clearance of the client returned from lab in mL/min
Sex factor for estimating creatinine clearance
Value used for gender for calculating creatinine clearance if required. For transgender populations, the sex at birth is used in the Cockcroft-Gault equation if the person is not using hormone therapy; among transgender populations using hormone therapy for more than three months, the current gender can be used.
Estimated creatinine clearance (Cockcroft–Gault equation)
If the laboratory does not have the capacity to estimate creatinine clearance, the provider can use the Cockcroft–Gault equation to calculate estimated creatinine clearance based on measured serum creatinine, the client’s sex at birth, age and estimated lean body weight.
Listing of contraindications to pre-exposure prophylaxis (PrEP)
Tenofovir disoproxil fumarate (TDF) allergy or contraindication
Allergy to pre-exposure prophylaxis (PrEP) tenofovir disoproxil fumarate (TDF)
Estimated creatinine clearance of less than 60 ml/min (if known)
When the client is reported to have had probable recent exposure to HIV
Other allergy or contraindication to a medicine in the PrEP regimen
Client has another allergy or contraindication to a medicine in the pre-exposure prophylaxis (PrEP) regimen
Other allergy or contraindication to a medicine in the PrEP regimen (specify)
Client has another allergy or contraindication to a medicine in the pre-exposure prophylaxis (PrEP) regimen (specify)
Client was prescribed pre-exposure prophylaxis (PrEP) on a first visit
Days of medication client has been prescribed
HIV pre-exposure prophylaxis (PrEP) regimen prescribed
Whether adherence counselling was provided
Date the client is to return for monitoring, re-supply, or any other reason
Male and female condoms and condom-compatible lubricants offered
Voluntary medical male circumcision (VMMC) referral
Offer or refer to harm reduction for people who inject drugs (needle and syringe programmes, opioid substitution therapy, other drug-dependence treatment and opioid overdose prevention and management) services
Behavioural interventions to support risk reduction
Offer or refer to services for behavioural interventions to support risk reduction, particularly for people with HIV and members of key populations
Number of condoms given to the client, if any were distributed
Male condoms were provided to the client
Female condoms were provided to the client
Whether any HIV self-test kits were given to the client
Number of HIV self-test kits distributed
Number of HIV self-test kits distributed to the client
Whom the client plans to give the HIV self-test kit (self, sexual partner, social contact, etc.)
Client plans to give the self-test kit to a family member to use
Client plans to give the self-test kit to a drug-injecting partner
Client plans to give the self-test kit to a sexual partner
Client plans to give the self-test kit to a social contact
Offer services (counselling) to help prevent of mother-to-child transmission
Offer cervical cancer screening and treatment services
Offer anal cancer screening (for men who have sex with men) services
Offer STI testing and treatment services
Offer testing for all partners and biological children of positive cases (includes partner services and index case testing), as well as partners and social contacts of people from key populations, where appropriate
Hepatitis B virus (HBV) and hepatitis C virus (HCV) testing and treatment
Offer or refer for HBV testing and vaccination and HCV testing and treatment
Co-trimoxazole chemoprophylaxis to prevent pneumocystis carinii pneumonia
Intensified TB case finding and linkage to TB treatment
Offer or refer for TB case finding and linkage to TB treatment
Whether visit was scheduled or unscheduled, clinical only, or for ARV drug pick-up
The client's first appointment for clinical care by a provider at the facility
Appointment for clinical care by a provider
Appointment for an antiretroviral drug pick up
Post-treatment follow-up visit for cervical precancer lesions or invasive cervical cancer
Appointment for a post-treatment follow-up visit for cervical precancer lesions or invasive cervical cancer
The client's current weight in kilograms
If the client's blood pressure cannot be taken, this should be indicated here. Otherwise, blood pressure should be measured.
Signs that may indicate the client has a serious illness and needs triage or an emergency referral
Client has a fever with a measured temperature of 102.2 F/39 C or greater
Heart rate above a rate per minute based on age
Respiratory rate above a number of breaths per minute based on age
Client is exhibiting lethargy as a sign of serious illness
Infant or child is not able to breastfeed
Client is exhibiting another sign of a serious illness
Client is exhibiting another sign of a serious illness (specify)
Total number of times the woman has been pregnant (gravida)
Total number of pregnancies lost/ended due to miscarriages and/or abortions before 22 weeks/5 months
Total number of live births after 22 weeks
Calculated parity is the total number of live and stillbirths
Client's HIV status is different from a current partner's HIV status
The date on which the client started or restarted ART
Is the client successfully established on ART?
Whether the client is ART naive or is restarting ART
Client is ART naive, having never taken ART to treat HIV before
Client is restarting ART after stopping treatment for any reason
The date on which the client was first initiated on ART
Time the client has been on ART since starting or restarting it in years and months
Date(s) client restarted ART after stopping (intentionally interrupting) for any number of reasons (see 'Reason ART stopped')
Month and year client originally started ART (documented) at a health facility in the system. The cohort is a group of patients who started ART in the same month (or quarter) and year, whose status is followed over time, using the ART register.
Client is transferring in with records or known ART drugs and ART start date
Date client presented at facility (with transfer/referral slip) from another facility (and on ART) within the system
Name of health facility client was transferred from
Date client first enrols in HIV care at the facility. Begins when a person with a confirmed HIV diagnosis presents to a facility where HIV care is provided and a medical record, patient card, file or chart is opened for the first time. This could be at an HIV care/ART, MNCH or TB clinic.
Client's age when the client was enrolled in ART care
Facility where client first enrolled in HIV care
Facility where the client first enrolled in HIV care
Antiretroviral (ARV) drugs received prior to enrolment
Whether or not the client received ARV drugs prior to enrolling into HIV care
Received ARVs prior without records/documentation
Client received ARVs prior without records/documentation
Received ARVs during pregnancy or breastfeeding
Client received ARVs during pregnancy or breastfeeding
Client received ARVs for post-exposure prophylaxis (PEP) or PrEP
ARV prophylaxis for an HIV-exposed infant
Client received ARV prophylaxis for an HIV-exposed infant
Date ARV drugs received prior to enrolment
Date ARV drugs were started prior to enrolment into HIV care/ART
Location ARV drugs received prior to enrolment
Health facility (or other location) where ARV drugs were received prior to enrolment into HIV care/ART
ARV drug regimen received prior to enrolment
ARV drug regimen received prior to enrolment into HIV care/ART
Does the client have any current chronic health conditions or problems?
Client does not have chronic diseases or any past health conditions
Client does not know whether she has any chronic diseases or past health conditions
Client has diabetes of other or unspecified type
Client has pre-existing type 1 diabetes mellitus
Client has pre-existing type 2 diabetes mellitus
Other health conditions not included in the list
Other health conditions not included in the list (specify)
Original full, first-line ARV drug regimen patient started on at this facility
The current ART regimen the client is taking
The date on which the client started taking the current ART regimen
The preferred first-line ART regimen for the client according to WHO (or national) guidelines
The alternative first-line ART regimen for the client according to WHO (or national) guidelines
First-line ART regimen under special circumstances
The first-line ART regimen for the client under special circumstances according to WHO (or national) guidelines
The preferred second-line ART regimen for the client according to WHO (or national) guidelines
The alternative second-line ART regimen for the client according to WHO (or national) guidelines
The optimal regimen for transition to DTG-based regimens for children established on ART
Current ART regimen (first-, second-, or third-line)
ART regimen for treating clients living with HIV, based on national guidance
First-line ART regimen for adults and adolescents
First-line ART regimen for adults and adolescents living with HIV
First-line ART regimen for children living with HIV
First-line ART regimen for neonates living with HIV
Second-line ART regimen for adults and adolescents
Second-line ART regimen for adults and adolescents living with HIV
Second-line ART regimen for children living with HIV
Third-line ART regimen for people living with HIV (Not defined by WHO. National programmes should develop policies for third-line ART)
Regimen containing abacavir, lamivudine, and atazanavir/ritonavir
Regimen containing abacavir, lamivudine, and dolutegravir
Regimen containing abacavir, lamivudine, and efavarinez
Regimen containing abacavir, lamivudine, and lopinavir/ritonavir
Regimen containing abacavir, lamivudine, and nevirapine
Regimen containing abacavir, lamivudine, and raltegravir
Regimen containing zidovudine, lamivudine, and atazanavir/ritonavir
Regimen containing zidovudine, lamivudine, and darunavir/ritonavir
Regimen containing zidovudine, lamivudine, and dolutegravir
Regimen containing zidovudine, lamivudine, and efavirenz
Regimen containing zidovudine, lamivudine, and efavirenz 600 mg
Regimen containing zidovudine, lamivudine, and lopinavir/ritonavir
Regimen containing zidovudine, lamivudine, and nevirapine
Regimen containing zidovudine, lamivudine, and raltegravir
Regimen containing tenofovir alafenamide, lamivudine, and dolutegravir
Regimen containing tenofovir alafenamide, emtricitabine, and dolutegravir
Regimen containing tenofovir disoproxil fumarate, lamivudine, and atazanavir/ritonavir
Regimen containing tenofovir disoproxil fumarate, lamivudine, and darunavir/ritonavir
Regimen containing tenofovir disoproxil fumarate, lamivudine, and dolutegravir
Regimen containing tenofovir disoproxil fumarate, lamivudine, and efavirenz
Regimen containing tenofovir disoproxil fumarate, lamivudine, and efavirenz (400 mg)
Regimen containing tenofovir disoproxil fumarate, lamivudine, and efavirenz (600 mg)
Regimen containing tenofovir disoproxil fumarate, lamivudine, and lopinavir/ritonavir
Regimen containing tenofovir disoproxil fumarate, lamivudine, and nevirapine
Regimen containing tenofovir disoproxil fumarate, lamivudine, and a boosted protease inhibitor
Regimen containing tenofovir disoproxil fumarate, lamivudine, and raltegravir
Regimen containing tenofovir disoproxil fumarate, emtricitabine, and atazanavir/ritonavir
Regimen containing tenofovir disoproxil fumarate, emtricitabine, and darunavir/ritonavir
Regimen containing tenofovir disoproxil fumarate, emtricitabine, and dolutegravir
Regimen containing tenofovir disoproxil fumarate, emtricitabine, and efavirenz
Regimen containing tenofovir disoproxil fumarate, emtricitabine, and efavirenz (600 mg)
Regimen containing tenofovir disoproxil fumarate, emtricitabine, and lopinavir/ritonavir
Regimen containing tenofovir disoproxil fumarate, emtricitabine, and nevirapine
Regimen containing tenofovir disoproxil fumarate, emtricitabine, and a boosted protease inhibitor
Regimen containing tenofovir disoproxil fumarate, emtricitabine, and raltegravir
Other regimen based upon WHO recommendations
Other regimen based upon WHO recommendations (specify)
Drug composition of client's current ART regimen
Treated with atazanavir/ritonavir (ATV/r)
Treated with lopinavir/ritonavir (LPV/r)
Treated with darunavir/ritonavir (DRV/r)
Treated with nucleoside reverse transcriptase inhibitors (NRTIs)
Treated with nucleotide reverse-transcriptase inhibitors (NtRTIs)
Treated with non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Treated with integrase strand transfer inhibitors (INSTIs)
Offer or refer people who inject drugs to harm reduction services (needle and syringe programmes, opioid substitution therapy, other drug-dependence treatment and opioid overdose prevention and management)
Prevention of mother-to-child transmission
Offer prevention of mother-to-child transmission services (counselling)
Date client was tested for hepatitis B virus (HBV)
Date HBV test result (HBsAG) was returned to client
Date when client started treatment (TDF) for hepatitis B virus (HBV)
Hepatitis B virus treatment regimen prescribed
Date client was tested for hepatitis C virus (HCV antibody, HCV RNA or HCV core antigen)
Hepatitis C virus test result (HCV antibody, HCV RNA or HCV core antigen)
Date HCV test result was returned to client
Date when client started treatment for hepatitis C virus (HCV)
Date when client completed treatment for hepatitis C virus (HCV)
Hepatitis C virus treatment regimen prescribed
Hepatitis C viral load test result (qualitative)
Client is prescribed direct acting antivirals
Client is currently on TDF-based ART regimen
WHO clinical stage of client based on signs and symptoms. WHO clinical staging is a way to categorize HIV disease severity based on new or recurrent clinical events. There are 4 WHO clinical stages that range from mild symptoms (WHO clinical stage 1) to severe symptoms (WHO clinical stage 4).
Client is currently assessed to be at a clinical stage 1, based on clinical assessment and diagnostics
Client is currently assessed to be at a clinical stage 2, based on clinical assessment and diagnostics
Client is currently assessed to be at a clinical stage 3, based on clinical assessment and diagnostics
Client is currently assessed to be at a clinical stage 4, based on clinical assessment and diagnostics
Number of doses of antiretroviral therapy (ART) the client missed since the last visit, used for monitoring adherence
Client received results from viral load test
Date viral load test results received by client
The date on which the client received results from viral load test
Date and time when the sample was collected to test the client's HIV viral load
Date of scheduled review of viral load test results
Expected date when client's viral load test results will be returned and reviewed
Date of client's ART interruption (ART stop or missed drug pick-up)
Client reported not being adherent because they forgot
Client reported not being adherent because of toxicity/side effects
Client reported not being adherent because they were busy
Client reported not being adherent because of a change of routine
Client reported not being adherent because of travel cost
Client reported not being adherent because of distance to clinic
Client reported not being adherent because client lost/ran out of pills
Client reported not being adherent because of a stock-out
Client reported not being adherent because of being too ill
Client reported not being adherent because of the pill burden
Client reported not being adherent because they felt well
Client reported not being adherent because of depression
Client reported not being adherent because of alcohol use
Client reported not being adherent because of substance use (i.e. drugs)
Client reported not being adherent because of stigma/disclosure concerns
Client reported not being adherent because of a lack of food
Client reported not being adherent because of poor palatability
Client reported not being adherent because of other reason for nonadherence
Client reported not being adherent because of other reason for nonadherence (specify)
Client stopped ART because of toxicity/side effects
Client stopped ART because of severe illness, hospitalization
Client stopped ART because drugs were out of stock
Client stopped ART because of lack of finances
Client stopped ART because HIV infection in infant was excluded
Client stopped ART because of other reason
Client stopped ART because of other reason (specify)
New or recurrent clinical event indicating severe immunodeficiency in adults or advanced or severe immunodeficiency in children
CD4 count at or below 250 cells/mm3 following clinical failure
The inability to achieve or maintain viral suppression below a certain threshold indicated by viral load above 1000 copies/mL based on two consecutive viral load measurements in 3 months, with adherence support following the first viral load test
General care activities to be performed during the care visit
Determine WHO clinical stage based on past and current HIV-related conditions
Determine if client is in an advanced stage of HIV, as a special package of services may be provided
Manage current medications being taken by the client
Provide family planning and contraception
Provide family planning and contraception counselling
Support disclosure and partner notification
Counsel on risk reduction and prevention
Counsel on risk reduction and combination HIV prevention approaches
Assess, prevent and manage noncommunicable diseases
Screen for and manage mental health problems
Screen for and manage and substance use issues
Provide psychosocial counselling and support
Manage pain and symptoms client is experiencing
Conduct a nutritional assessment and counsel on nutrition
Conduct a growth and development assessment
Provide support on infant and child feeding
Provide support on infant and child feeding to mother or care giver
Coinfection prevention and treatment activities performed during the care visit
Provide co-trimoxazole preventive therapy (CPT)
Provide co-trimoxazole prophylaxis for clients new to ART or identified as taking it
Screen for cryptococcal infection and fungal prophylaxis
Prevent malaria including with insecticide-treated bed-nets and prophylaxis
Offer anal cancer screening (for men who have sex with men)
Risk factors, comorbidities and coinfections signs and symptoms
Signs and symptoms of opportunistic infections or other comorbidities experienced by client
Client's comorbidities or coinfections or symptoms of these include oral candidiasis (after the first 6-8 weeks of life)
Client's comorbidities or coinfections or symptoms of these include vaginal candidiasis
Client's comorbidities or coinfections or symptoms of these include cough
Client's comorbidities or coinfections or symptoms of these include prolonged fever
Client's comorbidities or coinfections or symptoms of these include night sweats
Client's comorbidities or coinfections or symptoms of these include weight loss
Client's comorbidities or coinfections or symptoms of these include difficulty breathing
Client's comorbidities or coinfections or symptoms of these include pneumonia
Client's comorbidities or coinfections or symptoms of these include urethral discharge
Client's comorbidities or coinfections or symptoms of these include syphilis
Client's comorbidities or coinfections or symptoms of these include pelvic inflammatory disease
Client's comorbidities or coinfections or symptoms of these include ulcers - skin
Client's comorbidities or coinfections or symptoms of these include ulcers - mouth or other
Client's comorbidities or coinfections or symptoms of these include ulcers - male genital
Client's comorbidities or coinfections or symptoms of these include vaginal discharge
Client's comorbidities or coinfections or symptoms of these include malaria
Client's comorbidities or coinfections or symptoms of these include chronic obstructive pulmonary disease
Client's comorbidities or coinfections or symptoms of these include hypertension
Client's comorbidities or coinfections or symptoms of these include diabetes
Client's comorbidities or coinfections or symptoms of these include gestational diabetes
Client's comorbidities or coinfections or symptoms of these include mental health disorders (including depression, dementia, encephalitis, seizures)
Client's comorbidities or coinfections or symptoms of these include diarrhoea or abdominal pain
Client's comorbidities or coinfections or symptoms of these include presumptive TB
Client's comorbidities or coinfections or symptoms of these include severe or complicated malnutrition
Client's comorbidities or coinfections or symptoms of these include poor growth or development
Client's comorbidities or coinfections or symptoms of these include oedema
Client has previously been treated for tuberculosis (TB)
Other comorbidities or coinfection signs or symptoms
Other comorbidities or coinfection signs or symptoms (specify)
WHO HIV clinical stage condition or symptom
New or recurrent clinical events used to categorize HIV disease severity based at baseline and follow up
No HIV-related symptoms reported and no clinical signs on examination
Persistent enlarged lymph nodes >1 cm at two or more non-contiguous sites (excluding inguinal) without known cause
Moderate unexplained weight loss (<10% of presumed or measured body weight)
Client's symptoms include recurrent respiratory tract infections including sinusitis, tonsillitis, otitis media or pharyngitis
Unexplained persistent hepatosplenomegaly
Client's symptoms include unexplained persistent hepatosplenomegaly
Client's symptoms include angular cheilitis
Client's symptoms include linear gingival erythema
Client's symptoms include recurrent oral ulceration
Client's symptoms include papular pruritic eruption
Client's symptoms include fungal nail infections
Client's symptoms include seborrhoeic dermatitis
Client's symptoms include extensive wart virus infection
Client's symptoms include extensive molluscum contagiosum
Unexplained persistent parotid enlargement
Client's symptoms include unexplained persistent parotid enlargement
Unexplained severe weight loss in adults
Unexplained severe weight loss (>10% of presumed or measured body weight)
Unexplained moderate malnutrition not adequately responding to standard therapy
Defined as weight-for-height < - 2 z-score or mid-upper arm circumference 115 mm to <125 mm. For children younger than five years of age: stunting is defined as severe acute malnutrition - either weight for height < -3 z-score or mid-upper arm circumference <115 mm or the presence of oedema.
Unexplained chronic diarrhoea for longer than 1 month
Client's symptoms include unexplained chronic diarrhoea for longer than 1 month
Unexplained persistent diarrhoea (14 days or more)
Client's symptoms include unexplained persistent diarrhoea (14 days or more)
Unexplained persistent fever (above 37.5 C, intermittent or constant, for longer than one 1 month)
Client's symptoms include unexplained persistent fever (above 37.5 C, intermittent or constant, for longer than one 1 month)
Client's symptoms include persistent oral candidiasis
Client has fine white small linear or corrugated lesions on lateral borders of the tongue that do not scrape off
Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, meningitis, bacteraemia)
Client's symptoms include severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, meningitis, bacteraemia)
Client's symptoms include severe recurrent bacterial pneumonia
Client's symptoms include acute necrotizing ulcerative stomatitis
Client's symptoms include acute necrotizing ulcerative gingivitis
Acute necrotizing ulcerative periodontitis
Client's symptoms include acute necrotizing ulcerative periodontitis
Client's symptoms include unexplained anaemia (<8 g/dL)
Client's symptoms include neutropaenia (<0.5 x 10^9/L)
Chronic thrombocytopaenia (<50 x 10^9/L)
Client's symptoms include chronic thrombocytopaenia (<50 x 10^9/L)
Symptomatic lymphoid interstitial pneumonitis
Client's symptoms include symptomatic lymphoid interstitial pneumonitis
Chronic HIV-associated lung disease, including bronchiectasis
Client's symptoms include chronic HIV-associated lung disease, including bronchiectasis
Unexplained involuntary weight loss (>10% baseline body weight), with obvious wasting or body mass index <18.5; PLUS EITHER unexplained chronic reported for longer than one month; OR reports of fever or night sweats for more than one month without other cause and lack of response to antibiotics or antimalarial agents; malaria must be excluded in malarious areas.
Unexplained severe wasting not responding to standard therapy
Client has unexplained severe wasting not responding to standard therapy . For under 5 years old, defined as weight-for-height < -3 z-score
Unexplained stunting not responding to standard therapy
Client has unexplained stunting not responding to standard therapy . For under 5 years old, defined as length-for- age/height-for-age < -2 z-score
Unexplained severe malnutrition not responding to standard therapy
Client has unexplained severe malnutrition not responding to standard therapy . For under 5 years old, weight for height < -3 z-score or mid-upper arm circumference <115 mm or the presence of oedema
Client's symptoms include pneumocystis (jirovecii) pneumonia
Client's symptoms include recurrent severe bacterial pneumonia
Recurrent severe bacterial infections (such as empyema, pyomyositis, bone or joint infection, meningitis, but excluding pneumonia)
Client's symptoms include recurrent severe bacterial infections (such as empyema, pyomyositis, bone or joint infection, meningitis, but excluding pneumonia)
Client's symptoms include recurrent empyema
Client's symptoms include recurrent pyomyositis
Client's symptoms include recurrent bone or joint infections
Client's symptoms include recurrent meningitis
Chronic herpes simplex infection (orolabial or cutaneous of more than 1 month duration or visceral at any site)
Client's symptoms include chronic herpes simplex infection (orolabial or cutaneous of more than 1 month duration or visceral at any site)
Chronic herpes simplex infection (orolabial, genital or anorectal of more than 1 month in duration or visceral at any site)
Client's symptoms include chronic herpes simplex infection (orolabial, genital or anorectal of more than one month in duration or visceral at any site)
Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)
Client's symptoms include oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)
Client's symptoms include extrapulmonary tuberculosis
Client's symptoms include Kaposi sarcoma
Cytomegalovirus infection (retinitis or infection of other organs)
Client's symptoms include cytomegalovirus infection (retinitis or infection of other organs)
Client's symptoms include central nervous system toxoplasmosis
Client's symptoms include HIV encephalopathy
Extrapulmonary cryptococcosis, including meningitis
Client's symptoms include extrapulmonary cryptococcosis, including meningitis
Disseminated nontuberculous mycobacterial infection
Client's symptoms include disseminated nontuberculous mycobacterial infection
Progressive multifocal leukoencephalopathy
Client's symptoms include progressive multifocal leukoencephalopathy
Client's symptoms include chronic cryptosporidiosis
Chronic cryptosporidiosis (with diarrhoea)
Client's symptoms include chronic cryptosporidiosis (with diarrhoea)
Client's symptoms include chronic isosporiasis
Disseminated mycosis (extrapulmonary histoplasmosis, coccidioidomycosis)
Client's symptoms include disseminated mycosis (extrapulmonary histoplasmosis, coccidioidomycosis)
Disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidioidomycosis, penicilliosis)
Client's symptoms include disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidioidomycosis, penicilliosis)
Client's symptoms include cerebral lymphoma
Client's symptoms include b-cell non-Hodgkin lymphoma
HIV-associated nephropathy or cardiomyopathy
Client's symptoms include HIV- associated nephropathy or cardiomyopathy
Recurrent septicaemia (including nontyphoidal Salmonella)
Client's symptoms include recurrent bacteraemia (septicaemia) (including nontyphoidal salmonella)
Client's symptoms include invasive cervical carcinoma
Client's symptoms include atypical disseminated leishmaniasis
Client's symptoms include neutropenia, an abnormally low count of a type of white blood cell (neutrophils)
WHO clinical stage of client based on signs and symptoms at start of ART
Client is assessed to be at a clinical stage of 1 at the time of starting ART, based on clinical assessment and diagnostics
Client is assessed to be at a clinical stage of 2 at the time of starting ART, based on clinical assessment and diagnostics
Client is assessed to be at a clinical stage of 3 at the time of starting ART, based on clinical assessment and diagnostics
Client is assessed to be at a clinical stage of 4 at the time of starting ART, based on clinical assessment and diagnostics
Date on which the client's WHO HIV clinical stage changed, including the date when the client's stage is first determined
Date and time when CD4 count test was conducted
Date and time when baseline CD4 count test was conducted
Client had late ART initiation. That is, the client's first CD4 count from baseline CD4 test performed (such as at HIV diagnosis) was a count of <200 cells/mm3
Reason why ART was not initiated at diagnosis or within 7 days of diagnosis
Patient self-reported as not ready/willing
Client did not initiate ART at diagnosis or within 7 days of diagnosis because client self-reported as not ready/willing
Not completed education, support and preparation for ART
Client did not initiate ART at diagnosis or within 7 days of diagnosis because client had not completed education, support and preparation for ART
Client did not initiate ART at diagnosis or within 7 days of diagnosis because of client's fear of disclosure
Client did not initiate ART at diagnosis or within 7 days of diagnosis because client lacks finances
Client did not initiate ART at diagnosis or within 7 days of diagnosis because client initiated on TB treatment
Patient initiated on treatment for TB meningitis
Client did not initiate ART at diagnosis or within 7 days of diagnosis because client initiated on treatment for TB meningitis
Patient diagnosed with cryptococcal meningitis
Client did not initiate ART at diagnosis or within 7 days of diagnosis because client diagnosed with cryptococcal meningitis
Client did not initiate ART at diagnosis or within 7 days of diagnosis because client diagnosed with histoplasmosis
Client did not initiate ART at diagnosis or within 7 days of diagnosis because client critically/severely ill
Client did not initiate ART at diagnosis or within 7 days of diagnosis because of other reason
Client did not initiate ART at diagnosis or within 7 days of diagnosis because of other reason (specify)
ART initiated within 7 days of diagnosis
Client initiated ART within 7 days of diagnosis
Time from HIV diagnosis to when client started ART
Client started ART within 30 days of ART initiation (but over 7 days)
Client started ART within 90 days of ART initiation (but over 30 days)
Result from the viral load test in number of copies/mL
The client is virally suppressed for HIV, based on the client's most recent viral load test result being less than 1000 copies/mL
Date the viral load test result was received from the lab or completed in the facility
Date on which the client tested as becoming virally suppressed, as indicated by a viral load test result under 1000 copies/mL
Whether the viral load is being tested for routine monitoring on a set schedule or for targeted monitoring for suspected treatment failure
Routine refers to viral load tests obtained at standard intervals following ART initiation to monitor viral load response to ART
Targeted refers to viral load tests obtained based on a specific clinical indication (such as concern about disease progression or failure to respond to ART)
Follow-up viral load test after receiving enhanced adherence counselling
A follow-up viral load test within 3-6 months after enhanced adherence counselling after client received a high viral load test result
Hepatitis C test is recommended or should be considered
Name of examinations, test and results for any relevant investigations carried out for client
Provider ordered a Haemoglobin (Hb) test, number in g/dL test
Provider ordered a pregnancy test for client
Provider ordered sputum or culture for TB
Provider ordered an HBsAg test (HBV) test
Scheduled an HIV viral load test with client
Provider ordered a cryptococcal antigen test
Provider ordered a histoplasmosis antigen test
Scheduled cervical cancer screening with client
Date of scheduled monitoring examination
The date on which the client received results from a viral load test
Reason for ARV drug regimen substitution
Reason why a substitution was made to the antiretroviral (ARV) drug regimen
A substitution was made to the regimen because of toxicity/side effects
A substitution was made to the regimen because of a drug-drug interaction
A substitution was made to the regimen because of pregnancy
A substitution was made to the regimen because of new tuberculosis (TB)
A substitution was made to the regimen because a new drug was available
A substitution was made to the regimen because drug was out of stock
A substitution was made for another reason
Other reason for regimen substitution (specify)
A substitution was made for another reason (specify)
Switch to second-line ART regimen recommended
A switch to second-line ART regimen is recommended
Switch to third-line ART regimen recommended
A switch to third-line ART regimen is recommended
Reason why a switch to a second- or third-line regimen was made
A switch was made to the regimen because of clinical treatment failure
A switch was made to the regimen because of immunological failure
A switch was made to the regimen because of virological failure
A switch was made to the regimen for another reason
A switch was made to the regimen for another reason (specify)
Provider has made a regimen substitution
Date co-trimoxazole prophylaxis prescribed to client
Co-trimoxazole prophylaxis completion date
Completion date of co-trimoxazole prophylaxis prescribed to client
Dose of co-trimoxazole prophylaxis prescribed to client
Co-trimoxazole prophylaxis number of days prescribed
Number of days of co-trimoxazole prophylaxis prescribed to client
Suspicion of treatment failure or interruption
Client has been on ART, but has stopped taking it or a treatment failure is suspected
Client is experiencing antiretroviral drug (ARV) toxicity
Clients status of coinfections at the time when ART was initiated
Client was hepatitis B positive at the start of ART
Client was hepatitis C positive at the start of ART
Pregnant and breastfeeding status at ART start
ART status of women to prevent mother-to-child transmission
Client was pregnant when ART was initiated
Client was postpartum when ART was initiated
Client initiated ART at labour and delivery
Client was breastfeeding when ART was initiated
Date of delivery/birth of infant if breastfeeding at ART start
Client living with HIV was in an ongoing sexual relationship with an HIV-negative partner when ART was started
Name or regimen code of all other medications prescribed during the visit
Number of doses (quantity taken at a single point in time) of drugs prescribed/dispensed
Number of days supply of each medication or regimen prescribed during the visit
Any other medications that were dispensed to client, including preventive treatment
Number of days supply of each medication or regimen dispensed during the visit
Prescribed frequency for taking the medication
Counselling was carried out during visit
Type of treatment-limiting toxicity experienced by client. Treatment-limiting toxicity is defined as a serious adverse drug reaction that results in drug discontinuation or substitution. In addition, any reaction that leads to treatment interruption or requires changing the drug or regimen because of an adverse drug reaction is also considered a serious adverse drug reaction.
Treatment-limiting toxicity due to GI issues (nausea, diarrhoea, abdominal pain, vomiting)
Treatment-limiting toxicity due to skin issues (rash, hypersensitivity reaction)
Treatment-limiting toxicity due to peripheral neuropathy (burning/numbness/ tingling)
Treatment-limiting toxicity due to central nervous system symptoms (dizzy, anxiety, nightmare, depression, seizures)
Treatment-limiting toxicity due to weight gain
Treatment-limiting toxicity due to hepatic dysfunction (jaundice)
Treatment-limiting toxicity due to haematological (anaemia, neutropenia) disorders
Treatment-limiting toxicity due to fatigue
Treatment-limiting toxicity due to headache
Treatment-limiting toxicity due to bone dysfunction (fractures, osteopenia)
Treatment-limiting toxicity due to metabolic symptoms (body fat changes, hyperglycaemia, dyslipidaemia)
Treatment-limiting toxicity due to kidney dysfunction (nephrolithiasis, renal insufficiency)
Client experienced an unexpected adverse drug reaction
Unexpected adverse drug reaction (specify)
Specify the type of unexpected adverse drug reaction the client experienced
Date(s) of substitution within first-line regimen
Date on which ARV drug regimen (one or more drugs) for client was changed within the first-line regimen (substitution)
Reason(s) for substitution within first-line regimen
Reason(s) why one ore more drugs in client's first-line ARV drug regimen was changed (substituted)
New antiretroviral regimen after substitution within first-line regimen
New antiretroviral (ARV) drugs after client changed regimen within the first-line regimen
Date client was changed from a first-line to second-line ARV drug regimen (switch)
New regimen after switch to second-line regimen
New ART regimen after switch to second-line ART regimen
Reason for switch to second-line regimen
Reason why client was switched from first- to second-line ARV drug regimen (see 'Reason for regimen switch' for levels)
Date(s) of substitution within second-line regimen
Date on which ARV drug regimen for client was changed within the second-line regimen (substitution)
Reason(s) for substitution within second-line regimen
Reason(s) why client changed drug regimen (within the second-line)
New regimen(s) after substitution within second-line regimen
New ARV drugs after client changed regimen within the second- line regimen
Date client was changed from a second- to third-line ARV drug regimen (switch)
New regimen after switch to third-line regimen
New ART regimen after switch to third-line ART regimen
Reason why client was switched from second- to third-line ARV drug regimen (see 'Reason for regimen switch' for levels)
Date(s) of substitution within third-line regimen
Date on which ARV drug regimen for client was changed within the third-line (substitution)
Reason(s) for substitution within third-line regimen
Reason(s) why client changed drug regimen (within the third-line)
New regimen(s) after substitution within third-line regimen
New ARV drugs after client changed regimen within the third-line regimen
Enhanced adherence counselling was provided to the client during the visit
First enhanced adherence counselling session completed
A first enhanced adherence counselling was provided to the client during the visit
Date of first enhanced adherence counselling session completed
The date on which the first enhanced adherence counselling was provided to the client
Second enhanced adherence counselling session completed
A second enhanced adherence counselling was provided to the client during the visit
Date of second enhanced adherence counselling session completed
The date on which the second enhanced adherence counselling was provided to the client
Third enhanced adherence counselling session completed
A third enhanced adherence counselling was provided to the client during the visit
Date of third enhanced adherence counselling session completed
The date on which the third enhanced adherence counselling was provided to the client
Full name of person providing support to client for adherence, care, treatment and other needs (e.g. ARV pick-up if ill)
Full address or description of home of treatment supporter
Telephone number if available, or else telephone number of neighbour/friend
Name of individual or organization that provides home-based care to client
Whether counselling and treatment was provided to a client who has been diagnosed with syphilis
Client accepted offer for partner services
Offer voluntary testing for all partners and biological children of positive cases (includes partner services and index case testing), as well as partners and social contacts of people from key populations, where appropriate
HIV status of each family member at time of patient's enrolment, including partner (for mothers)
Unique ID number of each family member if enrolled in HIV care according to national guidelines (see unique ID number)
Date of death for each family member as appropriate
Provided support for disclosure and partner services
Date the client is to return for monitoring, re-supply or any other reason
Whether the visit will be clinical only, ARV drug pick-up or other. Client may have multiple follow-ups scheduled.
A test or screening recommended for the client's care plan at a future date
BP cuff (sphygmomanometer) not available
Other reason blood pressure can not be taken
Other reason blood pressure can not be taken (specify)
List of all of the medications the client is currently taking
The client is currently not on any medications
The client does not know if she is on any medications
Client is currently taking broad-spectrum antibiotics
Antihelmintic or antiparasitic medication
Client is currently taking antiparasitics
Opioid substitution to treat opioid dependence
Combination of two antimicrobial drugs (sulfamethoxazole and trimethoprim) that covers a variety of bacterial, fungal and protozoan infections
Pre-exposure prophylaxis (PrEP) medication for preventing the acquisition of HIV
Other medications or supplements that are not listed above
Other medications or supplements that are not listed above (specify)
Client does not have any known allergies
Client does not know whether or not she has allergies
Malaria medication (sulfadoxine-pyrimethamine)
Allergy to malaria medication (sulfadoxine-pyrimethamine)
Client has other allergies not listed here
Client has other allergies not listed here (specify)
Method the client reports currently using at intake
Copper-bearing intrauterine device (Cu-IUD)
A copper-bearing intrauterine device is being used as a family planning method
Levonorgestrel intrauterine device (LNG-IUD)
A levonorgestrel intrauterine device (hormone-releasing intrauterine contraceptive device) is being used as a family planning method
An etonogestrel one-rod implant is being used
A levonorgestrel two-rod implant is being used as a family planning method
Injectable depot medroxyprogesterone acetate (DMPA), administered intramuscularly, is being used as a family planning method
Injectable depot medroxyprogesterone acetate (DMPA), administered subcutaneously is being used
Injectable norethisterone enanthate (NET-EN) is being used as a family planning method
Progestogen-only pills (POP) are being used as a family planning method
Combined oral contraceptives (COCs) pills are being used as a family planning method
Transdermal combined contraceptive patch is being used as a family planning method
Combined contraceptive vaginal ring (CVR)
Combined contraceptive vaginal ring (CVR) is being used as a family planning method
Progesterone-releasing vaginal ring (PVR)
Progesterone-releasing vaginal ring (PVR) is being used as a family planning method
Lactational amenorrhea method (LAM) is being used as a family planning method
Client uses emergency contraceptive pills (ECPs)
Client uses fertility awareness-based methods (FAB)
Male condoms are being used as a family planning method
Female condoms are being used as a family planning method
The female client is relying on her male partner for contraceptive methods (e.g. male condoms, male sterilization, withdrawal)
The male client is relying on his female partner for contraceptive methods
Male surgical sterilization (a vasectomy) is the family planning method used
Female surgical sterilization procedure is the family planning method used
Client is not using any family planning methods
Current state of the client's taking of the medication
The medication is still being taken (active)
The medication may be taken at some time in the future
Actions implied by the statement have been permanently halted, before all of them occurred. This should not be used if the statement was entered in error.
The client has temporarily stopped taking the medication, but is expected to continue again later. May also be called 'suspended'.
The state of the medication use is not currently known
Hepatitis B negative counselling conducted
The brand or trade name used to refer to the vaccine received
Type of vaccine received (such as IPV, OPV)
Represents the visit/encounter date, which is the date and time when the vaccine was administered to the client
The service delivery location where the vaccine adminstration occurred
The quantity of vaccine product that was administered
The recommended number of vaccine doses for immunity according to national protocol
Vaccine preventable disease being targeted by vaccine administered
The client is receiving vaccination to prevent against hepatitis A
The client is receiving vaccination to prevent against hepatitis B
The client is receiving vaccination to prevent against tetanus
The client is receiving vaccination to prevent against COVID-19 due to SARS-CoV-2
The client is receiving vaccination to prevent against influenza due to influenza B virus
The client is receiving vaccination to prevent against tuberculosis (e.g. BCG vaccine)
The client is receiving vaccination to prevent against acute poliomyelitis (polio)
The client is receiving vaccination to prevent against measles
The client is receiving vaccination to prevent against diptheria
The client is receiving vaccination to prevent against rabies
The client is receiving vaccination to prevent against cholera
The client is receiving vaccination to prevent against mumps
The client is receiving vaccination to prevent against human papilloma virus (HPV) infection
The client is receiving vaccination to prevent against Haemophilus influenzae type B (Hib)
The client is receiving vaccination to prevent against varicella
The client is receiving vaccination to prevent against dengue
The client is receiving vaccination to prevent against yellow fever
The client is receiving vaccination to prevent against Japanese encephalitis
The client is receiving vaccination to prevent against rubella
The client is receiving vaccination to prevent against pertussis
The client is receiving vaccination to prevent against enteritis due to rotavirus
The client is receiving vaccination to prevent against pneumococcal disease
The client is receiving vaccination to prevent against meningococcal disease
The client is receiving vaccination to prevent against tick-borne encephalitis
The client is receiving vaccination to prevent against typhoid
Other reason why the immunization was not provided
Other reason immunization not provided (specify)
Other reason why the immunization was not provided (specify)
Date on which the IPTp-SP dose was provided
There was a stock out of malaria prophylaxis
Malaria prophylaxis in stock was expired
Other reason why the prophylaxis was not provided
More than 28 days have passed since client's last missed appointment
Age at final HPV vaccination dose received
Client's age at date received final HPV vaccination dose
Client's lifetime number of screenings for cervical cancer
Cervical cancer primary screening test type
Type of cervical cancer screening test used in primary screening
Screened for cervical cancer using HPV-DNA test
Screened for cervical cancer using visual inspection with acetic acid (VIA)
Screened for cervical cancer using cervical cytology
Screened for cervical cancer using other method
Screened for cervical cancer using other method (specify)
HPV-DNA cervical cancer screening test result
VIA cervical cancer screening test result
Negative for Intraepithelial Lesion Malignancy (NILM)
Atypical squamous cells of undetermined significance (ASCUS)
Low grade squamous intraepithelial lesion (LSIL)
High grade squamous intraepithelial lesion (HSIL)
Screening result was invalid or inadequate
Triage test for cervical cancer using visual inspection with acetic acid (VIA)
Triage test for cervical cancer using colposcopy
Triage test for cervical cancer using cervical cytology
Triage test for cervical cancer using test for HPV16/18
Triage test for cervical cancer using another test
Triage test for cervical cancer using another test (specify)
Colposcopy has normal colposcopic findings
Colposcopy has abnormal colposcopic findings
Colposcopy is suspicious for invasive cervical cancer
Result of cervical cancer histopathology
Result of cervical cancer histopathology was normal
Result of cervical cancer histopathology was low-grade squamous intraepithelial lesion (LSIL)
HSIL (inclusive of HSIL-CIN2 or HSIL-CIN3)
Result of cervical cancer histopathology was high-grade squamous intraepithelial lesion (HSIL)
Result of cervical cancer histopathology is invasive cervical cancer
Date of additional cervical cancer triage test
Date of tertiary cervical cancer screening test
Additional cervical cancer triage test type (specify)
Additional cervical cancer triage test result (specify)
Date of diagnosis of cervical precancer lesions or invasive cervical cancer
Client's screening outcome for cervical cancer
Screening outcome for cervical precancer lesions is positive
Screening outcome for cervical precancer lesions is negative
Client is diagnosed with cervical precancer lesions
Client is diagnosed with invasive cervical cancer disease
Cervical cancer stage at diagnosis of cervical cancer
Stage 0 cervical cancer at diagnosis of cervical cancer
Stage I cervical cancer at diagnosis of cervical cancer
Stage II cervical cancer at diagnosis of cervical cancer
Stage III cervical cancer at diagnosis of cervical cancer
Stage IV cervical cancer at diagnosis of cervical cancer
Date of treatment for cervical precancer lesions
Treatment method for cervical precancer lesions
Treatment for cervical precancer lesions is cryotherapy
Treatment for cervical precancer lesions is Thermal ablation
Treatment for cervical precancer lesions is Laser ablation
Treatment for cervical precancer lesions is Cold knife conization (CKC)
Treatment for cervical precancer lesions is Laser cone biopsy
Treatment for cervical precancer lesions is large loop excision of the transformation zone (LLETZ)/loop electrosurgical excision procedure (LEEP)
Treatment for cervical precancer lesions is not listed
Treatment for cervical precancer lesions is not listed (specify)
Date of follow-up for treatment for cervical precancer lesions
Date of start of invasive cancer treatment
Invasive cervical cancer treatment episode
Client's lifetime number of treatments for invasive cervical cancer
Invasive cervical cancer treatment method
Invasive cervical cancer treatment method is a conization
Invasive cervical cancer treatment method is a trachelectomy
Invasive cervical cancer treatment method is a hysterectomy
Invasive cervical cancer treatment method is management of invasive cervical cancer
Invasive cervical cancer treatment method is a radiotherapy
Invasive cervical cancer treatment method is a chemotherapy
Invasive cervical cancer treatment method is a chemoradiation
Invasive cervical cancer treatment method is a not in list
Invasive cervical cancer treatment method is a not in list (specify)
Treatment outcome from cervical pre-cancerous lesion treatment or invasive cancer treatment (specify)
Secondary and other cancers that client is diagnosed with (specify)
Cancers at other sites (HPV- and non-HPV related)
Cancers at other sites that client has (specify)
If deceased, the date that the client died
Cervical cancer screening interval amongst WLHIV
Country-specific interval between cancer screenings amongst women living with HIV (typically 3 or 5 years)
Assessment and provision of vaccinations, such as for people from Key population member type, pregnant women and infants; and, where appropriate, tetanus vaccination for adolescent boys and men receiving VMMC
Hepatitis B (HBV) and hepatitis C virus (HCV) testing and treatment
Client is eligible for differentiated service delivery (DSD) for ART
Date client was assessed for eligibility for differentiated service delivery (DSD) for ART
Client currently enrolled in differentiated service delivery (DSD) ART model
Date client started on differentiated service delivery (DSD) for ART
Type of DSD ART model client is enrolled in (country-specific)
Client is enrolled in fast track ART refill (DSD ART model)
Client is enrolled in facility adherence club (DSD ART model)
Client is enrolled in community ART distribution point (DSD ART model)
Client is enrolled in community health worker/peer educator community ART group (DSD ART model)
Client is enrolled in patient/client community ART group (DSD ART model)
Client is enrolled in another DSD ART model
Client is enrolled in another DSD ART model (specify)
Whether client was offered partner testing
Date partner contacted for index testing
Date on which client's partner was contacted for index testing
Date on which client's partner was tested for HIV
Date of next scheduled follow-up appointment
Date of client's next scheduled follow-up appointment
Type of client's next follow-up appointment (specify)
Type of diagnostic test used for syphilis (Treponema pallidum)
Type of diagnostic test used for Herpes simplex virus (HSV)
Client's mid-upper arm circumference (MUAC)
Date of start of fluconazole prophylaxis
Date of client's start of fluconazole prophylaxis
Client provided with fluconazole prophylaxis
Date started cryptococcal meningitis treatment induction regimen
Date client started cryptococcal meningitis treatment induction regimen
Date completed cryptococcal meningitis treatment induction regimen
Date client completed cryptococcal meningitis treatment induction regimen
Date started cryptococcal meningitis treatment maintenance regimen
Date client started cryptococcal meningitis treatment maintenance regimen
Date completed cryptococcal meningitis treatment maintenance regimen
Date client completed cryptococcal meningitis treatment maintenance regimen
Date started cryptococcal meningitis treatment consolidation regimen
Date client started cryptococcal meningitis treatment consolidation regimen
Date completed cryptococcal meningitis treatment consolidation regimen
Date client completed cryptococcal meningitis treatment consolidation regimen
Functional status of people with advanced HIV disease
Working, able to perform usual work inside and outside the home
Client is able to perform usual work inside and outside the home (working)
Ambulatory, able to perform activity of daily living (ADL), not able to work
Client is able to perform activity of daily living (ADL), not able to work (ambulatory)
Client is dedridden not able to perform ADL
Tailored adherence counselling for advanced HIV disease
Client provided with tailored adherence counselling for advanced HIV disease
Date tracing interventions to support reengagement into HIV care conducted
Current or considered medication/drug, for the purpose of determining drug interactions
Rifampicin currently being taken by, or considered for, client
Halofantrine currently being taken by, or considered for, client
Lovastatin currently being taken by, or considered for, client
Simvastatin currently being taken by, or considered for, client
Hormonal contraception currently being taken by, or considered for, client
Metformin currently being taken by, or considered for, client
Astemizole currently being taken by, or considered for, client
Terfenadine currently being taken by, or considered for, client
TDF currently being taken by, or considered for, client
Simeprevir currently being taken by, or considered for, client
Ombitasvir + paritaprevir/ritonavir + dasabuvir
Ombitasvir + paritaprevir/ritonavir + dasabuvir currently being taken by, or considered for, client
Methadone currently being taken by, or considered for, client
Buprenorphine currently being taken by, or considered for, client
Dofetilide currently being taken by, or considered for, client
Carbamazepine currently being taken by, or considered for, client
Phenobarbital currently being taken by, or considered for, client
Phenytoin currently being taken by, or considered for, client
Polyvalent cation products containing Mg, Al, Fe, Ca and Zn
Polyvalent cation products containing Mg, Al, Fe, Ca and Zn currently being taken by, or considered for, client
Amodiaquine currently being taken by, or considered for, client
Cisapride currently being taken by, or considered for, client
Ergotamine currently being taken by, or considered for, client
Dihydroergotamine currently being taken by, or considered for, client
Midazolam currently being taken by, or considered for, client
Triazolam currently being taken by, or considered for, client
Estrogen-based hormonal contraception currently being taken by, or considered for, client
Ribavirin currently being taken by, or considered for, client
Peginterferon alfa-2a currently being taken by, or considered for, client
Other medication currently being taken by, or considered for, client
Other medication currently being taken by, or considered for, client (specify)
A medication change is recommended for the client based upon current or considered medications
Client's symptoms include extrapulmonary tuberculosis (TB)
Whether the client has tuberculosis (TB) disease. Sometimes known as active TB
Final result of the TB investigation (bacteriological and/or clinical)
A person from whom a biological specimen is positive by smear microscopy, culture or a WHO-recommended rapid diagnostic
A person who does not fulfil the criteria for bacteriological confirmation but has been diagnosed with TB disease by a medical practitioner who has decided to give the person a full course of TB treatment
Client has signs or symptoms of tuberculosis (TB) without laboratory confirmation
Date client is registered as having signs or symptoms of tuberculosis (TB) without laboratory confirmation
A person with TB disease who has never been treated for TB before or has only previously ever taken TB drugs for less than 1 month
A person with TB disease who was previously treated for TB, was declared cured or treatment completed at the end of their most recent course of TB treatment and is now diagnosed with a new episode of TB.
A person with TB disease who had been notified previously as a TB case, but was not declared cured or treatment completed, and is now being registered for a new course of TB treatment.
A person with TB disease who has undocumented history of TB treatment
The date when the diagnosis was established
Currently on TB preventive treatment (TPT)
TB preventive treatment (TPT) start date
The date on which the client began taking TPT
TB preventive treatment (TPT) completion date
The date on which the client completed TPT
Screening algorithm selected for screening activities
Client screened for TB based on cough symptom
Client screened for TB based on any TB symptom
Client screened for TB based on the WHO-recommended four-symptom screen
Client screened for TB based on C-reactive protein (CRP) testing
Client screened for TB with a chest radiography (CXR)
Parallel screening algorithm with W4SS and CRP
Client screened for TB using parallel screening with WHO-recommended four-symptom screen and C-reactive protein (CRP) testing
Sequential positive screening algorithm with W4SS and CRP
Client screened for TB using sequential positive screening with WHO-recommended four-symptom screen and C-reactive protein (CRP) testing.
Sequential negative screening algorithm with W4SS and CRP
Client screened for TB using sequential negative screening with WHO-recommended four-symptom screen and C-reactive protein (CRP) testing
Parallel screening algorithm with W4SS and CXR
Client screened for TB using the parallel screening algorithm with W4SS and CXR
Sequential positive screening algorithm with W4SS and CXR
Client screened for TB using sequential positive screening with WHO-recommended four-symptom screen and chest radiography
Sequential negative screening algorithm with W4SS and CXR
Client screened for TB using sequential negative screening with WHO-recommended four-symptom screen and chest radiography
Client screened for TB with a molecular WHO-recommended rapid diagnostic test (mWRD), such as an Xpert MTB/RIF test to detect Mycobacterium tuberculosis (MTB)
Client screened for with a clinical evaluation for tuberculosis (TB) based on national guidelines. Clinical assessment may be used as an eligibility evaluation for testing with LF-LAM or for empiric TB treatment.
Client screened for tuberculosis (TB) with a different screening method not listed
Client screened for tuberculosis (TB) with a different screening method not listed (specify)
A screening for tuberculosis (TB) was performed
Symptoms that may indicate TB disease in clients living with HIV, based on a clinical algorithm
Client has a cough regardless of duration
Client has a prolonged cough of 2 weeks or more
Client has a fever with a measured temperature of 102.2 °F/39 °C or greater
Client reports experiencing night sweats
Client reports poor weight gain of child or infant or growth curve flattening or weight for age <-2 Z-scores.
Client reports reduced playfulness of child
History of contact with a person with TB
Client had a history of a contact with a person with TB
Record the result of the tuberculosis (TB) screening
Screening result was positive for tuberculosis (TB)
Screening result was negative for tuberculosis (TB)
Screening result was inconclusive for tuberculosis (TB)
The date when the result of TB screening is available
The type of diagnostic test performed to detect tuberculosis (TB) disease
Client tested for tuberculosis with a lateral flow urine lipoarabinomannan assay
Client tested with a WHO-recommended molecular diagnostic test to detect Mycobacterium tuberculosis (MTB)
Microscopy - Sputum acid-fast bacilli (AFB)
Client tested for tuberculosis with a sputum acid-fast bacilli (AFB)
Client tested for tuberculosis (TB) with a culture
The date when TB diagnostic test was performed
The date when the test sample was collected from the client
The date when the result of the TB diagnostic test is available
The date on which the client start or restarted tuberculosis (TB) treatment
Indicates patient's TB treatment outcome
The treatment regimen terminated or permanently changed to a new regimen or treatment strategy. Reasons for the change include: - no clinical response or no bacteriological response, or both (see note; - adverse drug reaction; or - evidence of additional drug-resistance to medicines in the regimen.
Client with pulmonary TB with bacteriologically confirmed TB at the beginning of treatment who completed treatment as recommended by the national policy, with evidence of bacteriological response and no evidence of failure.
Patient completed treatment as recommended by the national policy but the outcome does not meet the definition for cure or treatment failure
Client died before starting treatment or during the course of treatment
No treatment outcome was assigned. This includes cases 'transferred out' to another treatment unit and whose treatment outcome is unknown; however, it excludes those lost to follow-up.
TB drugs currently being taken by the client
Client is currently taking pyrazinamide, a first-line anti-tuberculosis drug
Client is eligible for tuberculosis preventive treatment (TPT)
Date when eligibility for TB preventive treatment (TPT) was determined
Date when a determination of the client's eligibility for TPT was made
Client's tuberculosis (TB) status when antiretroviral therapy (ART) is started
Signs or symptoms of tuberculosis (TB) without laboratory confirmation
Laboratory confirmed tuberculosis (TB) diagnosis
Client has no signs or symptoms of tuberculosis (TB) and is not diagnosed with tuberculosis (TB)
Indicates if the client accepts to be evaluated for TB infection and to take the treatment in case he/she is eligible
Type of extrapulmonary TB identified for the client is TB meningitis
The date on which the client has a test for C reactive protein
Test result of the client's C reactive protein test result in mg/L
The date when the client's test result for C reactive protein is available
Type of TPT regimen the client is currently on
The client's current TPT regimen is six months of levofloxacin daily
Other TB preventive treatment (TPT) regimen
The client's current TPT regimen is another regimen than those listed above
Indicates the current status of TB preventive treatment (TPT)
The client did not start the TB preventive treatment (TPT)
The client started the TB preventive treatment (TPT) and is currently taking the medication, without treatment interruptions
The client started the TB preventive treatment (TPT) and is currently taking the medication, with treatment interruptions
The health care worker has temporarily stopped the TB preventive treatment (TPT), but TPT is expected to continue again later. May also be called 'suspended'.
TB preventive treatment (TPT) was completed
Pregnant woman's family name or last name
Identification number assigned to woman at first visit to the ANC based on national system
Gestational age can be calculated multiple ways. This data element describes where the gestational age above has been calculated from.
Gestational age (GA) calculated from LMP
Woman's gestational age today calculated field using ultrasound GA and ultrasound date
Symphysis fundal height (SFH) or abdominal palpation
If LMP is unknown and either ultrasound wasn't done or it wasn't done early enough, then show the option for health worker to enter GA in weeks based on Symphysis Fundal Height (SFH) or abdominal palpation.
Total number of times the woman has been pregnant (including this pregnancy). Also referred to as gravida.
This calculates the total number of all previous pregnancies (i.e. not including this current pregnancy). This is done for easier obstetric history calculations.
Total number of pregnancies lost or ended due to miscarriages and/or abortions before 22 weeks / 5 months
Total number of stillbirths after 22 weeks
Whether the woman has had any complications or problems in any previous pregnancy
Does not know of any past pregnancy complications
Don't know if there were any problems during past pregnancies
A condition specific to pregnancy, arising after the 20th week of gestation, characterized by hypertension and proteinuria. Oedema may also be present, but is no longer considered a cardinal sign because it is present to some extent in most pregnancies. If not controlled, pre-eclampsia will lead to eclampsia which is characterized by fits, followed by coma, and has a high mortality rate.
A condition peculiar to pregnancy or a newly delivered woman, characterized by fits followed coma. The woman usually has hypertension and proteinuria. The fits may occur in the antepartum, intrapartum or early postpartum periods.
The woman's baby died within 24 hours of childbirth
The woman's experienced prolonged labour
Woman had convulsions during her past pregnancy
Hyperglycaemia first detected at any time during pregnancy
Heavy bleeding (during or after delivery)
Woman was bleeding heavily during or after giving birth during previous pregnancy/pregnancies
Woman experienced 3rd or 4th degree perineal tear
Illicit drug use (e.g. cannabis, amphetamines, prescription stimulants, opioids, opiates, ecstasy, cocaine)
Woman experienced other past pregnancy problems not described above
Woman experienced other past pregnancy problems not described above (specify)
Total number of live and stillbirths (calculated)
Any HIV diagnosis in a pregnant woman as determined by the national HIV testing algorithm, or a pregnancy in a woman previously diagnosed with HIV
Date new pregnancy of HIV-positive woman identified
Earliest date when a new pregnancy of an HIV-positive woman is recorded
Whether the mother had at least one ANC contact (visit)
Date of the pregnant woman's first ANC visit
When the pregnant woman or mother initiated ART, for women living with HIV.
Already on ART at first antenatal care visit
The pregnant woman was already on antiretroviral therapy (ART) at first antenatal care visit
The pregnant woman started ART during her pregnancy
The woman started ART during labour and delivery
Whether the mother is taking a recommended ART regimen
Outcome of pregnancy was early fetal loss/miscarriage
Outcome of pregnancy was induced abortion
Mode of delivery for current pregnancy spontaneous vaginal delivery (SVD)
Mode of delivery for current pregnancy was assisted vaginal delivery
Caesarian section (C/S, operative delivery)
Mode of delivery for current pregnancy was caesarian section (C/S; operative delivery)
Serious or life-threatening obstetric complications during pregnancy, delivery or postpartum experienced by mother or her newborn
A woman living with HIV had a live birth
Best estimate of gestational age in completed weeks when infant was born (an indication of prematurity, preterm and extreme preterm)
Whether the infant was small for gestational age (SGA) at birth (<10th percentile)
The woman gave birth when the gestational age is less than 37 weeks
The date on which the infant was started or restarted on ART
The type of place where the woman delivered
The woman delivered at a health facility
The woman delivered at another location that is not at home or at a health facility
The woman delivered at another location that is not at home or at a health facility (specify)
Facility where the infant or child was born
Biological mother's family name or last name
The date and time of the client's ANC contact (in the ANC DAK this is called 'Contact date')
The infant's date of birth (DOB) if known
If DOB is unknown, enter the client's estimated age. Display client's age in number of years
Infant age calculated using date of birth
The infant's current weight in kilograms
Head circumference of infant at birth in cm
Whether an HIV test of the mother was conducted
Whether an HIV test of the mother was ordered
Date when a mother's HIV test was conducted
Test result for mother after applying the testing strategy
Whether the infant or child was determined to have had HIV exposure through mother
Infant or child is not known to have been exposed to HIV
Don't know whether infant or child was exposed to HIV, such as if mother's HIV status is unknown
Whether the infant or child was determined to have had HIV exposure
Mother is a member of a key population which has an increased risk of HIV
The type of key population that the infant's mother is included in
Infant's mother is a person who injects drugs
Infant's mother identifies as trans and gender-diverse
People living in prisons and other closed setting
Infant's mother is in a prison or closed setting
Postpartum family planning counselling conducted
Infant's age when an HIV test is performed in months and years (calculated from date of birth)
Support on infant and child feeding to mother or caregiver provided
Date infant feeding counselling provided
Date support on infant and child feeding to mother or caregiver provided
Malaria prevention counselling conducted
Counselling provided on how to prevent malaria
Insecticide treated bednet (ITN) provided or referred
An insecticide treated bednet (ITN) was provided or the client was referred
Whether or not mother was treated for syphilis
Specifies whether the infant is exclusively being breastfed by the mother
Infant is not receiving any breast milk with a diet that provides all the nutrients needed until they can be fully fed on family foods
Infant younger than 6 months of age is given other liquids and/or foods together with breast milk. This could be water, other types of milk or any type of solid food.
Date on which infant feeding practice was recorded
The mother has fully stopped breastfeeding the infant or child
The date on which the mother stopped breastfeeding the infant
Taking iron and folic acid (IFA) tablets
Is client taking her iron and folic acid (IFA) tablets? Select whether the woman is continuing to take IFA supplements
Amount of iron supplements prescribed in milligrams for intake
Whether the amount of iron prescribed is for daily or weekly intake
Iron supplements prescribed for daily intake
Amount of daily dose of folic acid prescribed
Amount of folic acid supplements prescribed in milligrams for daily intake
Date infant ARV prophylaxis dispensed (or started)
Date HIV-exposed infant received ARV prophylaxis (for the first time)
The HIV status of the infant's mother at first ANC visit
Whether the client has developed hypertension associated with pregnancy
A recent history (in the last 6 months) of a sexually transmitted infection (STI) by laboratory testing or self-report of syndromic STI treatment
Mother's HIV status is different from a current partner's HIV status
Date woman received counselling for co-trimoxazole preventive therapy (CPT)
Date woman received counselling for TB preventive therapy
Infant's co-trimoxazole prophylaxis start date
Start date of co-trimoxazole prophylaxis
Infant's age when co-trimoxazole prophylaxis was started
The number of weeks or months infant was when started on co-trimoxazole (CTX) prophylaxis preventive therapy
Presumptive clinical diagnosis of severe HIV infection in infants
Infant is taking an antiretroviral prophylaxis to prevent infection from HIV exposure
The date on which the infant was started on an antiretroviral prophylaxis
Antibody test for HIV performed with a rapid diagnostic (RDT)
Antibody test for HIV performed with an enzyme immunoassay (EIA)
Maternal and child health service visit attended by an HIV-exposed infant
HIV-exposed infant attending MCH services for a 12-month visit
HIV-exposed infants attending MCH services for a 24-month visit
First visit after the end of breastfeeding
HIV-exposed infant attending MCH services for a first visit after the end of breastfeeding
Number of weeks postpartum on this visit date
Month and year of infant's birth, which the infant is registered into. The cohort is a group of infants born in the same month, whose status is followed over time.
Whether the infant has been registered in a birth cohort
Early infant diagnosis (EID) sample number
First sample used to test an infant for HIV
Second sample used to test an infant for HIV
Early infant diagnosis (EID) HIV test number using the same sample
First test on a sample to test an infant for HIV
Second test on a sample to test an infant for HIV
Early infant diagnosis test number 1 test result
Positive HIV test result from the nucleic acid test
Negative HIV test result from the nucleic acid test
Indeterminate HIV test result from the nucleic acid test
Early infant diagnosis test number 2 test result
The result of the first syphilis assay in the testing strategy
The result of the first syphilis assay in the testing strategy was reactive
The result of the first syphilis assay in the testing strategy was non-reactive
Test result of syphilis assay 1 repeated
The result of the first syphilis assay repeated in the testing strategy
The result of the first syphilis assay repeated in the testing strategy was reactive
The result of the first syphilis assay repeated in the testing strategy was non-reactive
The result of the first syphilis assay repeated in the testing strategy was invalid
HIV status reported after applying the HIV testing algorithm. No single HIV test can provide an HIV-positive diagnosis.
The date on which the infant was started or restarted on antiretroviral therapy (ART)
HIV-exposed infant final status at 18 months or 3 months after cessation of breastfeeding (whichever is later).
HIV-negative and no longer breastfeeding
The infant is HIV-negative and the mother has quit breastfeeding
The final HIV status of the child is unknown because the infant died, was lost to follow-up or transferred out without ever having an HIV-positive diagnosis or is active in care but was not tested at 18 months
HIV-exposed infant reason for unknown final status
The outcome for the infant does not have a final outcome, which may because of death, stopped treatment or lost to follow-up.
Twenty-eight days or more since last missed appointment
The client transferred to another facility
People living with HIV previously on ART who are confirmed to have died from any cause
Client was contacted and confirmed to have stopped ART
Infant died within 24 hours of childbirth
The infant died within 24 hours of childbirth
Action(s) needed during infant follow-up visit
Any actions needed during infant follow-up visit
Age in months when additional infant HIV test is performed
Date of sample collection of additional infant HIV test
Result of woman's haemoglobin test during ANC, labour or delivery. Full blood count testing is recommended, and if not available, use of haemoglobinometer over haemoglobin colour scale.
Mother's blood type and blood Rh factor is A+
Mother's blood type and blood Rh factor is A-
Mother's blood type and blood Rh factor is B+
Mother's blood type and blood Rh factor is B-
Mother's blood type and blood Rh factor is O+
Mother's blood type and blood Rh factor is O-
Mother's blood type and blood Rh factor is AB+
Mother's blood type and blood Rh factor is AB-
Asymptomatic bacteriuria (ASB) test result
Result of urine culture (or urine Gram-staining if not available over dipstick tests) for diagnosing asymptomatic bacteriuria
Result of test for asymptomatic bacteriuria is positive
Result of test for asymptomatic bacteriuria is negative
Result of test for asymptomatic bacteriuria is unknown
Results of urine protein test of mother during ANC visit
Result of urine protein test of mother during ANC visit is '0'
Result of urine protein test of mother during ANC visit is '+'
Result of urine protein test of mother during ANC visit is '++'
Result of urine protein test of mother during ANC visit is '+++'
Type of hypertensive disorder of the mother
Hypertension detected pre-pregnancy or before 20 weeks' gestation
Hypertension without a known secondary cause (pre-pregnancy or at less than 20 weeks)
Hypertension with a known secondary cause (e.g. renal disease; detected pre-pregnancy or at less than 20 weeks)
sBP greater than or equal to 140 and/or dBP greater than or equal to 90 mmHg when measured in the office or clinic, and BP less than 135/85 mmHg using HBPM or ABPM readings (pre-pregnancy or at less than 20 weeks)
BP that is less than 140/90 mmHg at a clinic/office visit, but greater then or equal to 135/85 mmHg at other times outside the clinic/ office (pre-pregnancy or at less than 20 weeks)
Hypertension arising de novo at greater than or equal to 20 weeks' gestation in the absence of proteinuria or other findings suggestive of pre-eclampsia
Hypertension arising at greater than or equal to 20 weeks' gestation in the clinic, which resolves with repeated BP readings
Among women with chronic hypertension, development of new proteinuria, another maternal organ dysfunction(s), or evidence of uteroplacental dysfunction.
Date of baseline CD4 count sample collection
Date and time when baseline CD4 count test sample was collected
The client's first CD4 count from baseline CD4 test performed (such as at HIV diagnosis) was a count of <200 cells/mm3
Date sample to be used for CD4 count was collected
Date of first viral load sample collection
Date and time when the sample was collected to test the client's HIV viral load for the first time
Result from the initial viral load test in number of copies/mL
The type of specimen to be used to test viral load
Liquid plasma specimen for viral load testing
Liquid plasma and using ethylenediaminetetraacetic acid (EDTA) or plasma preparation tubes for viral load test
Dried blood spot specimen (DBS) for viral load test
Dried plasma spot from a plasma separation card
Dried plasma spot from a plasma separation card for viral load test
Reason why a hepatitis B test was not done
Test delayed to next contact or referred
Test has been delayed to the next contact or client was referred to another provider/facility
Test out of stock or stock present but expired
Machine or technician not available or machine not functioning
Test machine or technician is unavailable, or machine is not functioning
Client declined or refused test being undertaken
Other reason test not performed (specify)
Whether a hepatitis C test was conducted
Reason why a hepatitis C test was not done
If the health worker performed other tests on the woman that are not explicitly listed in the application, select 'yes' here and fill in the details below.
Input the name of other test(s) that were done.
Input the date of other test(s) that were done.
The reason why the client is being followed up
Client did not present for a care appointment as scheduled / as expected
Client did not pick up medication as scheduled from pharmacy or other drug distribution point
Client did not initiate ART at the same time as diagnosis (e.g., because they required additional counselling) and required follow-up for ART initiation
Client presented for care, but left before services were completed, e.g., due to long wait times or not staying to have labs taken
Client has not returned for a follow-up test after an inconclusive test result
Client needs to be informed of test results (e.g., viral load)
Client was followed up for another reason
Client was followed up for another reason (specify)
An attempt to locate the client was made
Who attempted to reach out to the client
Method used to try to reach out to the client
Contacted client by short message service (SMS) text
The client was the source of information
Source of information was a treatment provider of the client
Source of information was a family member of partner
Information about the client's status was provided by someone else
Information about the client's status was provided by someone else (specify)
Detailed outcome from the attempt to locate the client
Client was located and agreed to return to clinic
Client transferred to another facility for care (client-initiated transfer, not provider-initiated transfer)
Client was found but declined to return to treatment
Attempt was made to locate client, but client was not found
The client moved from the catchment area (may be reported from the community level)
The date on which the client moved from the catchment area, if known
New catchment area where the client resides
The client was identified by an index case as a partner or contact
HIV status of the partner or contact given by the index case
The partner or contact of the index case already knew they are HIV-positive
The partner or contact of the index case is newly diagnosed as HIV-positive
The partner or contact of the index case is newly diagnosed is HIV-negative
The outcome for the client which is used for reporting retention/attrition.
Client was contacted and confirmed to have stopped ART (reasons may include stigma and discrimination, faith healing, etc.)
Date patient was lost to follow-up (LTFU)
The date on which the client's outcome (lost to follow-up, transferred out, death (documented), or refused (stopped) treatment) changed
Select if transfer to another facility is confirmed
Name of health facility client was transferred to
The date the client transferred out of the facility to be provided with care at another facility
Whether client is adherent or not to ART regimen per national guidelines (immunological or virological monitoring)
Client reported not being adherent because of client lost/ran out of pills
Client reported not being adherent because of substance use (i.e., drugs)
Client reported not being adherent because of other reason
Client reported not being adherent because of other reason (specify)
Reason why client intentionally stopped ART
Client stopped ART because of drugs being out of stock
Client stopped ART because client lacked finances
Client stopped ART because the infant was determined to not have HIV
Client stopped ART for other reason (specify)
Reason why the client is being referred. If diagnosed, this may include the reason for the diagnosis.
Client's clinical status warrants hospitalization
Referral for screening including diagnostics and lab testing
The client is referred because they need a lab test done and/or diagnostics done, but those services are unavailable at the current health facility or providers. This includes referral for TB screening (is symptomatic of TB, has had close contact with confirmed TB case, etc.) and other comorbidities or coinfections.
Client was referred because the client is pregnant
If none of the reasons above apply, this should be selected
Referral for other general services (specify)
If none of the reasons above apply, specify the reason(s)
If client was referred, was any treatment provided before referral?
Location of scheduled referral appointment
The name of the provider who made the referral
The contact details of the provider making the referral
Any additional relevant details of clinical significance for the referral facility to provide quality care
With interoperable systems, the provider receiving the referral should be able to access the client's health record digitally. However, in the absence of this, the referral provider should receive a summary of the client's health records that includes the client's history, medications, medications prescribed or dispensed, reported issues and concerns, and any other relevant clinical information the health care provider had already obtained.
Client is at elevated risk for HIV acquisition, defined according to country/programme context
HIV prevention intervention that client accessed
Client accessed opioid agonist maintenance treatment (OAMT) services
Client accessed needle-syringe programme (NSP) services
Client accessed sexually transmitted infection (STI) services
Client accessed voluntary medical male circumcision (VMMC) services
Client accessed other HIV prevention services
Client accessed other HIV prevention services (specify)
Date accessed HIV prevention intervention
Date the client accessed HIV prevention intervention
Client does not know contact's HIV status
Date client was provided with injecting equipment
Number of needles-syringes provided to client
Date client initiated opioid agonist maintenance treatment (OAMT)
Date client received opioid agonist maintenance treatment (OAMT) dose
Date the client was dispensed opioid agonist maintenance treatment (OAMT) take-away dose(s)
Client is currently on opioid agonist maintenance treatment (OAMT) at reporting date, defined according to country/program to account for medication dispensed and LTFU criterion
Client is retained on opioid agonist maintenance treatment (OAMT) at reporting date, defined according to country/program to account for medication dispensed and LTFU criterion
Client is currently being inducted on opioid agonist maintenance treatment (OAMT), defined according to country/program
Client is current on reducing doses of opioid agonist maintenance treatment (OAMT), defined according to country/program
First date on which client received maintenance dose
Date of loss to follow-up or OAMT stopped
Date of loss to follow-up or opioid agonist maintenance treatment (OAMT) stopped
The tuberculosis prevalence in the general population in number of cases per 100 000 persons or greater.
Population prevalence of soil-transmitted helminth infection
The percentage of individuals in the general population infected with at least one species of soil-transmitted helminths
Population incidence of HIV in the absence of PrEP
HIV incidence number of cases per 100 person–years in the absence of PrEP
The proportion of the population that are HIV-positive
Prevalence of pretreatment NNRTI drug resistance
Prevalence of pretreatment HIV drug resistance to NNRTIs among people initiating first-line ART
Whether the setting is a malaria-endemic setting
The proportion of the population with syphilis
The proportion of hepatitis B surface antigen (HBsAg) seroprevalence in the general population
The proportion of hepatitis C virus (HCV) antibody seroprevalence in the general population
The proportion of the population from the health facility's catchment area that are HIV-positive (estimated)
Ultrasound available at the health facility
Whether an ultrasound machine is available and functional in the facility and a trained health worker is available to use it
HIV burden of the setting (high or low) based on the national HIV prevalence or where the HIV prevalence and/or incidence in a geographical setting is higher than national prevalence and, therefore, needs priority in the HIV response
Settings with >5% national HIV prevalence and subpopulations and geographic settings where HIV prevalence and/or incidence is higher than nationally.
Settings with <5% HIV national prevalence but where certain populations (primarily key populations and their partners) and geographic settings may have higher HIV prevalence and/or incidence than nationally and, therefore, need priority in the HIV response
HPV DNA testing operational at the health facility
Is HPV DNA testing operational at the health facility for cervical cancer screening?
Routine viral load testing is available in the facility
Unique ID of the health facility that recorded the client. This ID could represent a universal health facility ID, if used in the country. Alternatively this ID can also be generated by the national surveillance system and assigned to reporting facility.
The facility where the client is receiving tuberculosis (TB) treatment
Other populations of priority of HIV prevention and care in local context (provided during adaptation)
Reporting date, for surveys performed on a specific date